0001144204-12-026326.txt : 20120504 0001144204-12-026326.hdr.sgml : 20120504 20120504165027 ACCESSION NUMBER: 0001144204-12-026326 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120504 DATE AS OF CHANGE: 20120504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001279704 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043321804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-119366 FILM NUMBER: 12814984 BUSINESS ADDRESS: STREET 1: ONE GATEWAY CENTER, SUITE 504 CITY: NEWTON STATE: MA ZIP: 02458 BUSINESS PHONE: 617-244-1616 MAIL ADDRESS: STREET 1: ONE GATEWAY CENTER, SUITE 504 CITY: NEWTON STATE: MA ZIP: 02458 FORMER COMPANY: FORMER CONFORMED NAME: COMMON HORIZONS INC DATE OF NAME CHANGE: 20040211 10-Q 1 v310237_10q.htm FORM 10-Q

U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

[mark one]

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: March 31, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______________ to ______________

Commission File Number 333-119366

NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

DELAWARE

04-3321804

(State or other jurisdiction of
incorporation or organization)

(IRS Employer

Identification No.)

One Gateway Center, Suite 504, Newton, Massachusetts 02458

(Address of principal executive offices)

(617) 244-1616

(Registrant’s telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

(Check one):

Large accelerated filer	¨		Accelerated filer	¨

Non-accelerated filer	¨	(Do not check if a smaller reporting company)	Smaller reporting company	x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

Number of shares outstanding of the issuer’s common stock as of the latest practicable date: 37,570,245 shares of common stock, $0.00001 par value per share, as of May 1, 2012.

NOVELOS THERAPEUTICS, INC.

FORM 10-Q

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	17
Item 4.	Controls and Procedures	22

PART II. OTHER INFORMATION

Item 1.	Legal Proceedings	23
Item 1A.	Risk Factors	24
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3.	Defaults Upon Senior Securities	26
Item 4.	Mine Safety Disclosures	26
Item 5.	Other Information	26
Item 6.	Exhibits	26

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

NOVELOS THERAPEUTICS, INC.

(a Development Stage Company)

CONSOLIDATED BALANCE SHEETS (UNAUDITED)

	March 31, 2012			December 31, 2011
ASSETS
CURRENT ASSETS:
Cash and cash equivalents	$	3,787,576		$	5,505,960
Restricted cash		55,000			55,000
Prepaid expenses and other current assets		183,300			254,967
Total current assets		4,025,876			5,815,927
FIXED ASSETS, NET		2,919,943			3,044,565
GOODWILL		1,675,462			1,675,462
OTHER ASSETS		27,222			27,222
TOTAL ASSETS	$	8,648,503		$	10,563,176

LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	$	471,629		$	478,041
Derivative liability		32,397			23,305
Capital lease obligations, current portion		2,275			2,235
Total current liabilities		506,301			503,581
LONG-TERM LIABILITIES:
Notes payable, net of current portion		450,000			450,000
Deferred rent		127,368			124,381
Capital lease obligations, net of current portion		3,507			4,091
Total long-term liabilities		580,875			578,472
TOTAL LIABILITIES		1,087,176			1,082,053
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS’ EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of March 31, 2012 and December 31, 2011		—			—
Common stock, $0.00001 par value; 150,000,000 shares authorized; 36,962,264 and 36,907,824 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively		369			369
Additional paid-in capital		41,398,287			40,961,180
Deficit accumulated during the development stage		(33,837,329	)		(31,480,426	)
Total stockholders’ equity		7,561,327			9,481,123
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	8,648,503		$	10,563,176

The accompanying notes are an integral part of these consolidated financial statements.

NOVELOS THERAPEUTICS, INC.

(a Development Stage Company)
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

	Three Months Ended March 31,						Cumulative Development-Stage Period from November 7, 2002 (date of inception) through March 31,
	2012			2011			2012

COSTS AND EXPENSES:
Research and development	$	1,328,314		$	471,404		$	22,133,353
General and administrative		997,671			131,726			10,660,282
Merger costs		—			250,434			799,133
Total costs and expenses		2,325,985			853,564			33,592,768

LOSS FROM OPERATIONS		(2,325,985	)		(853,564	)		(33,592,768	)

OTHER INCOME (EXPENSE):
Grant income		—			44,479			244,479
Loss on derivative warrants		(28,846	)		—			(41,004	)
Interest expense, net		(2,072	)		(156,167	)		(449,197	)
Other income		—			—			1,161
Total other expense, net		(30,918	)		(111,688	)		(244,561	)
NET LOSS	$	(2,356,903	)	$	(965,252	)	$	(33,837,329	)
BASIC AND DILUTED NET LOSS PER COMMON SHARE	$	(0.06	)	$	(0.08	)	$	(2.87	)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE		36,910,217			12,820,102			11,775,244

The accompanying notes are an integral part of these consolidated financial statements.

NOVELOS THERAPEUTICS, INC.

(a Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

	Three Months Ended March 31,						Cumulative Development-Stage Period from November 7, 2002 through March 31,
	2012			2011			2012
Net loss	$	(2,356,903	)	$	(965,252	)	$	(33,837,329	)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization		139,771			144,174			2,555,809
Stock-based compensation		417,353			58,462			3,272,226
Intrinsic value of beneficial conversion feature associated with convertible debt		—			—			471,765
Issuance of stock for technology and services		—			—			89,520
Impairment of intangible assets		—			—			19,671
Loss on disposal of fixed assets		—			—			36,477
Loss on derivative warrants		28,846			—			41,004
Changes in:
Prepaid expenses and other current assets		71,667			(5,458	)		(167,130	)
Accounts payable and accrued liabilities		(6,412	)		293,383			91,500
Accrued interest		—			145,802			463,722
Deferred rent		2,987			4,323			127,368
Cash used in operating activities		(1,702,691	)		(324,566	)		(26,835,397	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash acquired in a business combination		—			—			905,649
Purchases of fixed assets		(15,149	)		—			(5,501,741	)
Proceeds from sale of fixed assets		—			—			7,000
Purchases of short-term certificates of deposit		—			—			(5,500,730	)
Proceeds from short-term certificates of deposit		—			—			5,500,730
Change in restricted cash		—			—			(55,000	)
Payment for intangible assets		—			—			(19,671	)
Cash used in investing activities		(15,149	)		—			(4,663,763	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible notes		—			—			2,720,985
Proceeds from long-term obligations		—			—			1,677,945
Payments on long-term obligations		—			(49,998	)		(1,227,944	)
Payments on capital lease obligations		(544	)		(508	)		(5,192	)
Proceeds from issuance of common stock and warrants, net of issuance costs		—			—			31,874,254
Proceeds from exercise of warrant		—			—			250,000
Repurchase of common stock		—			—			(31,667	)
Cash in lieu of fractional shares in a business combination		—			—			(145	)
Change in deferred issuance costs		—			—			28,500
Cash provided by (used in) financing activities		(544	)		(50,506	)		35,286,736
INCREASE (DECREASE) IN CASH AND EQUIVALENTS		(1,718,384	)		(375,072	)		3,787,576
CASH AND EQUIVALENTS AT BEGINNING OF PERIOD		5,505,960			673,739			—
CASH AND EQUIVALENTS AT END OF PERIOD	$	3,787,576		$	298,667		$	3,787,576
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Interest paid	$	—		$	11,563		$	208,689
Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise	$	19,754		$	—		$	68,093
Issuance of common stock in connection with the conversion of notes payable and accrued interest	$	—		$	—		$	3,184,707
Fair value of assets acquired in exchange for securities in a business combination	$	—		$	—		$	78,407
Fair value of liabilities assumed in exchange for securities in a business combination	$	—		$	—		$	(439,615	)
Goodwill resulting from a business combination	$	—		$	—		$	1,675,462

The accompanying notes are an integral part of these consolidated financial statements.

NOVELOS THERAPEUTICS, INC.

(a Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

Novelos Therapeutics, Inc. (“Novelos” or the “Company”) is a pharmaceutical company developing compounds for the treatment and diagnosis of cancer. On April 8, 2011, Novelos completed a business combination with Cellectar, Inc. (“Cellectar”), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers, and Cell Acquisition Corp. (the “Merger Subsidiary”), a Wisconsin corporation and a wholly owned subsidiary of Novelos. Pursuant to the transaction Cellectar was merged into the Merger Subsidiary (the “Acquisition”, see Note 3). References in these financial statements and notes to “Cellectar” relate to the activities and financial information of Cellectar prior to the Acquisition, references to “Novelos” relate to the activities and financial information of Novelos prior to the Acquisition and references to “the Company” or “we” or “us” or “our” relate to the activities and obligations of the combined Company following the Acquisition.

Immediately prior to the Acquisition, Novelos completed a 1-for-153 reverse split of its common stock. Novelos then issued to the shareholders of Cellectar at that date 17,001,596 shares of its common stock as consideration for the Acquisition, representing a ratio of 0.8435 shares of Novelos common stock in exchange for one share of Cellectar common stock (the “Exchange Ratio”) as set forth in the Agreement and Plan of Merger (the “Merger Agreement”) dated April 8, 2011. The shares issued to Cellectar shareholders in the Acquisition constituted approximately 85% of Novelos’ outstanding common stock after giving effect to the Acquisition.

Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes. Accordingly, the Acquisition was accounted for as a reverse acquisition whereby Cellectar, Inc. was treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein as of and for the three months ended March 31, 2011 represent the historical financial information of Cellectar, except for the capital structure which represents the historical amounts of Cellectar, retroactively adjusted to reflect the legal capital structure of Novelos by applying the Exchange Ratio. On April, 8, 2011, Cellectar was merged into the Merger Subsidiary a wholly owned subsidiary of Novelos; as such, the financial statements presented herein as of and for the three months ended March 31, 2012 include the consolidated results of the combined company from January 1, 2012 through March 31, 2012. All per-share amounts and outstanding shares, including all common stock equivalents, and stock options, have been retroactively restated in these financial statements and notes for all periods presented to reflect the capital structure of Novelos by applying the Exchange Ratio. The number of authorized shares of common stock disclosed on the balance sheet (150,000,000) represents the number of authorized shares of Novelos common stock following the Acquisition.

As a result of the Acquisition, the Company has implemented a revised business plan focused on the development of the Cellectar compounds. Development of Novelos’ other compounds (NOV-002 and NOV-205) has been suspended. The Company conducts its operations from its headquarters in Madison, Wisconsin and the Company’s executive offices are in Newton, Massachusetts.

The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.

The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception in devoting substantially all of its efforts toward research and development and has an accumulated deficit of $33,837,329 at March 31, 2012. During the three months ended March 31, 2012, the Company generated a net loss of $2,356,903 and the Company expects that it will continue to generate operating losses for the foreseeable future. The Company believes that its cash on hand is adequate to fund operations into the middle of the third quarter of 2012. The Company’s ability to execute its operating plan beyond that time depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The accompanying balance sheet as of December 31, 2011 has been derived from audited financial statements. The accompanying unaudited consolidated balance sheet as of March 31, 2012, the consolidated statements of operations for the three months ended March 31, 2012 and 2011 and the cumulative period November 7, 2002 (date of inception) through March 31, 2012, and the consolidated statements of cash flows for the three months ended March 31, 2012 and 2011 and the cumulative period November 7, 2002 (date of inception) through March 31, 2012 and the related interim information contained within the notes to the consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s consolidated financial position at March 31, 2012 and consolidated results of its operations and its cash flows for the three months ended March 31, 2012 and 2011 and the period from November 7, 2002 (inception) to March 31, 2012. The results for the three months ended March 31, 2012 are not necessarily indicative of future results.

These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K, which was filed with the SEC on March 9, 2012.

Goodwill — Intangible assets at March 31, 2012 consist of goodwill recorded in connection with the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount.

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Topic 505, Equity of the Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”). As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The carrying value of long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivative Instruments – The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 50,419 at March 31, 2012. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At March 31, 2012 and December 31, 2011, these warrants represented the only outstanding derivative instruments issued or held by the Company.

New Accounting Pronouncements — In May 2011, the FASB issued ASU No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. Generally Accepted Accounting Principles (“GAAP”) and International Financial Reporting Standards (“IFRSs”). This standard updates accounting guidance to clarify the measurement of fair value to align the guidance and improve the comparability surrounding fair value measurement within GAAP and IFRSs. The standard also updates requirements for measuring fair value and expands the required disclosures. The standard does not require additional fair value measurements and was not intended to establish valuation standards or affect valuation practices outside of financial reporting. The adoption of this standard on January 1, 2012 did not have a material impact on the Company’s financial statements or required disclosures.

In September 2011, the FASB issued ASU No. 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment. This standard simplifies how an entity tests goodwill for impairment and allows an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This standard is effective for entities as of the beginning of a fiscal year that begins after December 15, 2011, interim and annual periods thereafter. Early adoption is permitted. The Company adopted the provisions of this standard on January 1, 2012. The adoption of this standard did not have a material impact on the Company’s financial statements or required disclosures.

2. FAIR VALUE

In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

Level 1: Input prices quoted in an active market for identical financial assets or liabilities.

Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

Assets and liabilities measured at fair value on a recurring basis are summarized below:

	March 31, 2012
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Warrants	$	-	$	32,397	$	-	$	32,397

	December 31, 2011
	Level 1		Level 2		Level 3		Fair Value

Liabilities:
Warrants	$	-	$	23,305	$	-	$	23,305

The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 5).

3. ACQUISITION

Merger Agreement

On April 8, 2011, Novelos acquired Cellectar through a merger with and into the Merger Subsidiary, pursuant to the Merger Agreement entered into on that date. As a result of the Acquisition, the Merger Subsidiary, which was renamed Cellectar, Inc., owns all assets of and operates the business previously owned and operated by Cellectar.

In the Acquisition, the former stockholders of Cellectar received an aggregate number of shares of Novelos common stock constituting approximately 85% of the outstanding shares of Novelos common stock, after giving effect to the Acquisition but before giving effect to the concurrent private placement of Novelos securities described below. Prior to the Acquisition, Novelos amended and restated its certificate of incorporation and in connection therewith, among other things, effected a 1-for-153 reverse split of its common stock resulting in 2,959,871 shares of Novelos common stock outstanding. Novelos then issued 17,001,596 shares of Novelos common stock to the stockholders of Cellectar upon the effective date of the Acquisition. Warrants and options to purchase Novelos common stock that were outstanding prior to the Acquisition remained outstanding following the Acquisition. These consist of warrants to purchase a total of 315,164 shares of Novelos common stock with prices ranging from $16.07 to $191.25 and options to purchase a total of 49,159 shares of Novelos common stock with prices ranging from $1.53 to $1,072.53.

XMS Capital Partners, the financial advisor to Cellectar in connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration of their services. Rodman & Renshaw, LLC (“Rodman”), financial advisor to Novelos in connection with the Acquisition, received a cash fee of $250,000 upon the completion of the Acquisition in consideration of their services. These amounts were recorded as merger costs and expensed as incurred on the date of the Acquisition. In addition to the investment banking fees, the Company also incurred an additional $250,434 of merger-related legal and other costs during the three months ended March 31, 2011 which were included as a component of expense in the respective period.

The Acquisition was completed principally to leverage synergies between Novelos’ strategic focus and experience in developing and funding the development of cancer drugs and Cellectar’s portfolio of cancer-targeted compounds.

Purchase Accounting

The Acquisition was accounted for using the purchase method of accounting as a reverse acquisition. In a reverse acquisition, the post-acquisition net assets of the surviving combined company includes the historical cost basis of the net assets of the accounting acquirer (Cellectar) plus the fair value of the net assets of the accounting acquiree (Novelos). Further, under the purchase method, the purchase price is allocated to the assets acquired, liabilities assumed and identifiable intangible assets based on their estimated fair values with the remaining excess purchase price over net assets acquired allocated to goodwill.

The fair value of the consideration transferred in the Acquisition was $2,219,903 and was calculated as the number of shares of common stock that Cellectar would have had to issue (adjusted for the Exchange Ratio) in order for Novelos shareholders to hold a 15% equity interest in the combined Company post-acquisition (but prior to the concurrent private placement), multiplied by the estimated fair value of the Company’s common stock on the acquisition date. The estimated fair value of the Company’s common stock was based on the offering price of the common stock sold in the private placement which was both completed concurrently with and conditioned upon the closing of the Acquisition. This price was determined to be the best indication of fair value on that date since the price was based on an arm’s length negotiation with a group consisting of both new and existing investors that had been advised of the pending Acquisition and assumed similar liquidity risk as those investors holding the majority of shares being valued as purchase consideration.

The following table summarizes the Company’s determination of fair values of the assets acquired and the liabilities as of the date of acquisition.

Consideration - issuance of securities	$	2,219,903

Prepaid expenses and other assets	$	71,892
Fixed assets		6,515
Accrued liabilities		(380,130	)
Derivative liability		(59,485	)
Goodwill		1,675,462

Total purchase price – net of cash acquired of $905,649	$	1,314,254

The Company determined that the acquired Novelos legacy technology had no value as of the date of the acquisition.

Goodwill

Of the total purchase price of $2,219,903, $1,675,462 was allocated to goodwill. Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets. The goodwill includes the value of the Novelos work force (management team). None of the goodwill associated with the Acquisition is deductible for income tax purposes.

The Company is required to perform an annual impairment test related to goodwill, which is performed in the fourth quarter of each year, or sooner if changes in circumstances suggest that the carrying value of an asset may not be recoverable. There were no changes in circumstances that would suggest that the goodwill is not recoverable. There were no changes in goodwill during the three months ended March 31, 2012.

4. STOCKHOLDERS’ EQUITY

April 2011 Private Placement

Concurrently with and conditioned upon the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement with certain accredited investors under which the Company sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000 (the “April Private Placement”). The warrants have an exercise price of $0.75 and expire on March 31, 2016. The warrant exercise price and/or the common stock issuable pursuant to such warrant are subject to adjustment only for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event. The relative fair value of the warrants issued to the investors was $2,124,286 at issuance and has been included as a component of stockholders’ equity.

The Securities Purchase Agreement includes certain registration requirements which were subsequently extended by the consent of purchasers holding a majority of shares of the Company’s common stock issued in the April Private Placement, which holders constituted the requisite holders, as defined. The Company is required to file with the SEC no later than May 29, 2012 (the "Filing Deadline") a registration statement covering the resale of the shares of common stock and the shares of common stock underlying the warrants issued pursuant to the Securities Purchase Agreement that are not otherwise saleable under an available exemption from registration requirements. The Company is also required to use commercially reasonable efforts to have the registration statement declared effective by July 28, 2012 (the "Effectiveness Deadline"), and to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the “Securities Act”), until the earlier of the date when all the registrable securities covered by the registration statement have been sold or the second anniversary of the closing.

In the event the Company fails to file the registration statement within the timeframe specified by the Securities Purchase Agreement, or if it fails to obtain effectiveness of this registration on or prior to July 28, 2012 (if there is no review by the SEC) or by August 28, 2012 (if there is review by the SEC) with respect to the maximum number of shares permitted to be registered by the SEC, the Company will be required to pay to the purchasers liquidated damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase price of the units purchased until the registration statement is filed or declared effective, as applicable, not to exceed 5% of the aggregate purchase price. The Company will be allowed to suspend the use of the registration statement for not more than 30 consecutive days on not more than two occasions in any 12-month period. The Company has also granted piggy-back registration rights with respect to any shares of common stock that it is required to exclude from the registration statement as a condition of its effectiveness, and has also agreed to file further registration statements with respect to any such shares six months after the effective date of the initial registration statement. As of March 31, 2012, and through the date of this filing, the Company has not concluded that it is probable that damages will become due; therefore, no accrual for damages has been recorded.

The Company paid to Rodman, the placement agent for the financing, a cash fee equal to $200,000 and issued warrants to purchase 192,931 shares of its common stock (having an exercise price of $0.75 and which expire March 31, 2016) in consideration for their advisory services with respect to the financing pursuant to the placement agency agreement between Rodman and the Company. Rodman is entitled to registration rights with respect to the shares of common stock issuable upon exercise of these warrants. The cash fee was recorded as a reduction of gross proceeds received. The estimated fair value of the warrants issued to the placement agent was $112,096 and was recorded as a component of stockholders’ equity.

December 2011 Underwritten Offering

On December 6, 2011, the Company completed an underwritten public offering of 10,081,667 shares of its common stock and warrants to purchase up to an aggregate of 10,081,667 shares of its common stock at an exercise price of $0.60 per share, expiring on December 6, 2016, for gross proceeds of $6,049,000 and net proceeds of $5,298,140 after deducting transaction costs (the “Underwritten Offering”). The warrant exercise price and the common stock issuable pursuant to such warrant are subject to adjustment only for stock dividends, stock splits and similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of the warrant holders prior to such event. The relative fair value of the warrants issued to the investors was $2,350,320 at issuance and has been included as a component of stockholders’ equity. In connection with the Underwritten Offering, the Company paid to Rodman, the underwriting agent, a cash fee of $302,000, which was recorded as a reduction of the gross proceeds received.

Common Stock Warrants

The Company uses the Black-Scholes option pricing model to value warrants and applies assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants.

The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2012. There were no outstanding common stock purchase warrants as of March 31, 2011.

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date

December 6, 2011 Underwritten Offering		10,081,667	$	0.60		December 6, 2016
April 8, 2011 Private Placement		6,839,468	$	0.75		March 31, 2016
Legacy warrants (1)		50,419	$	0.60		July 27, 2015
Legacy warrants		105,040	$	16.065		July 27, 2015
Legacy warrants		91,524	$	99.45-100.98		December 31, 2015
Legacy warrants		8,561	$	191.25		May 2, 2012

Total		17,176,679

(1) The exercise prices of these warrants are subject to adjustment for “down-rounds” and have been accounted for as derivative instruments as described in Note 2.

On March 28, 2012, the Company issued 10,285 shares of common stock in connection with the cashless exercise of warrants to purchase 27,310 shares of common stock. The warrants had an expiration date of July 27, 2015 and an exercise price of $0.60 per share. The Company reclassified $19,754 from the derivative liability to additional paid-in capital upon the exercise of the warrants.

On March 28, 2012, the Company issued 44,155 shares of common stock in connection with the cashless exercise of warrants to purchase 200,000 shares of common stock. The warrants had an expiration date of March 31, 2016 and an exercise price of $0.75 per share.

On April 26, 2012, the Company issued 582,981 shares of common stock in connection with the cashless exercise of warrants to purchase 833,333 shares of common stock. The warrants had an expiration date of December 6, 2016 and an exercise price of $0.60 per share.

On April 30, 2012, the Company issued 25,000 shares of common stock upon the cashless exercise of warrants to purchase 40,783 shares of common stock. The warrants had an expiration date of March 31, 2016 and an exercise price of $0.75 per share.

5. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for non-performance based awards is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Evaluation of the probability of meeting performance targets is evaluated at the end of each reporting period. Non-employee stock-based compensation is accounted for in accordance with the guidance of FASB ASC Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection with stock options granted to non-employee consultants:

	Three Months Ended March 31,				Cumulative Development- Stage Period from November 7, 2002 through March 31,
	2012		2011		2012
Employee and director stock option grants:
Research and development	$	78,044	$	23,526	$	566,602
General and administrative		248,968		34,936		2,397,155
		327,012		58,462		2,963,757
Non-employee consultant stock option grants:
Research and development		47,014		—		83,171
General and administrative		43,327		—		225,298
		90,341		—		308,469

Total stock-based compensation	$	417,353	$	58,462	$	3,272,226

During 2011, the Company granted options to purchase 670,200 shares of common stock that vest based upon the achievement of performance-based milestones. As of March 31, 2012, 335,100 of these performance-based awards remain outstanding. No compensation expense has been recognized related to the performance-based awards as the Company does not believe that it is probable that the performance targets will be met.

Stock Option Activity

A summary of stock option activity under stock option plans is as follows:

	Number of Shares Issuable Upon Exercise of Outstanding Options		Weighted Average Exercise Price		Weighted Average Remaining Contracted Term in Years		Aggregate Intrinsic Value
Outstanding at December 31, 2011		4,827,638	$	1.82
Granted		—
Canceled		—
Outstanding at March 31, 2012		4,827,638	$	1.82

Vested, March 31, 2012		1,096,038	$	4.27		9.09	$	56,121
Unvested, March 31, 2012		3,731,600	$	1.10		9.34	$	527,919
Exercisable at March 31, 2012		1,096,038	$	4.27		9.09	$	56,121

No stock option awards were granted in the three months ended March 31, 2012 or 2011.

The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.

As of March 31, 2012, there was $1,935,626 of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize $748,791, $728,122, $352,444 and $106,269 during 2012, 2013, 2014 and 2015, respectively. The Company expects 3,396,500 in unvested options, excluding performance-based awards, to vest in the future. The weighted-average grant-date fair value of vested and unvested options outstanding at March 31, 2012 was $1.15 and $0.89, respectively. There were no Cellectar options outstanding as of March 31, 2011.

6. INCOME TAXES

The Company accounts for income taxes in accordance with the liability method of accounting. Under this guidance, deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the three months ended March 31, 2012 or 2011 because the Company has experienced losses on a tax basis since inception. Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax asset.

The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions.

7. NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options and convertible debt. Since there is a net loss attributable to common stockholders for the three months ended March 31, 2012 and 2011, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

	Three Months Ended March 31,				Cumulative Development- Stage Period from November 7, 2002 (inception) through March 31,
	2012		2011		2012
Convertible debt		—		3,822,062		—
Warrants		17,176,679		—		17,176,679
Stock options		4,827,638		—		4,827,638

8. CONTINGENCIES

Litigation

Following the Acquisition, the Company is party to certain legal matters that existed with Novelos prior to the Acquisition. The following summarizes the status of those matters.

Class Action

A putative federal securities class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on behalf of himself and all others who purchased or otherwise acquired Novelos common stock in the period between December 14, 2009 and February 24, 2010, against Novelos and its President and Chief Executive Officer, Harry S. Palmin. On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs’ counsel. On October 22, 2010, an amended complaint was filed. The amended complaint claims, among other things, that Novelos violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer. On December 6, 2010, the defendants filed a motion to dismiss the complaint with prejudice. On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, the defendants filed their response to the opposition. On June 23, 2011, the motion to dismiss was granted and the case was dismissed without prejudice. Because the dismissal was without prejudice, the plaintiffs could reinstitute the proceeding by filing an amended complaint. On August 5, 2011, the plaintiffs filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. On September 9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiffs’ opposition to the motion was filed on October 14, 2011 and the defendants filed a reply brief on November 4, 2011. The Company and Mr. Palmin believe the allegations are without merit and intend to continue to vigorously defend against them.

BAM Dispute

On June 28, 2010, Novelos received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as “BAM”) alleging that it modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement Novelos had entered into with BAM on June 20, 2000 (the “June 2000 Agreement”). The letter references the amendment, submitted to the FDA on August 30, 2005, to Novelos’ investigational new drug application dated August 1999 as the basis for BAM’s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM. Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM. On September 24, 2010, Novelos filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the “April 2005 Agreement”), that Novelos’ obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied. On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, Novelos responded to the counterclaims, denying BAM’s material allegations and stating its affirmative defenses. On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos’ acquisition of Cellectar. In that amended counterclaim, BAM alleges that the acquisition evidences Novelos’ abandonment of the technology assigned to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement. On June 15, 2011 the Company filed its response to their amended counterclaim. On August 5, 2011, the Company filed a motion for judgment on the pleadings as to its declaratory judgment count and all counts of BAM’s amended counterclaim. The motion was opposed by BAM and a hearing on the motion was held on September 27, 2011. On October 17, 2011, the court ruled on the Company’s behalf for each of its declaratory judgment claims and dismissed all counts of BAM’s counterclaim. Judgment in favor of the Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.

We do not anticipate that these litigation contingencies will have a material impact on the Company’s future financial position, results of operations or cash flows.

9. RELATED PARTY TRANSACTIONS

Jamey Weichert, the Company’s Chief Scientific Officer and principal founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”).

During the three months ended March 31, 2012, the Company made contributions to UW totaling $81,500 for use towards unrestricted research activities and paid UW $92,754 for costs associated with clinical trial agreements. No payments were made during the three months ended March 31, 2011.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This quarterly report on Form 10-Q includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act. For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We cannot guarantee that we actually will achieve the plans, intentions or expectations disclosed in our forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those disclosed in the forward-looking statements we make. These important factors include our significant accounting estimates and the risk factors set forth below under the caption “Risk Factors”. Although we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the date of this quarterly report.

Acquisition

On April 8, 2011, we completed the Acquisition. Immediately prior to the Acquisition, we completed a 1-for-153 reverse split of our common stock. We then issued 17,001,596 shares of our common stock to the former shareholders of Cellectar as consideration for the Acquisition, constituting approximately 85% of our outstanding common stock after giving effect to the Acquisition. Upon the closing of the Acquisition, we completed the private placement of 6,846,537 shares of our common stock and warrants to purchase an additional 6,846,537 shares of our common stock. The Acquisition was accounted for as a reverse acquisition whereby Cellectar, Inc. was treated as the acquirer for accounting and financial reporting purposes. As such, references to the results of operations for the three months ended March 31, 2011 represent the historical results of Cellectar. References to the results of operations for the three months ended March 31, 2012 include the consolidated results of the combined company from January 1, 2012 through March 31, 2012.

As a result of the Acquisition, we have implemented a revised business plan focused on the development of the Cellectar compounds. We conduct our operations from our headquarters in Madison, Wisconsin and our executive offices are in Newton, Massachusetts. Further development of our other compounds (NOV-002 and NOV-205) has been suspended.

Overview

We are a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer. We believe our three cancer-targeted compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. Thus, our therapeutic compounds appear to directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. I-124-CLR1404 (LIGHT) is a small-molecule cancer-targeted positron emission tomography (PET) imaging agent. We believe LIGHT has first-in-class potential, and Phase 1-2 clinical trials are ongoing. I-131-CLR1404 (HOT) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells. We believe HOT also has first-in-class potential. A HOT Phase 1b dose-escalation trial is ongoing and, subject to our obtaining additional funding, we expect HOT to enter Phase 2 trials in the first quarter of 2013, as a monotherapy for solid tumors with significant unmet medical need. CLR1404 (COLD), a pre-clinical cancer-targeted non-radioactive chemotherapy, works primarily through Akt inhibition. Together, we believe our compounds are able to “find, treat and follow” cancer anywhere in the body in a novel, effective and highly selective way.

LIGHT is a small-molecule imaging agent that we believe has first-in-class potential for selective detection of tumors and metastases in a broad range of cancers. LIGHT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD, acting as a cancer-targeted delivery and retention vehicle) labeled with the short-lived radioisotope, iodine-124, a new PET imaging isotope. PET imaging used in conjunction with CT scanning has now become the imaging method of choice in oncology. In studies to date, LIGHT selectively illuminated malignant tumors in 52 of 54 animal models of cancer, demonstrating evidence of broad-spectrum, cancer-selective uptake and retention. Investigator-sponsored Phase 1-2 trials of LIGHT as a PET imaging agent are ongoing at the University of Wisconsin. The trials include lung cancer, brain cancer and, starting in the second quarter of 2012, other solid tumors. These human trials, if successful, will serve three important purposes. First, they would provide proof-of-concept for LIGHT itself as a PET imaging agent with the potential to supplant the current “gold standard” agent, 18-fluoro-deoxyglucose (FDG), due to what we believe to be LIGHT’s superior cancer-specificity and more favorable logistics of clinical use. Second, favorable results would advance potential partnering discussions for LIGHT. Third, tumor uptake data will accelerate clinical development of HOT by predicting efficacy and enabling calculation of efficacious doses of HOT for Phase 2 trials.

HOT (iodine-131 radiolabeled CLR1404) is a small-molecule, broad-spectrum, cancer-targeted molecular radiotherapeutic that we believe has first-in-class potential. HOT is comprised of a small, non-pharmacological quantity of CLR1404 (COLD) acting as a cancer-targeted delivery and retention vehicle and incorporating a cytotoxic (cell-killing) dose of radiotherapy (in the form of iodine-131, a radioisotope that is already in common use to treat thyroid and other cancer types). It is this “intracellular radiation” mechanism of cancer cell killing, coupled with selective delivery to a wide range of malignant tumor types that we believe imbues HOT with broad-spectrum anti-cancer activity. Selective uptake and retention has also been demonstrated in cancer stem cells compared with normal stem cells, offering the prospect of longer lasting cancer remission. In 2009 we filed an IND with the FDA to study HOT in humans. In early 2010 we successfully completed a Phase 1a dosimetry trial demonstrating initial safety, tumor imaging and pharmacokinetic consistency and establishing a starting dose for a Phase 1b dose-escalation trial. Radiation dosimetry measures how much radiation is absorbed by tumors and body organs in order to optimize delivery of radiation therapy. The ongoing Phase 1b dose-escalation trial is aimed at determining the Maximum Tolerated Dose of HOT. We expect to initiate HOT Phase 2 efficacy trials as a monotherapy for solid tumors with significant unmet medical need as soon as a minimal efficacious dose is established, in the event that we obtain the additional funding necessary for that purpose. We may determine such an effective dose upon seeing a tumor response in the Phase 1b trial or calculating it from ongoing PET imaging trials in cancer patients with LIGHT (since PET imaging is quantitative, enabling determination of tumor radiation exposure at a given dose level). Preclinical in vitro (in cell culture) and in vivo (in animals) experiments have demonstrated selective killing of cancer cells along with a benign safety profile. HOT’s anti-tumor/survival-prolonging activities have been demonstrated in more than a dozen xenograft models (human tumor cells implanted into animals) including breast, prostate, lung, glioma (brain), pancreatic, ovarian, uterine, renal and colorectal cancers and melanoma. In all but two models, a single administration of a well-tolerated dose of HOT was sufficient to demonstrate efficacy. In view of HOT’s selective uptake and retention in a wide range of solid tumors and in cancer stem cells, its single-agent efficacy in xenograft models and its non-specific mechanism of cancer-killing (radiation), we expect first to develop HOT as a monotherapy, initially for solid tumors.

COLD is a cancer-targeted chemotherapy that, in pre-clinical experiments, has been observed to inhibit the phosphatidylinosotol 3-kinase (PI3K)/Akt survival pathway, which is overexpressed in many types of cancer. As a result, in such pre-clinical experiments COLD has been observed to selectively inhibit Akt activity, induce apoptosis through caspase activation and inhibit cell proliferation in cancer cells versus normal cells. COLD also exhibits significant in vivo efficacy in mouse xenograft tumor models, including non-small cell lung cancer and triple-negative breast cancers, producing long-lasting tumor growth suppression and significantly increased survival. We believe COLD has the potential to be best-in-class versus other Akt inhibitors in development due to (a) cancer cell/cancer stem cell targeting, resulting in cancer-selective inhibition of Akt and cell proliferation or (b) suitability for intravenous administration that we believe offers the prospect of greater systemic exposure and hence Akt inhibition in cancer cells, which we believe would result in superior efficacy.

Prior to the Acquisition, for more than 10 years, Novelos had been developing oxidized glutathione-based compounds for the treatment of cancer, including NOV-002, an injectable small-molecule compound based on a proprietary formulation of oxidized glutathione that Novelos had been developing for use in combination with standard-of-care chemotherapies for the treatment of solid tumors. From 2005 through 2010 Novelos raised approximately $67 million in capital for the development of our compounds. From November 2006 through January 2010, Novelos conducted a Phase 3 trial of NOV-002 plus first-line chemotherapy in advanced non-small cell lung cancer which, when completed in February 2010, did not meet its primary and secondary efficacy endpoints. Following the completion of the Phase 3 trial, Novelos continued clinical development of NOV-002 in breast cancer and NOV-205 in hepatitis C during 2010, although further development of those compounds was later suspended. Novelos also explored strategic alternatives, which resulted in the completion of the Acquisition in April 2011.

Results of Operations

Executive summary. In March 2010, Cellectar completed a Phase 1a dosimetry trial of HOT in humans (the “Phase 1a Trial”), demonstrating initial safety and establishing dosing parameters for a Phase 1b dose-escalation trial. Following the completion of the Phase 1a Trial and as a result of limited funding, Cellectar suspended research and manufacturing activities, terminated certain non-key personnel and implemented salary reductions in an effort to contain costs while Cellectar concentrated on its fundraising efforts. These cost reduction efforts, implemented in 2010, continued in the three-month period ended March 31, 2011. The increases in research and development costs for the three months ended March 31, 2012 compared to 2011 are primarily attributable to the cessation of these cost reduction efforts and recommencement of research activities following the Acquisition, as well as costs associated with the on-going clinical trials in LIGHT and HOT.

Research and development expense. Research and development expense consists of costs incurred in identifying, developing and testing, and manufacturing product candidates, which primarily include salaries and related expenses for personnel, costs of our research and manufacturing facility, costs of manufacturing materials, fees paid to professional service providers for independent monitoring and analysis of our clinical trials, and costs to secure intellectual property. The Company analyzes its research and development expenses based on four categories as follows: clinical projects, preclinical projects, chemistry and manufacturing costs, and general fixed and overhead costs that are not allocated to the functional project costs, including personnel costs, manufacturing facility costs, related overhead costs and patent costs.

General and administrative expense. General and administrative expense consists primarily of salaries and other related costs for personnel in executive, finance and administrative functions. Other costs include insurance, costs for public and investor relations, directors’ fees and professional fees for legal and accounting services.

Three Months Ended March 31, 2012 and 2011

Research and Development. Research and development expense for the three months ended March 31, 2012 was approximately $1,328,000 (comprised of approximately $254,000 in clinical project costs, $70,000 of preclinical project costs, $62,000 of manufacturing and related costs and $942,000 in general unallocated research and development costs) compared to approximately $471,000 (comprised of $3,000 of preclinical project costs, $3,000 of manufacturing and related costs and $465,000 in general unallocated research and development costs) for 2011. The approximately $857,000, or 181.9%, increase in research and development resulted from increases in all categories. The $254,000 increase in clinical projects and the $59,000 increase in manufacturing and related costs in the three months ended March 31, 2012 versus 2011 were related to costs associated with the Company’s Phase 1-2 trial for LIGHT and its Phase 1b trial for HOT. The $67,000 increase in preclinical costs for the three months ended March 31, 2012 versus 2011 was related to contributions made to the UW for use towards unrestricted research activities. The $477,000 increase in general unallocated research and development costs for the three months ended March 31, 2012 versus 2011 was primarily due to an approximately $217,000 increase in salary costs as a result of increases in personnel following the Acquisition and the removal of salary reductions that were in place in the first quarter of 2011 in order to conserve cash, an approximately $102,000 increase in stock-based compensation resulting from stock options granted during 2011, an approximately $57,000 increase in patent costs as well as increases in subcontracted services, facilities and equipment maintenance costs incurred as we continue manufacturing and research activities in support of the ongoing clinical trials.

General and Administrative. General and administrative expense for the three months ended March 31, 2012 was approximately $998,000 compared to approximately $132,000 in 2011. The $866,000, or 656.1%, increase in general and administrative costs were primarily related to the following items: salary increased approximately $242,000 resulting from the addition of employees following the Acquisition and the removal of salary reductions that were in place in the first quarter of 2011 in order to conserve cash; stock-based compensation increased by $257,000 associated with stock options granted in 2011; the cost of subcontracted services increased by approximately $235,000 as a result of increased legal and accounting fees, investor relations activities, directors’ fees and costs associated with public company reporting. Insurance costs increased approximately $34,000, rent increased approximately $18,000 associated with the addition of the Massachusetts location and travel costs increased approximately $14,000 due principally to an increase in travel between our Massachusetts and Wisconsin offices.

Merger Costs. Merger costs during the three months ended March 31, 2012 were $0 compared to approximately $250,000 in legal related fees in connection with the Acquisition for the same period in 2011.

Grant income. Qualifying therapeutic discovery projects, among others, include those designed to treat or prevent diseases or conditions by conducting clinical or pre-clinical activities for the purpose of securing FDA approval of a product. The Company received payments of approximately $44,000 in the three months ended March 31, 2011, under a cash grant from the U.S. Internal Revenue Service as a qualifying therapeutic discovery project credit pursuant to Patient Protection and Affordable Care Act. The payment has been recorded as a component of other income in the three months ended March 31, 2011. No grant income was received in the three months ended March 31, 2012.

Loss on Derivative Warrants. We recorded a loss on derivative warrants of approximately $29,000 in the three months ended March 31, 2012. This amount represents the change in fair value, during the respective period, of outstanding warrants that contain “down-round” anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants is subject to change in the event of certain issuances of stock at prices below the then-effective exercise prices of the warrants.

Interest expense, net. Interest expense, net, for the three months ended March 31, 2012 and 2011 consists approximately of the following:

	Three Months Ended March 31,
	2012			2011

Interest expense, convertible notes	$	—		$	(146,000	)
Interest expense, bank note		—			(12,000	)
Interest expense, other		(2,000	)		—
Interest income		—			2,000
	$	(2,000	)	$	(156,000	)

The decrease in interest expense on the convertible notes and bank note was a result of the settlement of those obligations in April 2011. Interest expense in 2012 relates to notes payable to the Wisconsin Department of Commerce issued in September 2010.

Liquidity and Capital Resources

We have financed our operations since inception primarily through the sale of equity securities and securities convertible into equity securities. To date, Cellectar and Novelos have raised capital aggregating approximately $110 million. Novelos has raised capital aggregating approximately $83 million, including proceeds from the April 2011 private placement and the December 2011 underwritten offering. Since its inception and prior to the Acquisition, Cellectar had raised capital aggregating approximately $27 million. As of March 31, 2012, we had approximately $3,788,000 in cash and cash equivalents.

During the three months ended March 31, 2012, approximately $1,703,000 in cash was used in operations. During this period we reported a net loss of approximately $2,357,000. However, this loss included the following non-cash items: approximately $140,000 in depreciation and amortization expense, approximately $417,000 in stock-based compensation, and approximately $29,000 in loss on derivative warrants. After adjustment for these non-cash items, we used approximately $6,000 in cash for the payment of accounts payable and accrued liabilities. Other changes in working capital provided cash of $75,000.

During the three months ended March 31, 2012, we purchased approximately $15,000 of equipment.

The accompanying consolidated financial statements have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. We have incurred losses since inception in devoting substantially all of our efforts toward research and development and have an accumulated deficit of $33,837,329 at March 31, 2012. During the three months ended March 31, 2012, we generated a net loss of $2,356,903 and we expect that we will continue to generate operating losses for the foreseeable future. At March 31, 2012, our cash balance was approximately $3,788,000. We believe our cash on hand is adequate to fund operations into the middle of the third quarter of 2012. Our ability to execute our operating plan beyond that time depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. On April 9, 2012, we filed with the SEC a Registration Statement on Form S-1 for the sale of units consisting of common stock and warrants for gross proceeds of up to $10,000,000. The registration statement has not yet become effective. There can be no assurance that the registration statement will become effective or that any securities will be sold pursuant to it. We plan to actively pursue this and other financing alternatives; however we have not entered into negotiations for any such alternative transaction. There can be no assurance that we will obtain the funding necessary to execute our operating plan. Other than the uncertainties regarding our ability to obtain additional funding, there are currently no known trends, demands, commitments, events or uncertainties that are likely to materially affect our liquidity.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2012. Disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, are controls and procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive and financial officers, to allow timely decisions regarding required disclosures.

Based on the evaluation of our disclosure controls and procedures as of March 31, 2012 our Chief Executive Officer and our Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were operating effectively.

Change in Internal Control over Financial Reporting

The Company’s management, in connection with its evaluation of internal controls (with the participation of the Company’s principal executive officer and principal financial officer), did not identify any change in internal control over the financial reporting process that occurred during the Company’s first quarter of 2012 that would have materially affected, or would have been reasonably likely to materially affect, the Company’s internal control over financial reporting.

Limitations on Effectiveness of Controls

In designing and evaluating our disclosure controls and procedures, our management recognizes that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system are met. In addition, the design of any control system is based in part on certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

PART II

Item 1. Legal Proceedings

Item 1A. Risk Factors

We will require additional capital in order to continue our operations, and may have difficulty raising additional capital.

We expect that we will continue to generate significant operating losses for the foreseeable future. At March 31, 2012, our consolidated cash balance was approximately $3,788,000. We believe our cash on hand is adequate to fund operations into the middle of the third quarter of 2012. We have expended and expect to continue to expend substantial funds on the research, development and clinical and pre-clinical testing of our drug compounds. We will require additional funds to conduct research and development, establish and conduct clinical and pre-clinical trials, establish commercial-scale manufacturing arrangements and provide for the marketing and distribution of our products. Our ability to execute our operating plan depends on our ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. There can be no assurance that we will obtain the necessary funding or that it will be available on a timely basis or upon terms acceptable to us. If we obtain capital by issuing debt or preferred stock, the holders of such securities would likely obtain rights that are superior to those of holders of our common stock.

Our capital requirements and our ability to meet them depend on many factors, including:

	·	the number of potential products and technologies in development;
	·	continued progress and cost of our research and development programs;
	·	progress with clinical trials and pre-clinical studies;
	·	the time and costs involved in obtaining regulatory clearance;
	·	costs involved in preparing, filing, prosecuting, maintaining and enforcing patent claims;
	·	costs of developing sales, marketing and distribution channels and our ability to sell our drugs;
	·	costs involved in establishing manufacturing capabilities for clinical trial and commercial quantities of our drugs;
	·	competing technological and market developments;
	·	market acceptance of our products;
	·	costs for recruiting and retaining management, employees and consultants;
	·	costs for educating physicians regarding the application and use of our products;
	·	whether or not we obtain listing on a national exchange and, if not, our prospects for obtaining such listing;
	·	uncertainty and economic instability resulting from terrorist acts and other acts of violence or war; and
	·	the condition of capital markets and the economy generally, both in the U.S. and globally.

We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding sooner than expected. We may seek to raise any necessary additional funds through the issuance of warrants, equity or debt financings or executing collaborative arrangements with corporate partners or other sources, which may be dilutive to existing stockholders or have a material effect on our current or future business prospects. In addition, in the event that additional funds are obtained through arrangements with collaborative partners or other sources, we may have to relinquish economic and/or proprietary rights to some of our technologies or products under development that we would otherwise seek to develop or commercialize by ourselves. If we cannot secure adequate financing when needed, we may be required to delay, scale back or eliminate one or more of our research and development programs or to enter into license or other arrangements with third parties to commercialize products or technologies that we would otherwise seek to develop ourselves and commercialize ourselves. In such event, our business, prospects, financial condition, and results of operations may be adversely affected.

We are a development stage company with a history of losses and can provide no assurance of our future operating results.

We are a development stage company and have incurred net losses and negative cash flows since inception. We currently have no product revenues, and may not succeed in developing or commercializing any products that generate product or licensing revenues. We do not expect to have any products on the market for several years. Our primary activity to date has been research and development. In addition, development of our product candidates requires a process of clinical and pre-clinical testing, during which our product candidates could fail. We may not be able to enter into agreements with one or more companies experienced in the manufacturing and marketing of therapeutic drugs and, to the extent that we are unable to do so, we will not be able to market our product candidates. Whether we achieve profitability will depend on our success in developing, manufacturing, and marketing our product candidates. We have experienced net losses and negative cash flows from operating activities since inception and we expect such losses and negative cash flows to continue in the foreseeable future. For the period from Cellectar’s inception in November 2002 until the business combination with Novelos on April 8, 2011, and thereafter through March 31, 2012, Cellectar (and, from and after the business combination, the Company) incurred aggregated net losses of $33,837,329. Net loss for the three months ended March 31, 2012 was $2,356,903. We may never achieve profitability.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

On March 28, 2012, the Company issued 10,285 shares of our common stock upon the cashless exercise of warrants to purchase 27,310 shares of common stock. The warrants had an expiration date of July 27, 2015 and an exercise price of $0.60 per share.

On March 28, 2012, we issued 44,155 shares of our common stock upon the cashless exercise of warrants to purchase 200,000 shares of common stock. The warrants had an expiration date of March 31, 2016 and an exercise price of $0.75 per share.

These issuances were exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 3(a)(9) of the Securities Act, as the shares were issued in exchange for consideration consisting solely of other securities of the Company, as well as under Section 4(2) of the Securities Act, as a transaction not involving any public offering.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits.

			Incorporated by Reference
Exhibit No.	Description	Filed with this Form 10-Q	Form	Filing Date	Exhibit No.

2.1	Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011		8-K	April 11, 2011	2.1

3.1	Second Amended and Restated Certificate of Incorporation		8-K	April 11, 2011	3.1

3.2	Amended and Restated By-laws		8-K	June 1, 2011	3.1

4.1	Form of common stock certificate		S-1/A	November 9, 2011	4.1

31.1	Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X
32.1	Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101	Interactive Data Files	X

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	NOVELOS THERAPEUTICS, INC.

Date: May 4, 2012	By:	/s/ Harry S. Palmin
		Harry S. Palmin
		President and Chief Executive Officer

Exhibit Index

			Incorporated by Reference
Exhibit No.	Description	Filed with this Form 10-Q	Form	Filing Date	Exhibit No.

2.1	Agreement and Plan of Merger by and among Novelos Therapeutics, Inc., Cell Acquisition Corp. and Cellectar, Inc. dated April 8, 2011		8-K	April 11, 2011	2.1

3.1	Second Amended and Restated Certificate of Incorporation		8-K	April 11, 2011	3.1

3.2	Amended and Restated By-laws		8-K	June 1, 2011	3.1

4.1	Form of common stock certificate		S-1/A	November 9, 2011	4.1

31.1	Certification of chief executive officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X

31.2	Certification of chief financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	X
32.1	Certification of chief executive officer and chief financial officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X

101	Interactive Data Files	X

EX-31.1 2 v310237_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

I, HARRY S. PALMIN, certify that:

I have reviewed this quarterly report on Form 10-Q of Novelos Therapeutics, Inc., a Delaware Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2012

/s/ Harry S. Palmin

Harry S. Palmin

President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 v310237_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

I, JOANNE M. PROTANO, certify that:

I have reviewed this quarterly report on Form 10-Q of Novelos Therapeutics, Inc., a Delaware Corporation;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2012

/s/ Joanne M. Protano

Joanne M. Protano

Chief Financial Officer (Principal Financial and Accounting Officer)

EX-32.1 4 v310237_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. § 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Novelos Therapeutics, Inc. (the “Company”) for the quarter ended March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Harry S. Palmin, President and Chief Executive Officer of the Company, and Joanne M. Protano, Vice President, Chief Financial Officer and Treasurer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to our knowledge, that:

1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Harry S. Palmin

Harry S. Palmin

President, Chief Executive Officer (Principal Executive Officer)

Date: May 4, 2012

/s/ Joanne M. Protano

Joanne M. Protano

Chief Financial Officer (Principal Financial and Accounting Officer)

Date: May 4, 2012

EX-101.INS 5 nvlt-20120331.xml XBRL INSTANCE DOCUMENT 37570245

298667

27222

3507

2275

506301

32397

183300

55000

8648503

369

580875

127368

36962264

7000

4025876

1675462

33837329

3787576

0.00001

41398287

471629

8648503

7561327

36962264

0.00001

2919943

150000000

1087176

450000

673739

27222

4091

2235

503581

23305

254967

55000

10563176

369

578472

124381

36907824

7000

5815927

1675462

31480426

5505960

0.00001

40961180

478041

10563176

9481123

36907824

0.00001

3044565

150000000

1082053

450000

31667

28500

905649

7000

-4663763

1161

33592768

250000

5192

-26835397

89520

145

439615

127368

3272226

91500

-36477

55000

-471765

1227944

19671

-33837329

-244561

22133353

-41004

2555809

-449197

5501741

19671

-33592768

5500730

244479

31874254

2720985

3787576

167130

78407

208689

463722

5500730

799133

10660282

35286736

1677945

-2.87

3184707 1675462 68093 11775244

853564

508

-324566

4323

58462

293383

49998

-965252

-111688

471404

144174

-156167

-853564

44479

-375072

5458

11563

145802

250434

131726

-50506

-0.08

12820102 Q1 NVLT NOVELOS THERAPEUTICS, INC. false Smaller Reporting Company 2012 10-Q 2012-03-31 0001279704 --12-31

<div style="FONT: 10pt Times New Roman, Times, Serif"> 4. STOCKHOLDERS’ EQUITY   April 2011 Private Placement   Concurrently with and conditioned upon the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement with certain accredited investors under which the Company sold an aggregate of 6,846,537 units, each unit consisting of one share of its common stock and a warrant to purchase one share of its common stock, at a price of $0.75 per unit, for gross proceeds of approximately $5,135,000 (the “April Private Placement”).  The warrants have an exercise price of $0.75 and expire on March 31, 2016.  The warrant exercise price and/or the common stock issuable pursuant to such warrant are subject to adjustment only for stock dividends, stock splits or similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of warrant holders prior to such event.  The relative fair value of the warrants issued to the investors was $2,124,286 at issuance and has been included as a component of stockholders’ equity.    The Securities Purchase Agreement includes certain registration requirements which were subsequently extended by the consent of purchasers holding a majority of shares of the Company’s common stock issued in the April Private Placement, which holders constituted the requisite holders, as defined. The Company is required to file with the SEC no later than May 29, 2012 (the "Filing Deadline") a registration statement covering the resale of the shares of common stock and the shares of common stock underlying the warrants issued pursuant to the Securities Purchase Agreement that are not otherwise saleable under an available exemption from registration requirements.  The Company is also required to use commercially reasonable efforts to have the registration statement declared effective by July 28, 2012 (the "Effectiveness Deadline"), and to keep the registration statement continuously effective under the Securities Act of 1933, as amended (the “Securities Act”), until the earlier of the date when all the registrable securities covered by the registration statement have been sold or the second anniversary of the closing.   In the event the Company fails to file the registration statement within the timeframe specified by the Securities Purchase Agreement, or if it fails to obtain effectiveness of this registration on or prior to July 28, 2012 (if there is no review by the SEC) or by August 28, 2012 (if there is review by the SEC) with respect to the maximum number of shares permitted to be registered by the SEC, the Company will be required to pay to the purchasers liquidated damages equal to 1.5% per month (pro-rated on a daily basis for any period of less than a full month) of the aggregate purchase price of the units purchased until the registration statement is filed or declared effective, as applicable, not to exceed 5% of the aggregate purchase price.  The Company will be allowed to suspend the use of the registration statement for not more than 30 consecutive days on not more than two occasions in any 12-month period.  The Company has also granted piggy-back registration rights with respect to any shares of common stock that it is required to exclude from the registration statement as a condition of its effectiveness, and has also agreed to file further registration statements with respect to any such shares six months after the effective date of the initial registration statement. As of March 31, 2012, and through the date of this filing, the Company has not concluded that it is probable that damages will become due; therefore, no accrual for damages has been recorded.    The Company paid to Rodman, the placement agent for the financing, a cash fee equal to $200,000 and issued warrants to purchase 192,931 shares of its common stock (having an exercise price of $0.75 and which expire March 31, 2016) in consideration for their advisory services with respect to the financing pursuant to the placement agency agreement between Rodman and the Company.  Rodman is entitled to registration rights with respect to the shares of common stock issuable upon exercise of these warrants.  The cash fee was recorded as a reduction of gross proceeds received.  The estimated fair value of the warrants issued to the placement agent was $112,096 and was recorded as a component of stockholders’ equity.   December 2011 Underwritten Offering   On December 6, 2011, the Company completed an underwritten public offering of 10,081,667 shares of its common stock and warrants to purchase up to an aggregate of 10,081,667 shares of its common stock at an exercise price of $0.60 per share, expiring on December 6, 2016, for gross proceeds of $6,049,000 and net proceeds of $5,298,140 after deducting transaction costs (the “Underwritten Offering”). The warrant exercise price and the common stock issuable pursuant to such warrant are subject to adjustment only for stock dividends, stock splits and similar capital reorganizations so that the rights of the warrant holders after such event will be equivalent to the rights of the warrant holders prior to such event. The relative fair value of the warrants issued to the investors was $2,350,320 at issuance and has been included as a component of stockholders’ equity.  In connection with the Underwritten Offering, the Company paid to Rodman, the underwriting agent, a cash fee of $302,000, which was recorded as a reduction of the gross proceeds received.   Common Stock Warrants   The Company uses the Black-Scholes option pricing model to value warrants and applies assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants.   The following table summarizes information with regard to outstanding warrants to purchase common stock as of March 31, 2012.  There were no outstanding common stock purchase warrants as of March 31, 2011.    <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td style="BORDER-BOTTOM: black 1pt solid; FONT-WEIGHT: bold"> Offering</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Number of Shares Issuable Upon Exercise of Outstanding Warrants</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2"> Expiration Date</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 47%">December 6, 2011 Underwritten Offering</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 12%">10,081,667</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">0.60</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 20%">December 6, 2016</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td>April 8, 2011 Private Placement</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">6,839,468</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.75</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">March 31, 2016</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Legacy warrants (1)</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">50,419</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">0.60</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">July 27, 2015</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Legacy warrants</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">105,040</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">16.065</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">July 27, 2015</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Legacy warrants</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">91,524</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">99.45-100.98</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">December 31, 2015</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Legacy warrants</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">8,561</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">191.25</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">May 2, 2012</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right">  </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Total</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 17,176,679</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   (1)  The exercise prices of these warrants are subject to adjustment for “down-rounds” and have been accounted for as derivative instruments as described in Note 2.   On March 28, 2012, the Company issued 10,285 shares of common stock in connection with the cashless exercise of warrants to purchase 27,310 shares of common stock. The warrants had an expiration date of July 27, 2015 and an exercise price of $0.60 per share. The Company reclassified $19,754 from the derivative liability to additional paid-in capital upon the exercise of the warrants.    On March 28, 2012, the Company issued 44,155 shares of common stock in connection with the cashless exercise of warrants to purchase 200,000 shares of common stock. The warrants had an expiration date of March 31, 2016 and an exercise price of $0.75 per share.   On April 26, 2012, the Company issued 582,981 shares of common stock in connection with the cashless exercise of warrants to purchase 833,333 shares of common stock. The warrants had an expiration date of December 6, 2016 and an exercise price of $0.60 per share.   On April 30, 2012, the Company issued 25,000 shares of common stock upon the cashless exercise of warrants to purchase 40,783 shares of common stock. The warrants had an expiration date of March 31, 2016 and an exercise price of $0.75 per share. </div>

-15149

2325985

544

-1702691

<div style="FONT: 10pt Times New Roman, Times, Serif"> 7.   NET LOSS PER SHARE   Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding.  Potential common stock equivalents consist of stock options and convertible debt.  Since there is a net loss attributable to common stockholders for the three months ended March 31, 2012 and 2011, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.   The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:   <table style="WIDTH: 80%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">Three Months Ended March 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center" colspan="2">Cumulative Development- Stage Period  from  November 7, 2002 (inception) through March 31,</td> <td style="PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 52%"> Convertible debt</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">  </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 12%"> 3,822,062</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">  </td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 15%"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Warrants</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 17,176,679</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 17,176,679</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Stock options</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,827,638</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,827,638</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table> </div>

2987

417353

-6412

-2356903

-30918

<div style="FONT: 10pt Times New Roman, Times, Serif"> 8.  CONTINGENCIES   Litigation   Following the Acquisition, the Company is party to certain legal matters that existed with Novelos prior to the Acquisition. The following summarizes the status of those matters.    Class Action   A putative federal securities class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on behalf of himself and all others who purchased or otherwise acquired Novelos common stock in the period between December 14, 2009 and February 24, 2010, against Novelos and its President and Chief Executive Officer, Harry S. Palmin.  On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs’ counsel.  On October 22, 2010, an amended complaint was filed.  The amended complaint claims, among other things, that Novelos violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer.  On December 6, 2010, the defendants filed a motion to dismiss the complaint with prejudice.  On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, the defendants filed their response to the opposition. On June 23, 2011, the motion to dismiss was granted and the case was dismissed without prejudice.  Because the dismissal was without prejudice, the plaintiffs could reinstitute the proceeding by filing an amended complaint.  On August 5, 2011, the plaintiffs filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. On September 9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiffs’ opposition to the motion was filed on October 14, 2011 and the defendants filed a reply brief on November 4, 2011. The Company and Mr. Palmin believe the allegations are without merit and intend to continue to vigorously defend against them.   BAM Dispute   On June 28, 2010, Novelos received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as “BAM”) alleging that it modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement Novelos had entered into with BAM on June 20, 2000 (the “June 2000 Agreement”).  The letter references the amendment, submitted to the FDA on August 30, 2005, to Novelos’ investigational new drug application dated August 1999 as the basis for BAM’s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM.  Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM.  On September 24, 2010, Novelos filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the “April 2005 Agreement”), that Novelos’ obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied.  On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, Novelos responded to the counterclaims, denying BAM’s material allegations and stating its affirmative defenses.  On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos’ acquisition of Cellectar.  In that amended counterclaim, BAM alleges that the acquisition evidences Novelos’ abandonment of the technology assigned to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement.  On June 15, 2011 the Company filed its response to their amended counterclaim.  On August 5, 2011, the Company filed a motion for judgment on the pleadings as to its declaratory judgment count and all counts of BAM’s amended counterclaim.  The motion was opposed by BAM and a hearing on the motion was held on September 27, 2011. On October 17, 2011, the court ruled on the Company’s behalf for each of its declaratory judgment claims and dismissed all counts of BAM’s counterclaim. Judgment in favor of the Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.   We do not anticipate that these litigation contingencies will have a material impact on the Company’s future financial position, results of operations or cash flows. </div>

1328314

-28846

<div style="FONT: 10pt Times New Roman, Times, Serif"> 3. ACQUISITION   Merger Agreement   On April 8, 2011, Novelos acquired Cellectar through a merger with and into the Merger Subsidiary, pursuant to the Merger Agreement entered into on that date.  As a result of the Acquisition, the Merger Subsidiary, which was renamed Cellectar, Inc., owns all assets of and operates the business previously owned and operated by Cellectar.    In the Acquisition, the former stockholders of Cellectar received an aggregate number of shares of Novelos common stock constituting approximately 85% of the outstanding shares of Novelos common stock, after giving effect to the Acquisition but before giving effect to the concurrent private placement of Novelos securities described below.  Prior to the Acquisition, Novelos amended and restated its certificate of incorporation and in connection therewith, among other things, effected a 1-for-153 reverse split of its common stock resulting in 2,959,871 shares of Novelos common stock outstanding. Novelos then issued 17,001,596 shares of Novelos common stock to the stockholders of Cellectar upon the effective date of the Acquisition.  Warrants and options to purchase Novelos common stock that were outstanding prior to the Acquisition remained outstanding following the Acquisition. These consist of warrants to purchase a total of 315,164 shares of Novelos common stock with prices ranging from $16.07 to $191.25 and options to purchase a total of 49,159 shares of Novelos common stock with prices ranging from $1.53 to $1,072.53.   XMS Capital Partners, the financial advisor to Cellectar in connection with the Acquisition, received a cash fee of $200,000 upon the completion of the Acquisition in consideration of their services.  Rodman & Renshaw, LLC (“Rodman”), financial advisor to Novelos in connection with the Acquisition, received a cash fee of $250,000 upon the completion of the Acquisition in consideration of their services.  These amounts were recorded as merger costs and expensed as incurred on the date of the Acquisition.  In addition to the investment banking fees, the Company also incurred an additional $250,434 of merger-related legal and other costs during the three months ended March 31, 2011 which were included as a component of expense in the respective period.   The Acquisition was completed principally to leverage synergies between Novelos’ strategic focus and experience in developing and funding the development of cancer drugs and Cellectar’s portfolio of cancer-targeted compounds.   Purchase Accounting   The Acquisition was accounted for using the purchase method of accounting as a reverse acquisition.  In a reverse acquisition, the post-acquisition net assets of the surviving combined company includes the historical cost basis of the net assets of the accounting acquirer (Cellectar) plus the fair value of the net assets of the accounting acquiree (Novelos).  Further, under the purchase method, the purchase price is allocated to the assets acquired, liabilities assumed and identifiable intangible assets based on their estimated fair values with the remaining excess purchase price over net assets acquired allocated to goodwill.    The fair value of the consideration transferred in the Acquisition was $2,219,903 and was calculated as the number of shares of common stock that Cellectar would have had to issue (adjusted for the Exchange Ratio) in order for Novelos shareholders to hold a 15% equity interest in the combined Company post-acquisition (but prior to the concurrent private placement), multiplied by the estimated fair value of the Company’s common stock on the acquisition date.  The estimated fair value of the Company’s common stock was based on the offering price of the common stock sold in the private placement which was both completed concurrently with and conditioned upon the closing of the Acquisition.  This price was determined to be the best indication of fair value on that date since the price was based on an arm’s length negotiation with a group consisting of both new and existing investors that had been advised of the pending Acquisition and assumed similar liquidity risk as those investors holding the majority of shares being valued as purchase consideration.   The following table summarizes the Company’s determination of fair values of the assets acquired and the liabilities as of the date of acquisition.   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 87%"> Consideration - issuance of securities</td> <td style="PADDING-BOTTOM: 2.5pt; WIDTH: 1%"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left; WIDTH: 1%"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right; WIDTH: 10%"> 2,219,903</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt; WIDTH: 1%">  </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Prepaid expenses and other assets</td> <td> </td> <td style="TEXT-ALIGN: left">$</td> <td style="TEXT-ALIGN: right">71,892</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Fixed assets</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">6,515</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Accrued liabilities</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(380,130</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Derivative liability</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">(59,485</td> <td style="TEXT-ALIGN: left">)</td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt">Goodwill</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 1,675,462</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total purchase price – net of cash acquired of $905,649</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,314,254</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>    The Company determined that the acquired Novelos legacy technology had no value as of the date of the acquisition.   Goodwill   Of the total purchase price of $2,219,903, $1,675,462 was allocated to goodwill. Goodwill represents the excess of the purchase price of an acquired business over the fair value of the underlying net tangible and intangible assets. The goodwill includes the value of the Novelos work force (management team). None of the goodwill associated with the Acquisition is deductible for income tax purposes.   The Company is required to perform an annual impairment test related to goodwill, which is performed in the fourth quarter of each year, or sooner if changes in circumstances suggest that the carrying value of an asset may not be recoverable. There were no changes in circumstances that would suggest that the goodwill is not recoverable. There were no changes in goodwill during the three months ended March 31, 2012. </div>

139771

-2072

15149

-2325985

-1718384

-71667

<div style="FONT: 10pt Times New Roman, Times, Serif"> 1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN   Novelos Therapeutics, Inc. (“Novelos” or the “Company”) is a pharmaceutical company developing compounds for the treatment and diagnosis of cancer. On April 8, 2011, Novelos completed a business combination with Cellectar, Inc. (“Cellectar”), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers, and Cell Acquisition Corp. (the “Merger Subsidiary”), a Wisconsin corporation and a wholly owned subsidiary of Novelos. Pursuant to the transaction Cellectar was merged into the Merger Subsidiary (the “Acquisition”, see Note 3). References in these financial statements and notes to “Cellectar” relate to the activities and financial information of Cellectar prior to the Acquisition, references to “Novelos” relate to the activities and financial information of Novelos prior to the Acquisition and references to “the Company” or “we” or “us” or “our” relate to the activities and obligations of the combined Company following the Acquisition.   Immediately prior to the Acquisition, Novelos completed a 1-for-153 reverse split of its common stock.  Novelos then issued to the shareholders of Cellectar at that date 17,001,596 shares of its common stock as consideration for the Acquisition, representing a ratio of 0.8435 shares of Novelos common stock in exchange for one share of Cellectar common stock (the “Exchange Ratio”) as set forth in the Agreement and Plan of Merger (the “Merger Agreement”) dated April 8, 2011.  The shares issued to Cellectar shareholders in the Acquisition constituted approximately 85% of Novelos’ outstanding common stock after giving effect to the Acquisition.   Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes.  Accordingly, the Acquisition was accounted for as a reverse acquisition whereby Cellectar, Inc. was treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein as of and for the three months ended March 31, 2011 represent the historical financial information of Cellectar, except for the capital structure which represents the historical amounts of Cellectar, retroactively adjusted to reflect the legal capital structure of Novelos by applying the Exchange Ratio. On April, 8, 2011, Cellectar was merged into the Merger Subsidiary a wholly owned subsidiary of Novelos; as such, the financial statements presented herein as of and for the three months ended March 31, 2012 include the consolidated results of the combined company from January 1, 2012 through March 31, 2012.  All per-share amounts and outstanding shares, including all common stock equivalents, and stock options, have been retroactively restated in these financial statements and notes for all periods presented to reflect the capital structure of Novelos by applying the Exchange Ratio. The number of authorized shares of common stock disclosed on the balance sheet (150,000,000) represents the number of authorized shares of Novelos common stock following the Acquisition.   As a result of the Acquisition, the Company has implemented a revised business plan focused on the development of the Cellectar compounds.  Development of Novelos’ other compounds (NOV-002 and NOV-205) has been suspended.  The Company conducts its operations from its headquarters in Madison, Wisconsin and the Company’s executive offices are in Newton, Massachusetts.   The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.    The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception in devoting substantially all of its efforts toward research and development and has an accumulated deficit of $33,837,329 at March 31, 2012. During the three months ended March 31, 2012, the Company generated a net loss of $2,356,903 and the Company expects that it will continue to generate operating losses for the foreseeable future.  The Company believes that its cash on hand is adequate to fund operations into the middle of the third quarter of 2012.  The Company’s ability to execute its operating plan beyond that time depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise.  The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding.  The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.    The accompanying balance sheet as of December 31, 2011 has been derived from audited financial statements. The accompanying unaudited consolidated balance sheet as of March 31, 2012, the consolidated statements of operations for the three months ended March 31, 2012 and 2011 and the cumulative period November 7, 2002 (date of inception) through March 31, 2012, and the consolidated statements of cash flows for the three months ended March 31, 2012 and 2011 and the cumulative period November 7, 2002 (date of inception) through March 31, 2012 and the related interim information contained within the notes to the consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s consolidated financial position at March 31, 2012 and consolidated results of its operations and its cash flows for the three months ended March 31, 2012 and 2011 and the period from November 7, 2002 (inception) to March 31, 2012. The results for the three months ended March 31, 2012 are not necessarily indicative of future results.   These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K, which was filed with the SEC on March 9, 2012.   Goodwill — Intangible assets at March 31, 2012 consist of goodwill recorded in connection with the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount.   Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Topic 505, Equity of the Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”).  As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.     Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable and long-term obligations.  The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature.  The carrying value of long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.   Derivative Instruments   – The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks.  However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities.  In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 50,419 at March 31, 2012. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock.  Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At March 31, 2012 and December 31, 2011, these warrants represented the only outstanding derivative instruments issued or held by the Company.    New Accounting Pronouncements — In May 2011, the FASB issued ASU No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. Generally Accepted Accounting Principles (“GAAP”) and International Financial Reporting Standards (“IFRSs”).  This standard updates accounting guidance to clarify the measurement of fair value to align the guidance and improve the comparability surrounding fair value measurement within GAAP and IFRSs.  The standard also updates requirements for measuring fair value and expands the required disclosures.  The standard does not require additional fair value measurements and was not intended to establish valuation standards or affect valuation practices outside of financial reporting.  The adoption of this standard on January 1, 2012 did not have a material impact on the Company’s financial statements or required disclosures.   In September 2011, the FASB issued ASU No. 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment.   This standard simplifies how an entity tests goodwill for impairment and allows an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test.  This standard is effective for entities as of the beginning of a fiscal year that begins after December 15, 2011, interim and annual periods thereafter.  Early adoption is permitted. The Company adopted the provisions of this standard on January 1, 2012. The adoption of this standard did not have a material impact on the Company’s financial statements or required disclosures. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> 2. FAIR VALUE   In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.   <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.2in"></td> <td style="WIDTH: 0.25in">·</td> <td>Level 1: Input prices quoted in an active market for identical financial assets or liabilities.</td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.2in"></td> <td style="WIDTH: 0.25in">·</td> <td>Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.</td> </tr> </table> <table style="MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" cellspacing="0" cellpadding="0" width="100%"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.2in"></td> <td style="WIDTH: 0.25in">·</td> <td>Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.</td> </tr> </table>   Assets and liabilities measured at fair value on a recurring basis are summarized below:   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="14">March 31, 2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Level 1</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Level 2</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Level 3</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Fair Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 48%; FONT-WEIGHT: bold">Liabilities:</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 9pt">Warrants</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,397</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 32,397</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="14">December 31, 2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Level 1</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Level 2</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Level 3</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Fair Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold"> </td> <td style="FONT-WEIGHT: bold" colspan="2"> </td> <td style="FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="WIDTH: 48%; FONT-WEIGHT: bold">Liabilities:</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; PADDING-LEFT: 9pt">Warrants</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 23,305</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> -</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 23,305</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 5). </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> 6.  INCOME TAXES   The Company accounts for income taxes in accordance with the liability method of accounting. Under this guidance, deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the three months ended March 31, 2012 or 2011 because the Company has experienced losses on a tax basis since inception. Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax asset.   The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> 5.  STOCK-BASED COMPENSATION   Accounting for Stock-Based Compensation   The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for non-performance based awards is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Evaluation of the probability of meeting performance targets is evaluated at the end of each reporting period. Non-employee stock-based compensation is accounted for in accordance with the guidance of FASB ASC Topic 505, Equity.  As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.   The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection with stock options granted to non-employee consultants:   <table style="WIDTH: 80%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0" align="center"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="6">Three Months Ended March 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="TEXT-ALIGN: center; PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold" colspan="2">Cumulative Development- Stage Period from November 7, 2002 through March 31,</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2011</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">2012</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Employee and director stock option grants:</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt; WIDTH: 52%"> Research and development</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">78,044</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 12%">23,526</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 15%">566,602</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 248,968</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 34,936</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 2,397,155</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">327,012</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">58,462</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">2,963,757</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left">Non-employee consultant stock option grants:</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-LEFT: 9pt">Research and development</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">47,014</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">83,171</td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">General and administrative</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 43,327</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 225,298</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 90,341</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> 308,469</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">Total stock-based compensation</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 417,353</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 58,462</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,272,226</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   During 2011, the Company granted options to purchase 670,200 shares of common stock that vest based upon the achievement of performance-based milestones. As of March 31, 2012, 335,100 of these performance-based awards remain outstanding. No compensation expense has been recognized related to the performance-based awards as the Company does not believe that it is probable that the performance targets will be met.      Stock Option Activity   A summary of stock option activity under stock option plans is as follows:   <table style="WIDTH: 100%; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: bottom"> <td> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Number of Shares Issuable Upon Exercise of Outstanding Options</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Weighted Average Exercise Price</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Weighted Average Remaining Contracted Term in Years</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: center; FONT-WEIGHT: bold" colspan="2">Aggregate Intrinsic Value</td> <td style="PADDING-BOTTOM: 1pt; FONT-WEIGHT: bold"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="TEXT-INDENT: -9pt; PADDING-LEFT: 9pt; WIDTH: 48%"> Outstanding at December 31, 2011</td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%">4,827,638</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%">$</td> <td style="TEXT-ALIGN: right; WIDTH: 10%">1.82</td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="WIDTH: 1%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> <td style="TEXT-ALIGN: right; WIDTH: 10%"> </td> <td style="TEXT-ALIGN: left; WIDTH: 1%"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-LEFT: 9pt">Granted</td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right">—</td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 1pt; PADDING-LEFT: 9pt">Canceled</td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 1pt solid; TEXT-ALIGN: right"> —</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 1pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 1pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt">Outstanding at March 31, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 4,827,638</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">1.82</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> <td> </td> <td style="TEXT-ALIGN: left"> </td> <td style="TEXT-ALIGN: right"> </td> <td style="TEXT-ALIGN: left"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -9pt; PADDING-LEFT: 9pt"> Vested, March 31, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,096,038</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">4.27</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">9.09</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 56,121</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: rgb(204,255,204); VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -9pt; PADDING-LEFT: 9pt"> Unvested, March 31, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 3,731,600</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">1.10</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">9.34</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 527,919</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> <tr style="BACKGROUND-COLOR: white; VERTICAL-ALIGN: bottom"> <td style="PADDING-BOTTOM: 2.5pt; TEXT-INDENT: -9pt; PADDING-LEFT: 9pt"> Exercisable at March 31, 2012</td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left">  </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 1,096,038</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt">$</td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">4.27</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="TEXT-ALIGN: right; PADDING-BOTTOM: 2.5pt">9.09</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> <td style="PADDING-BOTTOM: 2.5pt"> </td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: left"> $</td> <td style="BORDER-BOTTOM: black 2.5pt double; TEXT-ALIGN: right"> 56,121</td> <td style="TEXT-ALIGN: left; PADDING-BOTTOM: 2.5pt"> </td> </tr> </table>   No stock option awards were granted in the three months ended March 31, 2012 or 2011.   The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options.  There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.   As of March 31, 2012, there was $1,935,626 of total unrecognized compensation cost related to unvested stock-based compensation arrangements.  Of this total amount, the Company expects to recognize $748,791, $728,122, $352,444 and $106,269 during 2012, 2013, 2014 and 2015, respectively.  The Company expects 3,396,500 in unvested options, excluding performance-based awards, to vest in the future.  The weighted-average grant-date fair value of vested and unvested options outstanding at March 31, 2012 was $1.15 and $0.89, respectively. There were no Cellectar options outstanding as of March 31, 2011. </div>

<div style="FONT: 10pt Times New Roman, Times, Serif"> 9.  RELATED PARTY TRANSACTIONS   Jamey Weichert, the Company’s Chief Scientific Officer and principal founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”).     During the three months ended March 31, 2012, the Company made contributions to UW totaling $81,500 for use towards unrestricted research activities and paid UW $92,754 for costs associated with clinical trial agreements. No payments were made during the three months ended March 31, 2011. </div>

997671

-544

-0.06

19754 36910217 0001279704 2012-01-01 2012-03-31 0001279704 2011-01-01 2011-03-31 0001279704 2002-11-08 2012-03-31 0001279704 2011-12-31 0001279704 2010-12-31 0001279704 2012-03-31 0001279704 2011-03-31 0001279704 2012-05-01 shares iso4217:USD iso4217:USD shares

EX-101.SCH 6 nvlt-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 103 - Statement - CONSOLIDATED BALANCE SHEETS link:calculationLink link:presentationLink link:definitionLink 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:calculationLink link:presentationLink link:definitionLink 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:calculationLink link:presentationLink link:definitionLink 107 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN link:calculationLink link:presentationLink link:definitionLink 108 - Disclosure - FAIR VALUE link:calculationLink link:presentationLink link:definitionLink 109 - Disclosure - ACQUISITION link:calculationLink link:presentationLink link:definitionLink 110 - Disclosure - STOCKHOLDERS' EQUITY link:calculationLink link:presentationLink link:definitionLink 111 - Disclosure - STOCK-BASED COMPENSATION link:calculationLink link:presentationLink link:definitionLink 112 - Disclosure - INCOME TAXES link:calculationLink link:presentationLink link:definitionLink 113 - Disclosure - NET LOSS PER SHARE link:calculationLink link:presentationLink link:definitionLink 114 - Disclosure - CONTINGENCIES link:calculationLink link:presentationLink link:definitionLink 115 - Disclosure - RELATED PARTY TRANSACTIONS link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 7 nvlt-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 nvlt-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 nvlt-20120331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Accounts Payable And Accrued Liabilities Current Accounts payable and accrued liabilities Additional Paid In Capital Additional paid-in capital Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to cash used in operating activities: Amendment Flag Amendment Flag Assets TOTAL ASSETS Assets [Abstract] ASSETS Assets Current Total current assets Assets Current [Abstract] CURRENT ASSETS: Business Combination Separately Recognized Transactions Additional Disclosures Acquisition Cost Expensed Merger costs Capital Lease Obligations Current Capital lease obligations, current portion Capital Lease Obligations Noncurrent Capital lease obligations, net of current portion Cash Acquired From Acquisition Cash acquired in a business combination Cash And Cash Equivalents At Carrying Value CASH AND EQUIVALENTS AT END OF PERIOD CASH AND EQUIVALENTS AT BEGINNING OF PERIOD Cash and cash equivalents Cash And Cash Equivalents Period Increase Decrease INCREASE (DECREASE) IN CASH AND EQUIVALENTS Commitments And Contingencies COMMITMENTS AND CONTINGENCIES (Note 8) Common Stock Par Or Stated Value Per Share Common stock, par value Common Stock Shares Authorized Common stock, shares authorized Common Stock Shares Issued Common stock, shares issued Common Stock Shares Outstanding Common stock, shares outstanding Common Stock Value Common stock, $0.00001 par value; 150,000,000 shares authorized; 36,962,264 and 36,907,824 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively Costs And Expenses Total costs and expenses Costs And Expenses [Abstract] COSTS AND EXPENSES: Current Fiscal Year End Date Current Fiscal Year End Date Debt Instrument Convertible Beneficial Conversion Feature Intrinsic value of beneficial conversion feature associated with convertible debt Deferred Rent Credit Noncurrent Deferred rent Depreciation Depletion And Amortization Depreciation and amortization Derivative Liabilities Current Derivative liability Development Stage Enterprise Deficit Accumulated During Development Stage Deficit accumulated during the development stage Disclosure Of Compensation Related Costs Share Based Payments [Text Block] STOCK-BASED COMPENSATION Document - Document and Entity Information [Abstract] Document Documentand Entity Information [Abstract] Document - Document and Entity Information [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Document Information [Line Items] Document Information [Line Items] Document Period End Date Document Period End Date Document Type Document Type Earnings Per Share Basic And Diluted BASIC AND DILUTED NET LOSS PER COMMON SHARE Earnings Per Share [Text Block] NET LOSS PER SHARE Entities [Table] Entities [Table] Entity Central Index Key Entity Central Index Key Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding Entity [Domain] Entity [Domain] Entity Filer Category Entity Filer Category Entity Registrant Name Entity Registrant Name Fair Value Disclosures [Text Block] FAIR VALUE Fair Value Of Assets Acquired Fair value of assets acquired in exchange for securities in a business combination Gain Loss On Sale Of Property Plant Equipment Loss on disposal of fixed assets General And Administrative Expense General and administrative Goodwill GOODWILL Impairment Of Intangible Assets Indefinitelived Excluding Goodwill Impairment of intangible assets Income Statement [Abstract] Income Statement [Abstract] Income Tax Disclosure [Text Block] INCOME TAXES Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable and accrued liabilities Increase Decrease In Deferred Liabilities Deferred rent Increase Decrease In Fair Value Of Unhedged Derivative Instruments Loss on derivative warrants Loss on derivative warrants Increase Decrease In Interest Payable Net Accrued interest Increase Decrease In Operating Capital [Abstract] Changes in: Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Increase Decrease In Restricted Cash Change in restricted cash Interest Income Expense Nonoperating Net Interest expense, net Interest Paid Interest paid Issuance of common stock in exchange for convertible notes Issuance Of Common Stock In Exchange For Convertible Notes Issuance of common stock in connection with the conversion of notes payable and accrued interest Issuance Of Stock And Warrants For Services Or Claims Issuance of stock for technology and services Legal Entity [Axis] Legal Entity [Axis] Legal Matters And Contingencies [Text Block] CONTINGENCIES Liabilities TOTAL LIABILITIES Liabilities And Stockholders Equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities And Stockholders Equity [Abstract] LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities Assumed 1 Fair value of liabilities assumed in exchange for securities in a business combination Liabilities Current Total current liabilities Liabilities Current [Abstract] CURRENT LIABILITIES: Liabilities Noncurrent Total long-term liabilities Liabilities Noncurrent [Abstract] LONG-TERM LIABILITIES: Long Term Notes Payable Notes payable, net of current portion Mergers Acquisitions And Dispositions Disclosures [Text Block] ACQUISITION Net Cash Provided By Used In Financing Activities Cash provided by (used in) financing activities Net Cash Provided By Used In Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided By Used In Investing Activities Cash used in investing activities Net Cash Provided By Used In Investing Activities [Abstract] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided By Used In Operating Activities Cash used in operating activities Net Income Loss Net loss NET LOSS Nonoperating Income Expense Total other expense, net Nonoperating Income Expense [Abstract] OTHER INCOME (EXPENSE): Notes to Financial Statements [Abstract] Notes To Financial Statements [Abstract] Notes to Financial Statements [Abstract] Operating Income Loss LOSS FROM OPERATIONS Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Other Assets Noncurrent OTHER ASSETS Other Nonoperating Income Expense Other income Payments For Repurchase Of Common Stock Repurchase of common stock Payments Of Merger Related Costs Financing Activities Cash in lieu of fractional shares in a business combination Payments To Acquire Intangible Assets Payment for intangible assets Payments To Acquire Property Plant And Equipment Purchases of fixed assets Payments To Acquire Short Term Investments Purchases of short-term certificates of deposit Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Preferred Stock Shares Authorized Preferred stock, shares authorized Preferred Stock Shares Issued Preferred stock, issued Preferred Stock Shares Outstanding Preferred stock, outstanding Preferred Stock Value Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of March 31, 2012 and December 31, 2011 Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Proceeds From Convertible Debt Proceeds from issuance of convertible notes Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock and warrants, net of issuance costs Proceeds From Issuance Of Long Term Debt Proceeds from long-term obligations Proceeds From Payments For Other Financing Activities Change in deferred issuance costs Proceeds From Sale Maturity And Collection Of Shortterm Investments Proceeds from short-term certificates of deposit Proceeds From Sale Of Property Plant And Equipment Proceeds from sale of fixed assets Proceeds From Warrant Exercises Proceeds from exercise of warrant Property Plant And Equipment Net FIXED ASSETS, NET Reclassification Of Derivative Liabilities To Additional Paid In Capital Reclassification Of Derivative Liabilities To Additional Paid In Capital Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Repayments Of Long Term Capital Lease Obligations Payments on capital lease obligations Repayments Of Long Term Debt Payments on long-term obligations Research And Development Expense Research and development Restricted Cash And Cash Equivalents At Carrying Value Restricted cash Revenue From Grants Grant income Share Based Compensation Stock-based compensation Statement [Line Items] Statement [Line Items] Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Statement [Table] Statement [Table] Stockholders Equity Total stockholders' equity Stockholders Equity [Abstract] STOCKHOLDERS' EQUITY: Stockholders Equity Note Disclosure [Text Block] STOCKHOLDERS' EQUITY Supplemental Cash Flow Information [Abstract] SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Goodwill acquired in a business combination. Supplemental Goodwill Goodwill resulting from a business combination Trading Symbol Trading Symbol Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line Weighted Average Number Basic Diluted Shares Outstanding SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE EX-101.PRE 10 nvlt-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 R9.htm IDEA: XBRL DOCUMENT

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2012

STOCKHOLDERS' EQUITY

4. STOCKHOLDERS’ EQUITY

April 2011 Private Placement

December 2011 Underwritten Offering

Common Stock Warrants

Offering	Number of Shares Issuable Upon Exercise of Outstanding Warrants		Exercise Price		Expiration Date

December 6, 2011 Underwritten Offering		10,081,667	$	0.60		December 6, 2016
April 8, 2011 Private Placement		6,839,468	$	0.75		March 31, 2016
Legacy warrants (1)		50,419	$	0.60		July 27, 2015
Legacy warrants		105,040	$	16.065		July 27, 2015
Legacy warrants		91,524	$	99.45-100.98		December 31, 2015
Legacy warrants		8,561	$	191.25		May 2, 2012

Total		17,176,679

(1) The exercise prices of these warrants are subject to adjustment for “down-rounds” and have been accounted for as derivative instruments as described in Note 2.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

EXCEL 13 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\U.&0X-6,S85\R93`V7S1C-39?830R-E\T-C`P M9CDW8F1A,C,B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/D%#455)4TE424]./"]X.DYA;64^#0H@("`@ M/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0 M#I%>&-E;%=O7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$6UB;VP\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!2 M96=I'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA2!&:6QE3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^4VUA;&QE M3QS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\U.&0X-6,S85\R93`V7S1C-39?830R-E\T-C`P9CDW8F1A,C,- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3AD.#5C,V%?,F4P-E\T M8S4V7V$T,C9?-#8P,&8Y-V)D83(S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'!E;G-E'0^)FYB'0^ M)FYB3PO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\U.&0X-6,S85\R93`V7S1C-39?830R-E\T-C`P9CDW M8F1A,C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3AD.#5C,V%? M,F4P-E\T8S4V7V$T,C9?-#8P,&8Y-V)D83(S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\U.&0X-6,S85\R M93`V7S1C-39?830R-E\T-C`P9CDW8F1A,C,-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO-3AD.#5C,V%?,F4P-E\T8S4V7V$T,C9?-#8P,&8Y-V)D M83(S+U=O'0O:'1M;#L@8VAAF%T:6]N/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,SDL-S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S&5D(&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6UE;G0@9F]R(&EN=&%N9VEB;&4@87-S971S M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=&3TY4.B`Q,'!T(%1I;65S($YE M=R!2;VUA;BP@5&EM97,L(%-E6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,40[*2P@82!P2!O9B!H=6UA;B!C86YC97)S+"!A;F0@0V5L;"!!8W%U:7-I M=&EO;B!#;W)P+B`H=&AE#0HF(W@R,#%#.TUE2`H=&AE#0HF(W@R,#%#.T%C<75I#(P,4,[=V4F(W@R,#%$.R!O2!F;VQL;W=I;F<-"G1H92!!8W%U:7-I=&EO;BX\+W`^#0H\<"!S='EL M93TS1"=-05)'24XZ(#!P="`P<'@[($9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O M;6%N+"!4:6UE#(P,4,[17AC:&%N M9V4@4F%T:6\F(W@R,#%$.RD-"F%S('-E="!F;W)T:"!I;B!T:&4@06=R965M M96YT(&%N9"!0;&%N(&]F($UE#(P,4,[365R9V5R#0I! M9W)E96UE;G0F(W@R,#%$.RD@9&%T960@07!R:6P@."P@,C`Q,2XF(WA!,#L@ M5&AE('-H87)E&EM871E;'D- M"C@U)2!O9B!.;W9E;&]S)B-X,C`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`T* M$$P.R!4:&4@0V]M<&%N>0T*<&QA;G,@=&\@8V]N=&EN=64@=&\@ M86-T:79E;'D@<'5R6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE&-H86YG M92!#;VUM:7-S:6]N("@F(W@R,#%#.U-%0R8C>#(P,40[*2!F;W(-"FEN=&5R M:6T@9FEN86YC:6%L(&EN9F]R;6%T:6]N+B!!8V-O2P@=&AE>2!D M;R!N;W0@:6YC;'5D92!A;&P-"F]F('1H92!I;F9O$$P.SPO<#X-"CQP('-T>6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!I;B!T:&4@9F]U M28C>#(P,3D[6EN9R!A;6]U;G0N/"]P/@T*/'`@$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE2!U2!T:')E92!Y96%R#(P,4,[1D%30@T*05-#)B-X,C`Q1#LI M+CQI/B8C>$$P.SPO:3X@07,@'!E;G-E#0IB87-E9"!O;B!T:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@ M;V8@;W!T:6]N2!T:&4-"G!E M$$P.R8C>$$P.R8C>$$P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE#(P M,30[(%1H90T*9W5I9&%N8V4@=6YD97(@1D%30B!!4T,@5&]P:6,@.#(U+"`\ M:3Y&:6YA;F-I86P@26YS=')U;65N=',\+VD^+`T*6%B;&4@86YD#0IL;VYG+71E M6EN9R!A;6]U;G0@;V8@ M8V%S:`T*97%U:79A;&5N=',@86YD(&%C8V]U;G1S#0IP87EA8FQE)B-X03`[ M87!P$$P.V9A:7(@=F%L=64@9'5E('1O M('1H96ER#0IS:&]R="UT97)M(&YA='5R92XF(WA!,#L@5&AE(&-A6QE/3-$)TU!4D=)3CH@ M,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO:3X@)B-X,C`Q,SL@5&AE#0I#;VUP86YY(&=E;F5R86QL>2!D;V5S M(&YO="!U$$P.R!) M;B!S=6-H(&EN&5R M8VES86)L92!A;F0O;W(@=&AE#0IE>&5R8VES92!P2!U;F1E$$P.R!3=6-H(&9I M;F%N8VEA;`T*:6YS=')U;65N=',@87)E(&EN:71I86QL>2!R96-O$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE#(P,4,[24924W,F(W@R,#%$.RDN/"]I/B`F(WA!,#M4:&ES('-T86YD87)D M('5P9&%T97,@86-C;W5N=&EN9PT*9W5I9&%N8V4@=&\@8VQA2!T:&4@ M;65A$$P.R!4:&4@2`Q+"`R,#$R#0ID M:60@;F]T(&AA=F4@82!M871E6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@ M1D].5#H@,3!P="!4:6UE#(P,3,[($=O;V1W:6QL(&%N9"!/=&AE0T*=&5S=',@9V]O9'=I;&P@9F]R(&EM<&%I6EN9R!A;6]U;G0@ M87,@82!B87-I$$P.R8C>$$P.T5A7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA6QE/3-$ M)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE2!G2!O9B!T:&4@87-S M=6UP=&EO;G,@=7-E9"!T;R!D971E$$P.SPO<#X-"CQT86)L M92!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0Z(#$P<'0@5&EM97,@ M3F5W(%)O;6%N+"!4:6UE6QE/3-$)U=)1%1( M.B`P+C(U:6XG/CQF;VYT('-T>6QE/3-$)T9/3E0Z(#$P<'0@4WEM8F]L)SXF M(WA"-SL\+V9O;G0^/"]T9#X-"CQT9#X\9F]N="!S='EL93TS1"=&3TY4+5-) M6D4Z(#$P<'0G/DQE=F5L(#$Z($EN<'5T('!R:6-E6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5#H@,3!P M="!4:6UE6QE/3-$ M)T9/3E0M4TE:13H@,3!P="<^3&5V96P@,CH@26YP=71S(&]T:&5R('1H86X@ M<')I8V5S#0IQ=6]T960@:6X@3&5V96P@,2P@6QE/3-$)U9%4E1)0T%,+4%,24=..B!T;W`G/@T*/'1D('-T>6QE M/3-$)U=)1%1(.B`P+C)I;B<^/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@ M,"XR-6EN)SX\9F]N="!S='EL93TS1"=&3TY4.B`Q,'!T(%-Y;6)O;"<^)B-X M0C<[/"]F;VYT/CPO=&0^#0H\=&0^/&9O;G0@2!A;B!A8W1I=F4-"FUA$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T M(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO M<#X-"CQT86)L92!S='EL93TS1"=724142#H@,3`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`E)SXF(WA!,#L\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T M9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@ M6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@ M,3`E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=72414 M2#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXF(WA!,#L\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[ M/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\ M=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!72414 M2#H@,3`E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)U!!1$1)3D$$P.SPO=&0^#0H\=&0@ M6QE/3-$)T)/4D1% M4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@6QE M/3-$)U!!1$1)3D$$P.SPO=&0^#0H\ M=&0@6QE/3-$)T)/ M4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U!3$E'3CH@ M6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0[(%!!1$1)3D$$P.SPO<#X-"CQT86)L92!S='EL93TS1"=724142#H@,3`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`E)SXF(WA!,#L\+W1D M/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^ M)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P.SPO M=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT M.R!724142#H@,3`E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL M93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3`E)SXF(WA!,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q M)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P M.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(')I M9VAT.R!724142#H@,3`E)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO='(^ M#0H\='(@6QE/3-$)U!!1$1)3D$$P.SPO M=&0^#0H\=&0@6QE M/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$585"U! M3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0[(%!!1$1)3D$$P M.SPO=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#(N-7!T(&1O=6)L93L@5$58 M5"U!3$E'3CH@6QE/3-$)U!!1$1)3D6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D3L@34%21TE..B`P<'0@,'!X.R!&3TY4.B`Q,'!T(%1I;65S M($YE=R!2;VUA;BP@5&EM97,L(%-E$$P.SPO<#X-"CQP('-T M>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6EN9R!S=&]C:RP@7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/&1I=B!S='EL93TS1"=&3TY4 M.B`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`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`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`V M7S1C-39?830R-E\T-C`P9CDW8F1A,C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO-3AD.#5C,V%?,F4P-E\T8S4V7V$T,C9?-#8P,&8Y-V)D83(S M+U=O'0O M:'1M;#L@8VAA6QE/3-$)T9/3E0Z(#$P<'0@5&EM97,@3F5W(%)O;6%N+"!4:6UE6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P M.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P M="!4:6UE2!S;VQD(&%N#0IA9V=R96=A=&4@;V8@-BPX-#8L-3,W('5N:71S+"!E M86-H('5N:70@8V]N2`D M-2PQ,S4L,#`P("AT:&4@)B-X,C`Q0SM!<')I;"!0$$P.R!4:&4@=V%R&5R8VES90T*<')I8V4@86YD+V]R M('1H92!C;VUM;VX@$$P.SPO<#X-"CQP('-T>6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE2`R.2P@,C`Q,B`H=&AE#0HB1FEL:6YG($1E861L:6YE(BD@82!R M96=I6EN9R!T:&4@=V%R2!*=6QY(#(X+"`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`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D M/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!C;VQS M<&%N/3-$,CXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0^)B-X M03`[/"]T9#X-"CQT9"!C;VQS<&%N/3-$,CXF(WA!,#L\+W1D/@T*/'1D/B8C M>$$P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T], M3U(Z(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG M/@T*/'1D('-T>6QE/3-$)U=)1%1(.B`T-R4G/D1E8V5M8F5R(#8L(#(P,3$@ M56YD97)W6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXQ,"PP.#$L-C8W/"]T9#X- M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T.R!724142#H@,24G/B8C M>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^ M)#PO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE M9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=72414 M2#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT.R!724142#H@,C`E)SY$96-E;6)E6QE/3-$)T)!0TM'4D]5 M3D0M0T],3U(Z('=H:71E.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT M9#Y!<')I;"`X+"`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`[/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SY*=6QY(#(W+"`R,#$U/"]T M9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D M/@T*/"]T6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P M.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P M.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)SXD/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!R M:6=H="<^,38N,#8U/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T)SXF(WA!,#L\+W1D/@T*/'1D/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C M>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXY.2XT-2TQ,#`N.3@\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT M9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D M('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SY$96-E;6)E6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0G/DQE9V%C>2!W87)R86YT6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXX M+#4V,3PO=&0^#0H\=&0@6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(')I9VAT)SXQ.3$N,C4\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SY-87D@,BP@,C`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`V7S1C-39?830R-E\T-C`P M9CDW8F1A,C,-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO-3AD.#5C M,V%?,F4P-E\T8S4V7V$T,C9?-#8P,&8Y-V)D83(S+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R6QE/3-$)TU!4D=) M3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE6QE/3-$)TU!4D=)3CH@,'!T(#!P>#L@1D]. M5#H@,3!P="!4:6UE2!U'!E M8W1E9"!F;W)F96ET=7)E'!E;G-E+`T*;F5T M(&]F(&5X<&5C=&5D(&9O2!O9B!M965T:6YG('!E65E('-T;V-K+6)A2XF(WA!,#L\+VD^ M($%S('-U8V@L('1H92!#;VUP86YY(')E8V]G;FEZ97,@97AP96YS90T*8F%S M960@;VX@=&AE(&5S=&EM871E9"!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A M;G1E9"!T;PT*;F]N+65M<&QO>65E0T*6QE/3-$)TU! M4D=)3CH@,'!T(#!P>#L@1D].5#H@,3!P="!4:6UE$$P.SPO<#X-"CQT86)L92!S='EL M93TS1"=724142#H@.#`E.R!&3TY4.B`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`[/"]T9#X-"CQT9"!S='EL93TS1"=4 M15A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X- M"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\ M+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!6 M15)424-!3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T.R!0041$24Y'+4Q%1E0Z(#EP=#L@5TE$5$@Z(#4R)2<^#0I2 M97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*/'1D('-T>6QE/3-$)U=) M1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=. M.B!L969T.R!724142#H@,24G/B0\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT.R!724142#H@,3(E)SXW."PP-#0\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T M9#X-"CQT9"!S='EL93TS1"=724142#H@,24G/B8C>$$P.SPO=&0^#0H\=&0@ M$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0[ M(%=)1%1(.B`Q)2<^)#PO=&0^#0H\=&0@6QE/3-$ M)U1%6%0M04Q)1TXZ(&QE9G0[(%=)1%1(.B`Q)2<^)B-X03`[/"]T9#X-"CPO M='(^#0H\='(@6QE/3-$)U1% M6%0M04Q)1TXZ(&QE9G0[(%!!1$1)3D$$P.SPO M=&0^#0H\=&0@6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S M;VQI9#L@5$585"U!3$E'3CH@;&5F="<^#0HF(WA!,#L\+W1D/@T*/'1D('-T M>6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P="!S;VQI9#L@5$585"U! M3$E'3CH@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0@6QE/3-$)U1%6%0M04Q)1TXZ M(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL M93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXU."PT-C(\+W1D/@T*/'1D('-T>6QE M/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[ M/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXR+#DV,RPW M-3<\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P M.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z M(')G8B@R,#0L,C4U+#(P-"D[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/@T* M/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/DYO;BUE;7!L;WEE92!C M;VYS=6QT86YT('-T;V-K(&]P=&EO;@T*9W)A;G1S.CPO=&0^#0H\=&0^)B-X M03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA! M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA! M,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P M.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4+4%, M24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M04Q) M1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S M='EL93TS1"=415A4+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(')I9VAT)SXF(WA!,#L\+W1D/@T*/'1D('-T M>6QE/3-$)U1%6%0M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\+W1R/@T* M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z('=H:71E.R!615)424-! M3"U!3$E'3CH@8F]T=&]M)SX-"CQT9"!S='EL93TS1"=415A4+4%,24=..B!L M969T.R!0041$24Y'+4Q%1E0Z(#EP="<^4F5S96%R8V@@86YD#0ID979E;&]P M;65N=#PO=&0^#0H\=&0^)B-X03`[/"]T9#X-"CQT9"!S='EL93TS1"=415A4 M+4%,24=..B!L969T)SXF(WA!,#L\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(')I9VAT)SXT-RPP,30\+W1D/@T*/'1D('-T>6QE/3-$)U1%6%0M M04Q)1TXZ(&QE9G0G/B8C>$$P.SPO=&0^#0H\=&0^)B-X03`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`P)3L@1D].5#H@,3!P M="!4:6UE6QE/3-$ M)U!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(&)L86-K(#%P M="!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!&3TY4+5=%24=(5#H@8F]L M9"<@8V]L&5R8VES928C>$$P M.V]F/&)R("\^#0I/=71S=&%N9&EN9SQB XML 14 R8.htm IDEA: XBRL DOCUMENT

ACQUISITION

3 Months Ended

Mar. 31, 2012

ACQUISITION

3. ACQUISITION

Merger Agreement

Purchase Accounting

The following table summarizes the Company’s determination of fair values of the assets acquired and the liabilities as of the date of acquisition.

Consideration - issuance of securities	$	2,219,903

Prepaid expenses and other assets	$	71,892
Fixed assets		6,515
Accrued liabilities		(380,130	)
Derivative liability		(59,485	)
Goodwill		1,675,462

Total purchase price – net of cash acquired of $905,649	$	1,314,254

The Company determined that the acquired Novelos legacy technology had no value as of the date of the acquisition.

Goodwill

ZIP 15 0001144204-12-026326-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-12-026326-xbrl.zip M4$L#!!0````(`%6&I$"L;E4R358``*AB`@`1`!P`;G9L="TR,#$R,#,S,2YX M;6Q55`D``R%!I$\A0:1/=7@+``$$)0X```0Y`0``U%WK<^,VDO_N*O\//%\V ME529,@F^/9ELZ9GU[8SMV$XV>U]<$`G)2"A21U*VM7_]=8.41%+4RY9D3M76 MQB,!8/\:_40WH9_^_CKRI6<6Q3P,/I^I#>5,8H$;>CP8?CZ;Q#*-7<[/I#BA M@4?],&"?SZ8L/OO[SZ7EI,&]((SD4 M"S;<<'0AR?+L8;^G=%Y*DME0]8:3^^HNG`3>I:0KMLL&CB7;CD5DO>]HLJWJ M`[D_L/L64YAE424WJQTQFL"*D@>T7DI$48FL&+)"'HAVJ5J7BOJ_^='A>!KQ MX5,B_>#^"(-A),Q0"SPX!\1N0VKZOG2'0V/ICL4L>F9>(UOIM1_Y$G`]B#^? MY7#CQXTP&E[`NMH%S]AVEHZ\Q&_]->/AT7\A7^?C\8/"^!=-C%8=Q[D0W\Z& M\CC4B6JM(R8=,5\[YE4KPU#UXH^O7^[=)S:BR4%576U-DTC_'J*?!%Q7`>/+,XJ9Z1?EO9% M!1#X!A\;5\X1WU1,0JJ]$I.S_30OTB\+0Y/*H48Z-#D#$93^92Q$X8X- M)"%QETC"Y[.8C\8^RH7XC$9N%/IL.]D6,YXB-OA\AKR49SQKO,;>&T1_>ZVZ M2&&!T%UV@X0GTW8X&H7!?1*Z?]T_T8C%-Y-$&$DPG)(;!@E[3>Z03A;ZC[== M4[-US91EE:B*_*L"BS_>/W0>E4>!P%#41S"\DX"G/J`_[>77= M.Y.X]_F,>X^$Z*KZV"/MCJIJJMQ16CU95QQ=;K5-73;,3K/3;?6L00&MV'-GI-A79:';-MDWLENIT'F$8(+4((0N@E527MW7,$^I_ M82#C-WV?#X4SK"](U0%!-I3";FY`L!7@=CW1ZK"GQ#(VHFU70?W":9_[/.&L MKO#`*AF*J2GJ`N`RT450'?"FSP#ZF=4?G@:R2C0G)ZSKJ"_BO(W8F'*O^SIF M03VB)4(4)3B:69=MXAK"9_I4*]/]TH`]TFW=C6"&I"LTQ"3+U2 MO38D&N`S4I;D!CSU=.<1END(,VS++ M1K[2:_\2AMX+]_V:H8#43S4M0S=S*=&,U+(1P4.8,=KW^X0.&23'+!I'/&:@ MG]SE2=-U)Z.)3\&1=R81R&QY1LV@:YCO:[9F:<3)&YOWPMRLJH>P2OMPBO:2 M4_P6(TR"QSC@(O.*^8;(,F>-;VET$\'>PI:+@;XXVR M#8&"TL!#+;72OZQ"5#*_'OA:2)VI?PL9RE60)=8UVV\-DBI=U1SX))=%KJ"] M!-`51^KQ+9W2OH_)%WP"^N/5/V\&*=N.7)+.,)@^,"BT768L)G3KQD@%5RU;A3WJ8KLPV<=@/6`=50-C(SP M(:8%^:3SX754]:UHM]I74H\ZZJ%!8AU55QRU'G74@Z,5=53MH^JH!XC$_%8*J:MU=1].\3B%U(,[21%B&HZIU*R0NA;X/@^12:T*J0?78UV< M=YBJ:BNU*:0>/$X2A52P76K]"JD'WW"K*L'ZH$KJ82WR(2JI1\BN#E!)/;A0 M0:#JZ#8^YMB5U,.F&F2K5.-HE=0C.L$Z5E(/+<8@Q9JBZX9I?&PE];`R_6&5 MU(/'KFDEE2A&=8_0WBNI!X]3WE1)A0_%.6(OC.[8>!*Y3UC+&>0V>'N8FJZ1 M=]6,MZND"J'4U,+;J)MA+-D9ES$O[D7A*#=75`1Z/*"!"ZE*TTWX\XZR>S0> M8#G'-HK'/3MAJD@_73!78*]Q`?%W+.+Z^H%7,8*`L%0OU]&K`:S>^GO(3F\& M*ZUV#9';RX=\6\,I\@%<$O(,1C]SCWFMZ6\Q@^SM2MSN4'/I)R#]8`E-S3)S MUGM[1!7]%-=A@&RC./`J<,,1RPJ%1T1O]TRUW6D9@3ER",69:/LRV/N[I;X='SM`H][\^]XEK=3_ MHE$$DM]]99'+#PNPXCJ)+&LY6)NQFI@5U-F'832,3T]:,PKOMVT,JL@*S2KPFZ&8@HAU0E$R$ M,`2X9]$S=UE\$[5]RDV6B%:?.0)31\Q3ZV@2=?#INN:8:O6KRS/22V(?N!&:B`Y+_WL5 MS$K8;\H\CZ;\VO)+S%M!*1WU8>[=PFO@(-%!MTCK&:^+*SRP&S1WB%Q-^Z;= MW>;@O7[X54A8';60K+T-6JG037GP)8SCFZ`B\*]Q$F.!Y]-,WV@;)*. M8H-;_8#CF5.I)V\3B')G0#_!FR`C<05D.X3,)DHX2$N+!:)F3OWT0[S>L<=H M,MGEU/A8;,#(1\=7&`J]J+LCVQP4XZKUPT^PJD:(Y>CZ^B`8R2_)_&A,>83# M;@9704*#(?(H;8:Y"CS@%)#,?/[,(%%R_0DV/NS>#W,L1IC`!\>T_`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`4/HUC/N`N3;UOY<4T#^&[7Y(\ M&@L@\C!MQ=$R!KP788Y9_V+X:WC,:X*0T"&[GHSZ+!):E*G0.]Y[7LV>99/P MUG()"H=J60;!VN<;$>VKG]5YW^]G;059W$1D&YI1O%US72_K0;H[WXEU*\$G M:6^G8J^O:G]8:^=Q>"`:.S6B&^;FN&=S6^=^^]N.Q`'1R9=_N_,#>MN.`Q4O MV;(+5WK4H:_M2-N,M6\'>QCVV];V_D:>(QD[?.'.<9P-YFXYIG]C:\IQW)5H M3'%,@QCD6&TI1P*&32FJJIJV_5%-*4<"*B[^UQ7]30TI^^VT.)(F8KN\KEIZ M?=HL=@3^QB8+<0.BK!JF:KZKR>)=9?;C2#46V5Y(XD!GAK*]@L[?CU MN"-M:?KZEJV\JQI7FP+3<2RA)EZ(U37]6R\O'8==*&*::N7?J/KPTM*1S`>> MKQB*H>RAK+2WZLH6T/=96TG/6&2ED3]KV[ZVUB0_=$*:3"US>_=[_-6^[OSU_/I:OK=B.EOXK0 M!8PF[(0G=L.GNRC!^R4"2!^`FK"4R@(=92[WN,^B-GC%81CM<-G?OI@,LGL/ M&@TT2'=LC.DUV`L\_*3!-,_C`IFK%/#?C$;'5S\,/F")*@6<$[1,\<-TO">9 MWI),;%*$)8MD(A7+M*5VHPO6'QA^5"))RDM9T62M9-(*1)6EN`T#('S!M_Q> M_\D^0(Z!<#09Q'(L/#M;2=F"\.R*UX6@[)7?N]".T0"L/>?X*LHV716*+0>+ MR/D!,+3\G;K6UP&R.QW3)(HC=S0%!,C2VK+=M32YTU&TKN+8O6;+2J7\>S_Y MY/%G*4ZF/OM\UKNY?KB45&6<2`]\!"'I-7N1[L(1#<[3#\ZE>Q"MP=GWP^33 MZ0G.'L_F?FW>_7)U?2GA9&7\^DG::3% MCL:?_OL5L#J?I.ZOOUT]_!O'7O1GLR[&>R<&%DN?VE0.^(@98OR#XQ_-<<1] M"8,ZZ59T+3#IUJ>N:.@09/`YYF\>?7O^! ME#PQB;TR=R).P\.!^""]FN7TI#F,F&#.N?@X\X02$_F^)_$@"24*3W6Q\103 MK-OLOD)I/O/T1#S;95%">2!1UQ4_QB%F8S]J&,4068/:2B]/W'TJ/"<&?0:J M3T_H$)8;XG8!@>:YK9OGAF:)B!Q0,PKS\&]$%W-Q01H.!)"2B-7A'Z<236`BB)(K!GRG-"Q#@I1( MT'`N#<)(&D9X[CS..N3$\^D8_OD*"0.F_-)WQKFJ&>=@;*0?$/)""=N9E&8" M>GJRD-#YF,ZG'QL+$9(>8($,1RP]T6<&V'!3Q85;HYJH6Y8M7Y8JP!-F*P%7 M@8^3_I_,%5]2[\])VI4,U`!CD'OI6F`U(0,./-CA](-X[.-FA""8,1]QGT:2 MF_5-12R,AC3(JB$Q2`[0!MN$!$:84<4ST<[H.#W)G(5$!R#,*8UX7IU(HA>M M#UHQ/\-%.@LK@5!G<&:K`%N0'V%NH3(O([SIB,/F#"B/I&=\&>'TI$A5+!@( MNI$]<*$B+S26OB/G*M'/B6VB!/*L_PXD"S84Y!9H9@%,P;L$8`GX@.+F@)(+ MY@Y2+F8$YXW^Z0D3'K-Q#)M\Z$<`I\&]K;-(,Q;%(+TL/ M#]ELR#D*B;B)@GD-(:,SR\OC.1^$,`X@X4F=""YTWVU+02CAQ5UH`RA:D:E$ M'&%#B#!HIR=GD"0A]`ZC'OS!SGX$+N0Y#=A@@>QUYV>&OXJ2D1F#U@E.XC\7 MS%JRWJN_/CT1/L6?SA8M*UC>/@E(RQ*3$'3BH0*R!!UAP6-V(2IQ87S3$DJE,) MC^##0!#!!F`\`2(,$TY`;,,*CGO8QXEKPB1\4P2&@R3_SP16)'9Q'[NS$7B` MG=O.\W0/0NDOQL;9SE4]2P@B^.1).(E1<^8/3)E6XG[3%;9*=31-B"<="3T[ M/5ERD\5)!>=X#FLGH",BN*&1S^$YF;9YPJ>^/(&I!/X5R$8>QHM%A5`N-+QH M)!:<%*P6IE>$*YE7A'5"C"^"@.--/S2:9@0`-R`C`;%L?+LV]BI(D:3^,A^Q M@6OSX[G!6"T3PI;P(-7P!-8?1'BJ%H^9RP=\P?2UAOPE(]LV*:,*-@L\99!"18.:(0&DY&4B`.?'-.`N+*$4^25/O[,W[F!1,6/4\7 MF>W"+(+)&XXQ6.C,UN7\D\]A!*H$*)A'1W0(3X1)$%'!6+5A_$W$M6!6@>0? M('Z5L6+E(>LH:!('AO4I1-PB:H,G@^\3YR)(OX^,%\Z!2H,)$"16^7&FAXN0 M?AYVB]!R'A*)X'[^I9?3Z!4BA62`U'DB0%RV;ZDU&4,,Z:*FGPM3#BC9*\;H M$D"=*>@JTE89ZAF[P9Z$+X+;&.'"_F8N"FUV!FH%Z<@^)&<41BSEF::D_ELD M9L]HMJ8QLKTX*GD!@7==&HN@%],K($\N"*U*T:N\L_"5/EN(()FZZ8JE'7,.0+'C-5DZFL;I0*=( M0ZJ>U9":L8!0R+5(YC^?HG`R?)K[IKFM&HCPJ9!X0])"8R$"P)HLS%]P&M/- MOG!BXK.9.F?2B5U%DC=AGX3-C1B(G-`!D9'_?WO?VM0XDJS]G0C^@V*B-Z([ M0J8MWST]9R*,@1G.=C>\0._LV2\GA"U`V[;$2C8TY]>_>:N;+`/F:M..V$L# M4JDJ*RMOE?DD'GCD0?6.]B8R>"^#S[R(LGH1UT!Q/V:AX+8?I4-ZF@2C,J6! MF=2QQ-^?J!9%1E"^JU6KY,KCAHJ!J0U..[`0=&M^MQZ`>-#' M9B8L\1X,"G(92EQX3WOP:,*@L2^.O.O%?T!10+&0823,*$L!QS,<7L5YF@$S MY0(]7*:1S)IG3&5-)92443*XX:-'=#N-)M?(-TQ5;:0+T6U))$^@@(@P-#WB ML^M:R>5RQS'[2SPEML@QN*4)R.MF)[ED,@NZ8#%1YS(SLH M7@818O@5I2SB](])61IWWYOK[;,A5.0_Z'3]H5"4`..1#CN$"DX0%4\YAXNP(V[YG.;,Y\=G2^*FR<95@7#QX MZDGLE%R6Q8.G^&$)GJ+,>V#TU,28'A(]+8_#ED50Y\5-M:E^W[AIO5GUZ[6J M'3=5UN/FQD/CIMY,V'1S8Y\4;\+@&R9B5LHO[M$5@V1SP[9(]!$FB^"JX\+84@F/1 M3K%B&+=W&\R([Y7C`;`L"E^.0:+@028:I\.(C%:Y@-`GB*[#T#V&=T+L4'#) MPH`D@3(F@?N`IN<<`MWAA]7;`;V<3"P:TO*Z/=6'JKO;UG M*8852#%QA'(Z'H?8GQ")`(L=AT;4H!+.2`JF)D'0VF/;%W%U/,EEUS\M6+1X M;T?W((DSNCN.'MVPE3ORY@8:+:][TR1TY,_\M;]S\B<.6_W;`I_P!M%HE%^& M>*0H_1-_O@R'0_G9^EBFOO2/W:.3_7[O?\/6-AI.IFD8_O1H7IT^^!H M9_>HLGUP4[[8CJ9I[Z!_G:?41VHG%&=)ZRL6OIL_8F9;P3+! MD?4/3T:`CY/L@4+J3LK>3?HB_1XUVEO^W)Q=VN[U__['T<&WKSN5_L'G@Z-? MO>S\]'VMVO!K37!LJXT/G[P%U(WHP$;[;[\X<14),=P26BEG1Z53_W;_4VB? MLE%T!O+@D8.0MVE&J?$P)C;QW'-Y!AJ\>]32,:RR@HM^Y,;7JJ4\W7J>&=W[ MN(*O/HGN=4;QWYSPT_%ORUQ=5$C-6>PC:$ZOMOQ.O>LW6ITG_>;CEK/0N9&S MTFXNT0(>L1_NQ=`3?OAE-%/IK#Z#ESNX,2[F^^##,I&\6?4;07>)V.DGC:Q_U,>Z6>0](OP_#*1.*@V_6ICF?AE<88/6EO5UAL1^:_.\L\N M\9>)VMW`;]8:2\0YBS-_M[O5:%:":G6KNTQFVR,V15O[8OBL)?^SD+GC-UO! M$G',`^1^-]BJO1&Y3S48?'6SEVCB>E`UHYGIC:9&>A#M/KI)*ETV1HY27N M?)+,1E66&#)L.99X49D6EORJEAU>;'7AIK_D@RP^Y5IC1%"!#7LVZKQ(OC0' MP%5QGIMR*4FC0=6O=9KS2IDPTZPLI1.3,*G&S2XR*,NTVMRHM?UZ4)WS@:TB M?,.0\Z)5;H!4K,);3F"'\_7ND4"]Y3E9@IENX`(K?Q=T_7:S8"^PA9UZW:_7ZX_>PN*=]OU%PEO8 MQ'KUEDVL-6\Y))L;6F3=>]>\1M5O=^KSZL[NM6DS*;8M+@1YT+G[.(RO\">K M74+&$ MJEJKUYI.G^_7Z+WU,AN+O;<:C67MO?4B-*#>6T&[6FMU@\9;O;;53V:OW67KM>1[3-985#;&_9:LO[NGOB?3XX M/O8.=X^\XS][1[LD;4TZ[DJJ34*0WMS`,L@1U7XIO8*X`5CL1B!1IS=<9H-E M'?I101FY%F!J4%D,33T+55*T=NTJD>%4X3MI6`I/09,O-JO-#7R6T3S(-8Z& MOIID/AUKYT/FZ\U,UZZ^+X64&N*\T`6Z!/V9$+"#:SZ8VD8JN$KLE=I5,X?W M>%\@"W6=H=1KY0JM4750!8ER.G%*#8]CK&+42#.AH6,XF8`3/^4Z%S!B[*^K M=EK+D)JC&Y\09@92`S:/8<`LY]JW'&&$*,PQ M&NG/7,)N8^;^*E,IE[RX%K9YW%?J#K2#Z,L**S[=)86]*NOZ15%&=P!VKYYM%:MUMR_OD>Q07KL@_L' M03NZ%U<8DVOE*J!6Y1PS8]Z1,?)S5C:BP;,FRFMPRNODF_4`?(1U^M5KYA(M+SF?]NBL"?JB_+E4IAN]>\P15PFJ M_HS[WP!#H.VWZHN4]JQ/TUH\O3WVO#6M=#:?8NZ=Z5UMO55S\\^20;>,M\O8 M)K+;:=_6U;MD&86>>]*:-QIB]DV4Y*%@IB[54F&EC:!=;UH]VLLG?M>V]CB/ M-I?\;IHR5)EL&=]I59O MMKK5NI,Y8:9<6$V:I"J!@I]9O%/ZRZP,=[->[096J^RYDW?7B%6DHR_A9!)E MF#+4IXX\B-X.>_O$R2![V_#&=GVOTMMN-BN-WDZWTMEK[E9VVIWM>JNWVVO7 M]Y8L&80'HPN'CGV!WX=!0,WL?NWO[QX7+B56\A;96BC^8XK_^`P'G).GZ*-3 MO<*57^N>@4[%MFD#;G\&"RWFC'J784:)[KHEW`C/"[;EH1/#(+C1#^R\,^2< M7[P6&Z46;'7A$Y)V;V[L+=Q62E28A).IU']@2H1\Z4WDRO-@#,*,Q0;8GTNQ M5[S:3-5#^/N)X)%'V%YCY/0,H^5J\/CQY0B8B1LY2&\B74;0I.R:JDJ4^990 M4]3C"<$;[V`3C'@P`1Z=9J81B?JU9/#G>3BXF.;19$)I6B&U-(O.81C*WN!4 M'V0Q858?(?1/HXMP=$;).Q?Q.(_@WY2$/!HQJC/V/$RMODOP:=/P+AQ(+Q\9 ML=A]@][@_IC42PM_$`P:G_#+/LQCO>\@[#T3A.;%%^D'@' M@TE*TU"?XUP8(#!U9TUCZH(TBL*AQ_L6GYWEWOOM-`,)\2U3#4V.$`([]+X, M=K`<9OB!V[','2@?*+.*6?R4E%(IQQW&.]"/8ZJ%.7<^Y"8`! M^(>!SS/=V2WR#BE'OP[G+T[B`7;ER6*4W\C[!_^H5*LUZ;&55/(QLCHF]'BC M*>)78S.`K+`C5FF%VA$NCSJ#E5**/Q_GT!NGM`B8%TP79I_KM#?9LY@Z<671 MOZ?#0@\Q^,Y_APF>`>!'NYN'Q7W\&4K`PBC694GOP/[A"/*>IU^3-G<6>0:8B&8&RZ)8M3S%1\T?I-RT%7:*V_R)U`YF9Z+X035^G#F\X&PAC[,UPLTUL$V=WIZYYY`H MXYP]=\\>>7'B4]Y^?FA,Z/.3YR4'1]L(D+G!VET'%U.^-AT;^-! M^]089II873-G]H*D7+E,+1X+PZMF`VW]:WZK]0'KG\"T92F9<19=8K?##%5/ MFG@J*\J3=PM5ECC0ETSI(="$HSCBCJR\,U)W@2F6BLO'H#0G/`74(]Q:53JG MTC&]BL_3C'NH\ORTNH1AQ\]H."I;KF!HT@C[G1)=:XH0;+L.-(EEZAJ*'L9/BR[^F^ MU:IS-M`"I=$IB%!8)PP<>I-H<)&DH_2)3C1'7M M\&$2D4B\5*DZTK_5:DFK)_D[_$TWGG6(4[3%9.^(OE$R8'G M#;K=+FXS?LZT;'4VNON)_!>P&CG9/@(.'O(;U!+K##N^(/%!]*.$(F;"#HBP M@V#Q@_\L'9ZP.65$L7/-`;@2^)A-*S!6OGO;X2C\O_0J_WZ#?8V&X%J`3+9= M%CX#M`>PA!;V]<8VL%K\`J&D[G6.SZ,;;`+C@B9$6O".-M7YB]$B9G/J>Y)> M@[@_C[!K5BSMH<^CA-P\/3NR]X&7DT%\B>Z?^UTYI`7SP:A&[>WHO=4ZQA@+ MH#..IV=GZ>@[_#^Y4YFX@GD4?:=SH7KHUV+.,A!\ MM@UA.DP^M*BK+I>K=,5FQ=F&W1!4+R:WL1J27'P;;)S:2`(DH969@4(K!E@@W% MY1-)ZHU2\"HRK.6AEEK4WMB?^4C9(<;=_HCBT'UV8QN`![4?IISG.6+B+;K4X=_=56'@^*%NU#M6V/C[5/-F6/R]X> M=V$2BZ1:1,5"*#?*R679)CJVX%"N1$PY%`.ND;%`3IZ%5VQIV/M+W1.5J9A: MD;FJ6;21\D:>6F)KXZO`O4#(IK8A*_=#@F41:\.6($J3L M4/%5Y4Z1^X"2%@WI&H65!8B&<#"YE2?.II-IIOM/HWDI'H5/!WHZXD,BEYZD MQS/IB#E*KVJU3#QP$A5L6<%?F MPQY([']@<\6#LV_)!=K',(@"BMJW$,26C!`=3`3H=!JMV[(?[KLXETA?HNP< MV<.6I+]A;076O&O3JE9WM>KO2:`3;E>Y.!B#K^([3;"M1WK&1W-" M.JF8[>B4VJ91CSL@H][0QJR5",#F7#D)Q_:*?/`1!EN^EUZCRS,: MD=D>L5JBFQA237+/?SK-P=JF=LO@&7#X%EX4=U(>10R$&\]R1]Y`$@#Y46C, M%],NR)O.7#0*H)QA&!,(33":IUK+E^&-*+9S;J%M=XDN9K/T!S8*QDA!I_DW MQ08V/,F\$:59O2]-XL_C*WR:O:22I`_8;0R5P`HC>5:Y5,:_3@;3+$,;]%+Z M>%VJ/E[VYTU.`3H/"I3S%/YV[2",S,D^L0ZD\AV0W;#;,CG(:&1CP"`^PW`A MV:IQ,DBSRU3PRO@:PKI6HH.217AVRR^5>9WD'045H$`E:-;A@U>PO1%WGZ?H M(7W9WBT^FQ0QL)R0FM]M=OU..YC=FD+.@8V]8@7]L*6[P'NV_6HU\)O=EHW> M5LHY0LCYK*F`X]2V4A1&"%A,`+*VZ2^[R;8">,&8J(:7*Y\."C3JN6SSJIUQ MY!PO(.4X)-?>?OQL7A(475DA'J$%05,*?1?"3PCT"7^O@\L-)M>=A"01+Q"W M,""%:RB2^PX[[;1Q^'?<>X$5@:%)Z6<;73]H=N\ZI;=]=0N8D3[J5]LU^&&% M?;)_?CG>W!#T,^\PS"8)L*F(5NTTA<,KL*6)30SW%@ZTQJYT!(=U#<5>5<1X MA`IXU!P!"F1&ZK*G*`KY8]0U/K2>P3R&/,JN<)/L(W*4#C'!AGZ#__6.P#.Y M"*]][_/GOO?>CBCSHVX,&>_T2]:N^&0.:*=K"=-=N3>ST5ZDB6A/(8WDH7$`4*2T@(ZM[K$_ M*;(9VJ;"B4`,?1\UHCS6422P9_D-B(=SC,C(%4[Y10NXN;!7Y_$`],5@:A@M MBS&6C00=TL8INO\*:5^8:'2L%)W87JI?QFW,-23M4H]!0T1Z>(64>K^W$T MN4B')#]"31@^X\J*#.<+-/6,!ZT[) MAAJH['`6-^S-78"=E&:4(8523*[2910")W0'ME?"GG'FO=>GX0/8_E,>F"Y% MKC`,I<7W[#1G1XN\]W*:/SC8@'O3#$6M[W'"90FA??>7C#L4@ MO:^1X5&HP!^GZFZ4,G3!H\`B(O+MT01#E!09X93SB1-1AIC","8%81:? M:]V,PANM6?*W?@S(@W8GBW?`-I%TZ,%=`MX^83!ZZR4.^XL<+4,NQ1BNN:&R M-3@V,F.8T1W'NYI?"[I^MUJGK2-=$HX&4];8DB@R'^%36=SDH1@#DW$!*>J/ M.3=X^X4^F/=>(76J3/;-#9W0>(23_H`319,GXYQ#Y06;U`KR#?"?Z%\V_\8@ MFI,;RD1!M]8"G.3SJZR6F>/__E2E(FD6O\TK_^![8W10^4Y3,@TT[Y;M1NFU MANNS)G*>]:S`RR\$KD[LSW@+?47[0Z%[Z.!58`OQ(0<6]UA3RY'$,;O[)2$* M$Q8[!6/.LC\,"<$`X:1G03!E&Q$>,?8S["U=0-YJIYZ`L*4\FX$D%#M7UZ>< M37G*6S]464\PI$TJ6H=$!0V8I6<&U>1!&`84[Y5_IW/:IHK(QZ_@\=$H^V.PW^#QN*;>#G&IQ'^E4A$ M9UT+5D>.K+#9=>*67@D@J%N`57I^%(\I9K*/MU'#17TC6<.N7M2NH8H/.=;+ MRY.V#!4UJ#X[+.HKP[9UVA9LFZ4C*Z29T..@GM5MS4X?!V-5 M59_0-L+CL1E>&\/JSKVY]^8]==O69_GH*_;J/LPB[!"E8C&Y%?AAP?GDQ%^\ M[6\[\#O=5^F2^T1-H??B'Z2ZGX6>CV#FEM]\*SWG!0/#UNK+1.GW]4[5#^K5 M13_YX=5YUV37F!YS2T799M=O=!;FXD<0]EE:9_\A<8\%+)J5;YP=^*UVTV\\ M$O3T=3HRHDQGI[L6]MU)#T(W3Z$9WZS*W M0%S9[EX*<66_FJ][V::&Y5BT.@K7:?8=+PF`).^!C.$Y!Z8G43C^@`E@B9Z) M&I5"J.D@#C5XTTRN"D;^AM,!@_KC#41,4&K>)/Q!25I81K/*]]".Q(DQIU5V M%!.NN,"1-CI)IE*E$6="UGSBH$4HHJH,V3BW*B3E#N8,RW\NO/],PVS"]T=4 MW',38>XL7KOD*6Q3AA5J?`G$"3IQ-IB.,6\-\[?RZ?EYE%LEK`/$]M%Q:\V: MR$7>.+S!LG*\%,#4&4Q]@(TDWD*$!?P?$)7F6YL;[LN-4+.R@#!GRC`?_F7";$?1RGV23^OZ7$ M\:QA54NWW;:Z8=YG&<7:%KXM=)`2;0C%K]'DV1:^_W7O874L7:QCJ;8=$,^[ MU^&N_%`:J)ZD/9;FAU*U?S@*DPEVD87?7DI=XE)M?-"&G7>[_-Y_,2X1#ERD MS&5$+VT2>&FATV_)O`OMB\$CP5(V^+]=TX21>X`52YZ6;7_K3>IT&W1@$E9S MXP56=%?]FH2D%:"Q'!<8_0##TCV^SELRJ@15H$H[:+5NQ6B^S\H*1R`[#Q.1 MC7@EA@&54.3F(1N&]./!V9Y*J"5,0CIO1K/`T\?Q>4+U`W#B=&+2(8SW#)BR MW4:KO]VO=RKU5@\.3Q"T*YU6HUKI]W;J_[NSUUG6DK=@:W/C:^_DV]&N M=[#G;7\[WO^Z>WSL>P='?_2^[O^KAW5P7N_KCO?'`;C&B#G;WSUZ$Y5QNF`# MK:3P,II.XD'.U5-N1O=,1NK.)T\E"MG/S=S9(S@1];Z]O`BS<3B@3W"_77&N M5=*J@!-A/JF&TYS`*9IHC)!A')XGJ>3S6:AFJM*-`#VL4C>3^Q(:QXC3CZQ4 MD4+5V.:&L_"2Q%A"1`E5ZLWHAFKQO;_@Y.$%-IIENDI');=$`AK!L#VT8LH( M3M&EH<0I##(@K@.MF)X#(S0F,!NL`QBBLY7%$6>)7$PQ$Y\ID/LZ@=?QF/HP MBZT2M*292KJ9A96N1$$37%^D(UT@E^M!K)*/+>^P4!A(Z6ZAU#18N6@J=UX* M!$OK_$I68*W2GKN/R#LPB4GDU<'//#+P3NST8,30E"#D6F32RL!OB&@?[MQ[ M\;4T,%]H&M03=H;^0IR@SZ63GLRZYY8'^0XFE3N7L@.H9Z(P3NXWDS)@9#<= MF"O1YDVE-#>'Y(&[3]=145S8?YW."!/[K^"?+D#T$LR@F2Q#G6S$(_3>2.1M M?PQN?F@#M.'$U/]6UKP MQS`L;KOWO)`WJ]1"XD8G#+PQ@(C`[J1N7[.NA7Z!7AYT3\S0S/O[?P@UP%*TAR=L%W M,5%5J*#WRQ;$SJZ5Y"/K[ULYEL;> M5G4_(WA'@.K@J(8#;+]L`G(.N#@>2'*:!1Y*&TO7E$8JN7`WGMJR+");&52HENW.RK[5!="IFELDJ5X40F*&967H$3AJ&;7!-.N!JU?$/L"0. M_CJZ\6=5RFR%R;S"$5@ES!A!@`N6&8TQ9ZH\HE5]0050M\V<3D6I/2#B!%/' M<29Q(I]P M<+=P5V!]1=(3"P(E(]BLKKZJB5%$8KP M\G*DX?%<$6@,<]^RS!$K(U;ZKWH#VE M!=34[8 MDM$S@X[@R_SH`!#LEB5U(Q.C\?EX2*4#%W;[G@%4='G$0!*(&6THC&.4F-%T M%GGB<3JT#E2!S1":NLC6"S`879F8"IAP.KE(,7M\.%,,(R00?&U=;;&Y<1J. M*,,XOXA`0;\/N(X8__NA>+3*/B2&PGSC8GYI_^HJ-\1K44!?98`M3D7R!99` MH\TY9@8@B8]%%4![C;N"Q@\5M5IETFZ]*@VI9(<5*+"/RH[[2JE)(M7-\C:X M^@K^%ID7_UVK-C_0I.D@Y-/\D@1!T9J2Y1$R`[OP:#%;B&<$:H"_NXC"H5RS MD6WU)00N1"II+]N`FI<6/$2JBP;6!A%P0D@EUKA'$ZJ*=]J,K#!C%:]`0=C_ M6X!90NOX84U-KFMM2'6@582(<[B]<"8)`+\TWA2CXC_4P,",DL)"C8<%VB*< M"^TZE1XDWO?HANJ7KN+A-!P12O?X,IJPK4+[C%I)>AJHD`YOZB@49`"-\,VU MK`.\T3^;CAPVIYA/F'V/I%IIG9!=:(``BN>GF'^>`R@@HB)7B`NN'2!^*B]\$RM$)AT9$$1/@2)G1 M9\$)8\1>$!M"KA^6,![7>1E860-*&9.VE4X`9-B>I^SW$-`VZUMZC8+M""^L MX*?D-:G_,L3WJ1^%NNJEHFNI:I)M9HACZ60$KSK%3538-Q['$UZ=@EM(T-PD M/,Z,CXP2PENV6&.IK6`D0(ABD0#5YF&M'!JF`J(![,M>!IT`Q)]DYV8T4D$$ M<._`\,80TG68#4EM,!:^%0G5S(N?I626P70L_#V,0.913&)SXUV][G?J;;]> MZV(XH6`T>3NWP57PTYL;ZG%72[%?QOH),PAQR9+.4V^V=`WNQ!906#U!L5L! MW'=Y`,N:95!/7_D**8U5CS!4>111W1Q`/I0%OJ2)O8XW@X'*G\&V3).!O::2!%^_-DGEJ2M'#\&&NHB.6562RI M]=/H)M7HWG`T/9:M.4Z<\*?U,*7B2A`LKN)06)[G+I7%`F\\C$XG"%FC*L0P MAFW0,JS@L],I:ZY*QWGGQ=8>VAHFT+O($J3A"$B74+8\?/D4N^A,*.5D0,O' MI!.4&UG(I:T6L\AZ662+--:H'3,-I.Z48,.4,FS$14$%I/R[L1BQ\.TQ)H@J MM#U27A,&6J-D*F(+%'?31,#*)S=O5`FXEC\[@[JGE`:UT9;@$$LBJ)@<:1:" MCT5AC))]V)K=KFDB+S"2EW8:R^;@2C4%UFQ>%5"W9/5ZEH53$+-&PLD>H7X`78NE)`CF@^<1,$ MZP5C=FL;`/-S+ZV\#KVO<_`C2OE*-_6Q#2,)6@G*0VFPJN"VJG:.YF@:8^7^ M9U/O.9]'$9JSI]*6(^F,/7="AY!FNM`D*-%SHBD=(VLI_`GRHA6`N0R^VAXS MWFH;GKY3ZH"NH21:RL,-&4<$7OHW*'P7>.\V%2>2B.4CG6NQ>2:IP7Z+;T&0 MW\-LYJ!:^;N-XBO=#_4,0$R9EHG=.=FWJ[-7BQ9)6/=_#430*F(US7A`#DSH MN2DF$*#"NP$607[^X:928X`$\W014PHQ>0IYZ9ZAW*E0XU%5%XZ9ZIC MJDCFX:K.X,PJ2DKA&%4S$7&N+T`-8,4"_`^;!]F#$\\YK"_N\KS$G"'8B(2IG6*,1E=>=T(V8W,)A2B9C)8NZ MD0WD"XXW=LJ/D?"5;<(QPJV)DIS4[=VGWN;+::X:U6WCL:D<#RY2-(OX_J:" M^XH4'*=#;D6HP<*X1@)!@RMD!N/&;&[HG;%O@;P0HS2YK7OE]EY/6J%&^`BZ MI"$]!R(!SJ(852N0A.Z`:#2YQ&:U#.XUUZ(@#U<8VXFDRB`]3^CNAJ)NZ+ZC MIUHAMA8,/ZEHTNBTRMQ7M73X-:OHQ5RVL]&`Q2TYBRGGYFL+U9%#!L&XFYTI M-?7##")LB1CG*DQ'05:D4@QQ,)0G:2J\94DRD.YW[[`N(]U#^)0 MT!N`X8^'F`NDHC%G%9[JTI<'[]WLXET*Q3G7V:A=4^5F8!:`!$68-FN6`NV* MM5\5#'ZF-UAE0P/*X,XTXV*J0+E;M+EQ/HV'"B'H!(S^@=?$KHSZY.U2G,B< M,\4J.G':0OC^FH)EYKA5>[WC[MSH7+3:I?H77='YLQ MMZPE6;]6UD-YO-*)7EGF*OF;;H;"0)J&788WH12G;FY@+[P*5F/;*9_%4&G! MFE#C,R"E?(#3F>4;P./\$3.0E>9F?DGGQOQH46LX-2WL,"D`S!R>9A*61?5G M#5:],`R#ZY79"1T6CW;SPB*2">"T9V$\Z(:EF\? M)12D'@52787QB/8`\QKDWM7FA+=EKEGH-W<>U5MENP-,X5QN&PD[3"/VM'"S MAN;+]HE"6%7L>@4,_.-2VL.3@2>OX$MOFMC_3:_2K?'68P88O:R`Q MV]1"HGMCC$RS7B>I(:%+BL6-L!>FUH7@B/"UC#\OBFD(*]?C?\*JD+59CBG= M+-+-)]VB/D(9?W#^S1UG`5^:5`Q239PC,'`J1"',BABI[IH&J_.NS$:??#)C MB.'9-"%7JX0>0\%9.#`7,&0;#CF9."R;QQ:5V^21Z>5!*Y5,9[KT+.4#ZTQ; M/;2Y+@[EM&V,#-/KI))AEHN31F_L5I5E*??"11QAG#RK>ERN,]'H1Y0-XEP) MY8^J#$A^'[G0MGE MKDFP23RS6/H6+H>V5%UOG4MQ(?;/)%_' M7J"9-JQ/B2QMZ?`SR-%R;^Q*KAG;6XDQG,^5]C"3?J#QDK6B$J+WC;^"<;M&65:H-RY[N87NKBRUFHOOARO,P_>KU#]_:. M#&."&^"J1E!GQC(_T@=(N["%`L?]O:/C?-9E=6T8("""?7NY#.)-+X=L&UK^ MLW934+R#C1B?,8N.+2_M:916Q0#.$.]SI/X/& MPH06TJX@>=!:P8TQVD/+W9DTE*%$"B55Q"P)?E=(;T=2T/V0=!GV%FHR7.HR MIIFY@'#HO+(R;Q_VRFK=?0_IU+&DD[D6RNW:2_`W]$T.<@UA#7COVA?I-=UH@%#`,B2$)S)7*=[,30HW M`[G.S3N4OQ9G.;<-R6%A_YF"E)BP08P)CRFG4BM<-@Y+1;3&F"ZIBG<3W!]; MWQ>Y88[0*]Q+Q(CFEN=\JR&I=FY$@6P?CDJ?40+:O(E8>5T6CA,9KM=I)9]$ MEQ9ZD8OIM#6/ZN9LXQ=,ET,R<)""#KH]V,K@8R62H1#*)=7F!D;#F2+T0"Y5 M>=J`"9JJ<:RZKZ*]HILO%1/,^9Z*WBR=[FZ849&1R`Q&HAK'$]!U6ZY'3,^( M160Y*?>0,NQ-W2*8[B6$]$SF2"'O`4)H%AGJI:$]7&`1W4?[^1I?]^JUO=;N M3J>RVPEV*HW67K6R7>U7*[5F;V^[UZPW^MNM944!04[:Z^T?>?_H??ZV^Q;0 M/5"W%`,QY19K7C!9JVPE5=H*ZB8") MB5-T1RDP0&!LV"@/RRZ<&Q".=Y$:,&$**T'>^A;0(",,BJ'5"22+-+*UU31D M.I8+%"I%$E0.@OZTVXR\>F\0_DSEY."0/G7_SWSRY%6%[@IOW-DS!/AF.+GX MKU^P%4EI`Y$BVN\DO2R%^I7^$M6M6ISHHS<'F-8\V[0>MG-(K#4?WXQ/TY$- M4KO=_N1D>)1\:=Z8E>/]?^WRP#3B9V0_+_C5VT\NISH"]9]IRCF$&,F4['`5 MA"4;ASJMN=6^JE5<5HACWCK16Z%UUUSQNEQ1$Z[(=:?M,!$.0:M56,03%C(9 M.RX3(;^H:Q7+[2F79AQ5\+03,]2@JD0"8T^T,OU0>HJW MOGP/E*GJ!E`N67J:A#OF#5FAM;5$6W M9T&'[Q*#HL85-[K,ED\OT4-C%M/R5G'88YAK=8PYA@J4NE*+;G/LIY1;KJHD M='96J;I5=UD;\CW*KZ]MSKQ_&*'Z8E[3HG! MV>C\;=YY_VP,[%_O=M46Z2Q[5]O8A0R"UNA*N^4M2S!8P>5:]QUUEH1U]Y.K?&O'J-;_>;:\IN&:_-\U^KQW_ M7<-/O=+]QI?PSAB>.S&Y4AO<0Y ML$[)H`)$],KP$#T7#Y%J%TU]C^G%09`KOC2"X21^[+.+5)-N+24XEA8]Q-Q[3*.E/@B(S4Q\V7 M-%3?>]USM_GA'@60MY8@SC2)3\?12?C#//K$Q8K;]6J_OQW4*XUFO5=I[+6# M2J<;]"O]G?KNSDZ]M;O7V%O68L76EGW<]K_V#[[L>B>]?^X>$^%/U<.K6;CH ME@8K)#A&@J1&%9/PARJ%F<69TI5]B`D![$P(H0:H8LO[1C!Z5"6L,"=\[#03 M4;\;&'M>C0+C-(TOI]R]P>Y7%I])NV0XBY/K*)*JXI("8H:WT.M0Z*9G<\H7 M?4[Y)\!.IY$,H\@!40AEU?<0KI=AXJ(D)%!/')T$"S#+CEJ>]64!E\0*BU.0 M!V=04`2HCP(\NG21@=P&(Y`)W`NFQ<6NE_)K10A%LP]1WVQ\F M/*X(._V.?*85_A4;Y"`^"$\:Q#;M^_W!X%.&5'"AL^PN1TB"+,9]TXV.J'+" M;`SU/3*-(X"4VS*85+:,XC$AI9O=X2Z<-[[N[:1;_W!)K-5=!3<]'<14/J49 M>(H:0S=^HE]]/?AL-H+QZWVKMP&M18#'D,1G4T1^0&`%!E1!:*:""TBR-!&$_+;$")20W-+0NJV?^0RP(X/H(9A%L9>*>&&X:*>A3V`$S'C#8FD$',L"WU)K& M3!&D11'=2ELD.'LX\.%(FB29X6*-2JZA'7P;'I2JIK&/$B]20?\+A5QJ4GL8 MM3Q%E_N`(]RF\%W3P#QP<&8#:A_QO/II/LF/$=J-,+FBV]_I! M?V^[TMUI[U4:W9U.I=NLUROMG>V=6K.^M]UOUY?,>N#!R#9H.MAQ)P?]OU>V M>\>[.QX8$H>[7X][)_L'7]^"*6&MV4+70D%P*RS[BJ_Z_H[2+<#Q+(`*R/'& M%;H;.+[@*\P#0Y\!'V?0:AM`G&T2P9._'UX\J#B%2?X@O'B&R,F-_[,X7OSF MAL;8?AA>O*5%?DJ\^%V#6*870[/5P!T(]BCPD/KM"79=961-TYY$H)\BM+]P M(2$W3R^@2]H`]=XM^/2,JW(70+UGX].[J-V;&V5(]444QS5&_"K+7ZOY-Z<` MJL+K7#5R1Q<+>)51_,09,PTJREC/,KTTGW(@"1ABHN02-O&EQ\\%>S<9SN?F M\@Y!THC)/<2&9YR=HA@2B'S\UK)4DW>>-,&282K_ZQ?.S?GI\RU;PN2@)LWW MOY`?;G[>18>*V25]W<+2I9?5TK[B_N5X M`IZ_F>8AR5_W$8S-N+]1'?C,>VW??0+[\IF_2H?,5]_#=4ZM\,F+`#:L(%'6 MR<6OPBDOD[Y6>DV[.]_X$6ME/WMA^7I/#PWY^XWU^M9YO4\ M8\+4_)P!G2NE,[N:-85A=A3E$=V3L#.F;8Q;UOP,Z6ZWY5G$0L<8QY*D\AOMK^>>Q2ZSLJ2Z-[&B3MT/VK=%:%=#?ZS]M<6-Y4;=!\MN[6T\F(`/E`9K,A:L#+VY][/;M6O-Q91*>L#L98KST#&>A5=_>[2R)4'&3S+:SFNG<2?<#VO MXO3.5EB?I!/N/5R>-;F`E%OUPO5&T/;KS=O0U]:U_W>0<.&(\)J"14WKU]HU MO[;@U?=*XL4^T2=V*!`3OI4E$H`18BN`6Z_I> MO=[T`_BX=)W-HY*J$JD!RJ)Q&"?4O1[[/%-9]]?4$=%XHEV58! M2J&&<=Z'L.K9(=XP!;)@A[K3:(0+9HIPY;2JI-&=QMW:&U670MV^3R-O'$V* M!1_/G#?_HA\;2=D=U=EY!UR0T,/.??'DAB9`?WZAJ3Q'1S[52^]FMAQ.END1 M5(C[M\M12/507IBK&I%GJYIX!>*NX:X?Y5[>/\7WZ]3-Y4_/Z,B9$@$2X>[O M]O-\2@I-O_7MDHU9\\SNCR@;Q'DT?^0#(W4+?V"-\H*D78VM^BM"4Z98#=.[ MBC*LXKB#^H?8=G5-TH>3](ALA1EF[:?))".@%/?W)U$V-@N+"Z?C?[`H>+T; MA=WHG9]GT3D85`5Q`Q2.DSP>N+]^5:3JY[@FW/^ZLXNZK=(MO1+4N:B-CDK! MMD0HEB:KS@7*&+XMMKV\R*,-OU-K^ZWZ8A6GP`G>+A10&CA*4K.;!RUWGQJQO!-;K>2'#9(%LI3Z&IT:E9_W-7MVNX`WX M$\^E1*>XK+-I^E)=DZ>6WM"JW7LZ+K>?E>3_>) MI\MX_XCR233T"VDD/Z-A%?C5;LNOK@VKNQ1?8^N1Y4C+2Z.GMQ*Z6]7'I;;_ MY#F+S98?U!Y7I;($%M;3R>MOR=5:8LOX=;\-RV]5JRMTP%[)%0[>*HV>0V+7 M%X-$6TML5V+7VGXW>`&EM]1VM:2@<<^9R5I8K\WKM7F]-J^73UB_AGF]NO5` M7U.I9G1;]GC741;IDB#N,#>WL1[8K87.>JO>HR-4B:O8`(US56=;I5A51EBW MH1LD#0LM5[C;V=6\;I!62Y;+**M0B=7FAMN=Q2FV,CUK5,^B+,JQ`0]^0UJN M$"X3/26)X]3Y5CG+>]8 MU82YLXSS?&I5@F'9E%T!WZTV_56O1YF!],2S?E*05NF4-4FPB;*K4IN(]>_-*DH&9 ML3DP-X1TMOG@C)N=\C>Y]XQ;$LA]G7)J!J1GY+UK-SI^NPMK>=>N=4#:PGK> MU9LUO]%H$';TNZ#:\FNMKFK\0TNF^^TZK9^?@G\T?8MU1S<%'BQ.`]WC.EA< MS6H5)9)>N3`3=E(>C*;#0M\GIV[/I_Z-5*@H,HV;9A:_?"UE!)60*P>*[D"'U#R>[.V"/')W\CW=R MU/MZW.MCQ\4WT;WYO\-Q=+.Y\5<4#X"I74ECTNZZGW*O?Q%'9][Q(`8^PXZE M(*G@?Z.,M1HHLF007X+(.DNYCA*87I\,GYNZF^8/U.0*N?!C;HB>5+^$PSK'/N9EX_].WO\Q/ M.Y\^O+$B7E4X?J\.RZX:&8?#B%K3@RD%VEU5EW_[BU4/BJYWG8#D.G;-HX[, M*9NAJ`ES>&U`9E6F82>YD#;FULG>91@/<;AWW9K?;C9H%%24>;&/,K;!C9,8 M3#4/!D6M!W:>:$8L%+\4X<82%^>M=)A>]N;&_'7?1]HN("!=R2K@@;UDV'.0 M`W>EG/VATA1L+7X).+I1"]K_^^UXYQ=O&`W`*!WE5&CK"-S.7BOH[VPW*]M! MJU%IM-K-2G=O;[?2:G7[O5:]WV]T>B!P:[_\WNVV6^W`+/V.%;C+_1I-^F%^ M<2C=J[=OOH'RV4_VN'-Z^T>J)I:M08K[_'(`'VDWYX&:,MNV0,T0#C(^B"8/KMXY.LSR*5JG>5 M"E:"("."@U%O=H`JD%M(LOAXFABR*IK'`HNAE M>!T-C`_OWTTO]4/@K*Q M'JM7Z@$./;0>^NVC-?AO'X4@BU*GBM0)EI$ZP?VH$SPC=>J->FU9N0=$#ZZ] M\YK@D5D_O@?F$)A%DS33O[[/UYDVY>_3L#M1 MDH(_-F_@,MJ8,6=?_NVC-7>]]-\^_CC-T'3]_U!+`P04````"`!5AJ1`D@`L``00E#@``!#D!``#M7=USXK86?^],_P=?^G+O3`F0[#8?LVDG(>+ M@=.C/J'8N6W>8\G)B_/-Q3[F2&+G$;TPRJ8+IXM\=^XC"=TZ=X3^/40"_^RH M?ST''GV['-PYAP<=QYE(.3MKM9Z?GP^P-T:\R8+.#UPV;3G-YG+@WT,6SYQ? M#CH?#DX3?QFP.?7.G`_M$Q>/3H^;)Z?'A\T/P].CYDGGPZ@Y')T,CW$;'Q^C M=H*JRW'(G`=LGSF'[CY;-.ZUO]W-4'"1YV#%^$U?E4#?N+,QP,\ M<@(>SN1BAL\;@DQG/FY$SR8-95$ M+F[IB/%IP'W#4?U_'=RF8%#VA'TF@MDEH[G:4@U;1GVVRG(^`,J_'B3,.35& M;W1#*+PO@OP^$T0-T?61$&1$L%<4@&&O_R2$/N*X$LHT+6<8$E%"QE M-L47OL2M#?RZ!L?&+O/29^W=1X52(\WV_BAM$^._(G^.8N7W(+7^8 M?8.\QWP,[L2%^]\Y"?6*@#<`K,PB-2/VB_Z5X^];+`\21IDPWP/>KH$UN5!M M8U;V(`GS(?<-/AX3-"";SC`5P<1KEXY`B6E+NF9_<`O%3-?HN8YN0@]8:"WOERS!D"7@`+D!2J9%]%:@RGIX;TY$D>E/T>._(A],@'Y%0U\Y:/"$S[%W1]"0^,`A M%MTY5S'(WQMF16I-C:XC-[<'0;WH3?TR3A8U5O8WD)4(1Q?&'5?`R5!9P>-F"CS M"!_*#WY"OK(@%[*+.%^`P0R")2TB$UHKJ-ATRFC@Y.<"6&]F@]Q@4-["3'D%X!Z,,3@JF,\X$1C$35RB MTB/SZ3QPK:[F'.;W.H46:>F.;,_%UAGGU9QN$::,AKUD"\LJ*?46V#POF`]E!P2&Q@&6$A.7)4<+>%%%^W%!E)C^Y5GL1*YG`N>9AUQ M=]DA_'X8]:M,1\&F:0FD3BZ9)^Q-ET(RI?#L9T`;'#.+`.%BNTAQ=KLY.W M)H?\K'`,_/2M`=^VU14O_'8MH6_F>E(Z+C.1%6.ND<-BC#E_$R?&7D^/)1^[ MP89H+(`:1==FMBTSF1CCK5&$9H9W- M*?F.O60!8KR<$G7FB6IT56,&!3< M*H2YIS\E.K2#']0'%C)4)M&;`*=-;1P@52NMWXDS(K6!"<8->;IC M0O>:TFVL<)F05$J$.HZU[:WL^:=9R9%T5DMK50I%A;Z%R-)^,P9_3VT/)%RN M?!CY-'90/&$ZQS?@FGX&*ZU5IYOMK#K/.B.]MHN3]X)JN75E@GNK4U#+W2H3 MY'MW@FNYV95IAE,;VUDVI)95"5NAYMB=6J:!M]K1M$++AC+6]5U&GS"79.CC2_">56(= M^>%#==W8#482_$(-UE=U90?S#!8%"58@_-_'@3:",&'*@.'O*&>*&I%:R8`B M0I5BZ]$'F&.]4:K4=E5GJTN$FA%;R0=.9^"F+#<8)*)C-:/"VCO0;C"O*"A^ M'SP6T-NN/U8SSP4:=50/WLJ#A-3"S:*N!ZKUE^-?9 M73K?T03,R_`;D%8#4U0SO)QTF;7#QBB-.JL&[G3)N#'"-3(K6(28J\M">Z.@ M(@&D^P?B07K@AO$'S)^(BT6/=WU$IMI75Z@/2WM12L)@X9\(Q!F7BZ\"@R<: ME1C0\84+.B)/L1;HH$+X;L'O%+($OJP.*H1O%>*^%E]6!__?*]6>$XWNF8-5 M/<"S.7[&-5*6N[E52DK"-,(JFKE\P=XF^)C67Q$YUT6SE M&RW5@^:`BK;NR+R'JB#,T9S:YE;N$5G='YV\85K#N::QW9J@5VQ4I:I!"@25 MM3PUMB$\"RO0V5@(ZJI&`BN?-UBZ^T7O\\82I41GB[N2A\[AC ML=1(T903B]Z(QL)X527*FY&&UFF*!?3QW0C((`J/Q5*GNL:=264S7H@%4J=2 MQG(",4A6QV(Y>3_+IVC2.Q;2Z?L14M%<4NS=U:E\O/"NX<8=<;I*QUI>,E%. M'D5V)31W;-5S39G*ITC.KI;7<>UX_F3O^FBN,WE74Z=0PKN65Z*4D]?V`B7- MG2EO>Q9MWP0O>5=*M<224QVSEL3*/OE7_SR5H03,*N-K>6ZVG&!T6P1U/0A; M:HZ\YL1(R:-4M914P8K2NIXT+B.A4J<[ZGEHMY3`3(_Y:$[LONWEMI,3SF\@ M__5J>9D=6M"<`7YGLC([@E7/RQ1V+*JL\SVUO$9^UX+)/,Y6[DKB?_;,N?[7 MGGM\C&@4,8`[*)A//!1%$Z!FA/K9Y3!7D?NC[^HR=S*F!/Q*E1D+UQQ(N@_] MI7\SNU+H5X8G<9E.15D-]SZ25_VH.Q"`[UETV:BH/H;-*V15VZP?%J\4VS&# MP6[<*JQ,;D3%@>'+_P!02P,$%`````@`58:D M0/XXX:E\$@``6C8!`!4`'`!N=FQT+3(P,3(P,S,Q7V1E9BYX;6Q55`D``R%! MI$\A0:1/=7@+``$$)0X```0Y`0``[5U;<]LV%G[O3/\#5WW9G:DLRTZ:V!.W M(]\ZFG5BC^VTW7W)0"0D<4N!*D@Y5G_]'H"42$H$"5*D`"K,0VQ+N)SO`#@7 MX.#@PR^O,\=XP=2S77+1Z1\==PQ,3->RR>2B\_FI.WBZ&@X[O_S\_7C7OBV`0;P^Y'[%/[U?C#Q`ZFR,?&,WIUB3M;&M=X;!/;AU:-.YO\ M.4(>_M%@_UL&?/3'Y>.=<7+4-XRI[\_/>[VO7[\>86N":-?E;1^9[JQG=+NK M?G\+*#PW?CKJOSDZBWWSZ"Z(=6Z\.7YOXO'9N^[[LWCL]/N^_Z;<73XY/>^_.S_N_S=>VITO MJ3V9^L8_S7]!82@)-?H);OQH#(EY9`P?(I9,>M'W:6Q7L?/^=$10^?_7L1(6OIZOB_=X?'^^>S"F>H:Y- M/!\1,U&1-996M7]V=M;CW\9+`QV6ORX>)^MM+_@R*.W9YQ[O\\XU.2,EX!C" M$NRO[JI8EWW4A?$X[1^]>E;G9];A!^HZ^!&/#4[QN;^4P-"_X!U0;+=5 M.;E7R)O>.NY7;T@LFV+3WX'<[;:J(?>3ZV/OV5V/Z;I+[YY.$+'_YDOLRB6> MZ]@6_V-`K`<*(A=6(_LS-B&BRM>V9P*F!<50^LF>$)@>)B+^P#1!C?B@]!Z@ M/=.&OO&K?^FXYI]%F:,1Y74/Q2VRZ6_(6>"(N#KXEMU-W2`_8CH!XV-@_K6P M`[GBP0@`*?-0S'CUHB_9?]UL>?*AEZGK6$#;#9#F+UG9B)0:."'?9=W@HSY! M`KJS.28>7[F/V($BUI7K`;534#J7S.!]0$M>JP:6[$I(W8P*M!DX!;5.C,Q> MZH9X@R@!Z>L]8,HY70,^<1=U@[O#$^1\1+[/)!"!^<0U#3B(]6A(N>[J!ATN M'C`:_>4S1;"DS`TY6P/T(IV&#$#4E.6!P/-:^73,Y7K+68,-L'/1V?Z^5SL]5PO*G.];D&/(^0]&]`:L5Q!U*:0) MB]9/Y6K,@KY!T=JN=0N?>2EDBLONFT[&(SDJHY+[HS$V[6&9X2%HNBQ"4XOO MC]I@',63,[W<_NA[AF8SR.)?UT\-%VC,&D,C)XV6C(#&Z[BI4C\U MM[:#Z16LNXE+Q:.<++4OVA[QQ/9@=A'_$YH)E\9FL?JIXSY5T/?@U4X3P)LE MZJ<)'!PVBY^6LY'KI%"4_'Y-3V2V#6B2,K#Y5LV$YI^HGB_(T)YUGB4J?;X&F#_^$``9CMN$5Y%!D[J'NDFZE27?05SRSN( M)JFJ,=S:1=\$)/!HDB.WT9+-F0"SX!/P7Z\Y&(]OA\RD4=!ON6YD6RCN< M.R"T+#L8^`=D6T-RA>:VCS:=T;S22BCW/.QO^O$;7ZJC:S!BMHLIG!;)0NKH MS)F]B3+*J91BZF99%52'Z^(.(P_?CQQ[PI5L#K-S*FF$XY-+S#)08O74H/&F M+)P"?K"XJ1?DL(B#@7^%*%V")<.#ZX2(9.HJ006VF>WSX(G-6!$1EHP:JA"$ MUF7F$&P64T'K-1YCF,'6(W#O"G[:?NYBR*RB!@.%"'=>Q3GE^Q125@6;R$8@I9X/U6"'(^V>G5=,228V9*5U>,+5NB M:R+'M\F0Y[X.EGZ,G%Q#(+VL-E3+,SZECA(4+ID\8SKCT<3A!HN(^+2B*FB^ M]Z>8!HYJ[GQ)+ZN"Z@<:VK"Y1GI:2444SY%MW;RRNR!LVRW&S&S!*%-3#2)W MCJF_?'#8=3=B,67#CS)O9T69N]ILY.FG'W:];'3B7[1,_+@ MLD5OA%&_X!EYC)'+'N'1+TI&'H_`T(K`Z1*8P>BDC?8WX5+]HFL*(A=A4A0:KC3)1,59%=__BPY>U M6Z5S+'3%V-/VC'2.DZX8OM[QTE6`S3Q3UCF*N@KP6:5U#K.N>)8+CGET#L.6 M/U1(Z.0B07XZAVB7@Y\=#:!SL'8YO'FQ63I';Y=#G#FNJF*VBZ$4GU(E@*8> M"$50&Z&LY:!FQR%%D!NAHN4@2P0C1K@;H9XE9W7Z$7.$59$BWKHXG'_VD32S MDB<.!WAON!A#-K?]H@'6UZ&40R9OD4:8%7F1N5>)L@_,-+Y/)#.815R%U)B` M:/ST-8^+N\+)X.0(H[XF<3&,PDM`T6[SH!!PM_"O/B[V@8Q4BV:FB! M8.AY"WGJP]):4"[.GB55Y5"N*=1`S9>3]FI"JIE74(Q)5E:/2U*8Y532!4>F M2,NHH`O]^8(MKU8;\EESR&=M80BK]-9QH[:!<0A5QE6`-E*/J-WMJW9/3%:O M-B&LI`SB;8W;A`B2\DA7.KD)H2/E4:;GA=(X4$0.JI0CWX38D,)PLY:IO@$@ M)6%NKU&==[%+010L4$4[V;J1Y,E9%-^)GZ$YXC M]HRMLWS$ICLA;.'''^.)S@MB;Z[%7F9C[VV%0=TB+[3N7M5LT'D\7C(D0IQ^ M9Z.8#K3FW$H3%E=!^^8[8)?(LTW^&*"S\(4S+J^65AN0:K*V8((I&F$FE<-`%?,VKI0()"%;*PH2N5@CT_4##A2'P")31GSY/#*A#?&9>JVFZ.!\P"7@1\NG,]T=1) MEE%"96ST$L,JHEA87BOJP M2Y:QD(YL&-EUU*!XP62!;\$[^I7EQA?-GNUR[9&(#EDPME]A99]\^1W;DRE8 MH8,76"\3_&G!'']NH8;F:=[!6-E6U&U@Y'D@&]>DL]9N$_9KBL#--<25;]Q4 M#+CV/8@F7.HIPK#MK0;U%WJ^O:ODTJ9I4I9M:?`F1/J7PKJ+'Z[\*D!]3)%Q MSIMP:ZT4_#Q_H@EWUTH!E\*LZ.BPC>ZH^MQ-I,L/)YXC=2OC<((X)-;XX<1R M;&QD'D[D1NY94?.C-DIO("B/Y/C&C_]9KK=;Q_WJ#6%`*`:)HF#+:V#];^$% MJ7Z>7>9J$]-V<$(>/+N,T@?JOMB`^7+Y&73XD*S%_P`<\I?@?AFY$=^\I5+0.#[ M-DC%2TSX#5;D!!\R:7J+D;\0WLXIU90:S',0CS;?%X3?'I;"\S:)'>U&QQ.P*S`+(FJ>F!:V^MA(I$F!.YFM7!KA1C65`9$LOTU.X",O4DE0![M.@H@) M@BAV#6-(0*].0>_B6Y?&;&Z>LS`MJ*-$*THXO":3$PCS]W?P!]GY)E#XA.F+ M;6+OGEXYR!9&`15KHPU"#;@6SZX&#)QAJR_@;UI)16&S:=L\82J?^#:/.*96 MM@&]\>7%L!9O2".\0Q!+GK_#>*8UH#>^%.V88OA3&N@#=L79D9! M2^ZH@.Y[Q/,%!7WO):T``>D2%57BN1]_Q'2"@3:>98\?E=QPL*MY<3=;B<6!&=B_D\B.5&SBK$ M;4C&+IWQL->*!U3QP3R4+U M#[WJPZ-R$6P1!_6]-[$O#A8\:XM8I^^=C+VQ;J>0JHB3^E[XV!Y=D;[.OBONPI_I>5%''1W'(4<0W??.5%@^ARN:&7("2\ENG"C@C%SRJ_&U% M!9Q)"T1LPG-N5?,A-ZP>"#<5(_8HJ\+6>="29PZ1\S0UPNLGAG;QV(1'_3U["KB@T0H M5L0-?:WI:KDA'<@5L49?<[KZ!2,5%1&Q1E\+NQK6%`GZCKBB;W[#\D'!B41! M6:D$FI#7LAHV%(DQ;$+RRXJX4B3NI@DI+FN:+.D!F^HS8JJ:)X4BU!J1?+(2 M-N5?:&Q$SLEZUM!VB'HC,E!6PHPB]Y>4IZ=L4S7N)_7=J;XVEQRP>@[C(O[H M:WU)#[ST+;GT-),FLM(7RHT6X]36& M=L&]E>TN`JROP2.IY&5#<"/(BC8M=4D!JF0LBP5*I^60#_*9-"*G='&P%5V" M:41*ZI+<*9-BIA%9J\LOC8Q4AHU(:UT>>6HBF$;DMRXY^].O;Q1-:[W/[,]\ M"3Z[H;V)G+56\^[I!)'P3@6L6<]U;`N%]RT>0-0SD('\2ZD'B MDOAAM!N8.`_0GLGD)!!_Z;`#RP/)>7I8N9SV/@N2;%!&1GO_K^;[?VTT8KNG MNL>G8?8NQI2[0+HXLGI8,VLC//8XX\&9'A6D6T]E3[IDSZ[3&E"M4F^5>JO4 M:U3J.4*KU`@-#?^(K+'GSWSYF[XYR&KYL-2:B7',EV9E&RL5>:M,F^5 M^<$H\[(BI=7R6FEY?MXW=1V@W6.A#?Z2E8V&KE7L6BOV;TK![95.V64A@B!; MOU7?K?I6$>`E/\%;C:V5QH[&B,?LK',$QB_11ED$U]`L``00E#@``!#D!``#476USHT:V_KY5^Q]Z?6_5G519MD"OGLUD2Y;Q MA%I9.)(\F;VI6U,86C(;!+J`/'9^_78WM`")EP9)W225Q+9$GS[G\#RGWT__ M^(^WM0U>H>=;KO/I0KIJ7P#H&*YI.:M/%T_SUF@^5M6+?_STU[_\^+=6"RAW MGTCI`00+_`GP M_TW@.N#K[6P"Y"L)@)<@V'R\OO[^_?L5-%>ZUW*)W"O#75^#5HO6^274[B/H M7TG=JYO$-S-WZY@?0;<]-.#R9M`:W@SD5O?YIM,:2MUEZWDY?![`-AP,]':B MU-B#>H`$`A-I_!'(;4ENM7NMMKR0.Q^EP<>V]+_)I]W-NV>M7@+PP?@!/8R> M1"6DE"H85V!DVV"&'_7!#/K0>X7F523)COP`D+L=_]-%PO2W9\^^V/`B^NS%@\ML+6S/N\;EKQVX0B_0Q#4,6ZB2L(;_ MBCZ^`/BAIYFZDT(D;/WKK=]:Z?HF%&)CG%)1%]>A>N1##-V4@O`M@(Z))8>? MXO(%C@K%8Q\3H5BL:Z0$VMC;KI=I,I&UU/UG(I"JC)%W#>U@9P3!8JLM4>.C MC[^-#`-Q(_`?]7?]V88CQT2?>%MH3BS]V;*MP(+^>.MYT`EH]<3H3Q=U)%SO M+,0R4C9ZT'>WG@$K.0U+.5ZM;_8SEK*VD0PII?`,O\=&&9WV2Y*TG? MNCU9D@??I&_2Q4]4-(AD`R0<1-)!0CR(Y/\8*GI:VP,4[."$NP/DE`,VD0-T MY``]?3$M>&B`+8)6BD`+#UW70^65"&WOO>N M17#7-"T,VN#Y*"&&ACY9G'C43'(4IPI\(,8?OQ[ZP=K1%%_X?S;\][OR#:7U3@>P<,%."X#4`*$>`"N"O\2J`*H+N'T'6!L< M"';Z@%@A\!M5Z?]$!0BAWI7WO1NXP-MYUT'>M;%;T:<&=NL6NQ(%'W?G2GU7 M^T>QH>A\?$['L3.]KOI!T(?&U/@]AP!S4"D3;KOM_K`7105:&.#2?/E[C/(RF_+GYDXN*##@L^T3TE3[/@S\ MO/`9?LFS.20ULKWMGB1U(JB24N>!J(LZ4H5-3%6-^UCCA;883@W>FD\"J^=U37B##$-@2\A1V*0PO%@;ED M-B_U#'=;V.+P-4-"`,QE@Z,L##0*=QUA]V!E(7TAL3N^C:1$#Y^FLV4Z2+JAX@=8A8!*A?_PB/[ M[=:W'.C[8W?];#ED96X.-SI>:;7?\0AVY5A_0'/AZ8Z/!_.NX\>3=7>6;]BN MOT4`&1G_O[5\\OG8]0/E;0,=/U[(VGOYYZZ5(S?/;`I;IZ;7'D13850=D-`' MQ`J!6".05`DDII`32H&$5@"K!:A>8H)&"M'G5;;SF.PK&NN>]6\[JBVYO8='++BW+FUQE M"K'A\$:6^DF:.6:XX2(A%XP"0"4#(OHLG-M`SW)-Q3%+>7="R[O$\M'\9S": MW@'EER?URVBB3!=S,%H`!7VDW8-'9:9J=V>T>1[H7L#3ZEZ1U;?*9W4Z5:>? MSVP[6XP]H=6):(M03O:_P%BN\/C*&IP.(BV3BYH3$\`B+IZ@$3Y+FJ\'6 M;/0[@V[$R5A42,VD,$'-XTFL"QM%[>%!73R$/0#$KK$V7:`.@#(=J\H(9'%<.YW) MT(HGR1@1ND\V%N<()AU1Q!]M@Q?7PRM=Y:_ZH(08DNVKP=:7Z@[I88L4N4)A M()8FG%!'F)=!)#^T3R^T3P"A\M"70Z1,IS2"0*KO;]G)$STMDCBA"FRHZO2Z M[7S2A)(:0IC*9N63QO(".=$F2])`G[J`!U\]HA!A]BOZ/ M9&P@/ID)[?>&,#-_$C_K;8AAH$_F2Z(]??FS>WN/<65@NFXVY'8&,0/]:`:/ M2A`T=U[?CN0A$F(-I@`LL(8?UK/AD\9ZAMU-P'K)B9+48R*N?\<3^H!N=B:4'JT)!`$L""NY.(%G\DP^7* MHG)]&+<'#&CBV:1,L!,:II]-B!7%JI,:+!\83)+,EIC)CVWL0$VSCM%)8MCG M6:\ZGA]E3OY<6(0KV_+U8)Q&D^CA^UA6<\^FJM9Z'0X"^S2'"KQ MA1CNO$+;W>">Z3S05U!QT#O=>!;>JHO[IL'(,+;KK8V[Z'=;U+E?[9?(??-' M"^;*PV.U94P>T^[NV+HK#X@`$-<)HDI!HE805@L.R@D;3G+TV##JLA*GZ`FG MF*%3@A<\7(P=X^TY=A=XVEATFF80:(MF3`F MR_>W^!J51_T]3&,+WX);I-7O>2`\4BK/"'.;ADM5&TJ M-(:"8(+<[]/H:],FW.]<@LV'T)QHCH6"&.G2JLW2] M-5$J9Q6S>OD3L]RD=6:,ZBLKQP+47K?;E:5O'<+K2"9H@=VO>(`95@`2-9Q[ M'30KV)W3?"EE?D*X`-MSP]/Z%9:I*N*@7'FV\ M1Y_M[RXJ?I;3TG*N`JS9X*6;/=)%R[#1R5TBB__:\BG,DNN8Q6-QN11@='6Y MV`N\F8"7M]EX$#\IA`6[ZEEW(M`<^?M@(5L1&L&`.B9EXK_8)/[H/P!5-O;3 M]O-#?J(5FE@.5`.X+H)_YN.<.9"E`VO4[.\3(=75F)#K4K$\SAVN$YHGUS:/ M)S>*8+=/D%R'\&/)(TV$E+/_+OLYSKQ(5YN_W%-6BN-,>HDJK!<,MJ/-*51THD4\P<^.D,)?2X'S]H4S#_ M>3131$Y[,^(S.:W-XJ@F4*UL.2O_>8'TJK:FTD6(N\DEEOAUI5-81]B4XD[C M2%.X"E3L@_/WF,@LK@7]!;ZA/*,/D/Z>4Y\I52GS?9E1IXD61@#'Q06,@>NJ M+[.JSZ/OE`D,VGDZM)`34M_'J,OFZ;;JF/#MG_`]S_L'S_%$[G[EK'WG3C^! MX'<020%$#$!R!"'Y"'/DJN9P0W8>D%((S[2<&]+9\[\P%N++@:-3I+3[73E- MB":E@CFYI7*.I9>,IG*D#F-6F`HNXD6J.W>M6_L;10Z^YDJ4L$[6H-J^25'B MM["TJ$Y.=>5E1N7YH3D-B31N$^;Q0NB]94-OK`=PY7KYW9OT4USQFJJ:-;[= M=%*P)3(`%2(*O'4MD2M9P@_)F=!)`_K09%ZXGL&5A?<'.<%47^>.-/@!U+[9>.!7:R+OK2G&:2;5,'XJ@V6IWG!SP)$:[#C`M?^/ZNHT9N[3><.I4@E^1S*L& MW20-*_A*"">A`SW=QKDI>[+`T!)*9XL+%:%K<'HR>VH,8S$ MA+IS)239I+D)"F!0EG&!L84O1C\(H17KFM^M^SR!(`3=IEPB$JNL-ZB'BQD=; MJOAXW0HGI0N[BGCU<8G8%$`;<KS6;&/Q'?\3L&2).V/=JN04.&@`3`D M=Z%AS4ORB^<]S9/@V2HPCDC:@^BX>2@&[.0(SRU^O%UR#;NX<:T89BD:%3A" M'$,6^EL\KUDV^UY8A#M7LO5@O9)KF"8,$I:8>V_`U/N);)2CZYRU!P4L1E\5 MH?D[U5$G$]"*0%13.,,1UI5,&"F,H.=U#*'NS@>;R`=D^B/R M@5WL`XZT/H(1>X2OZ]-FA`*:Z[D.\[/*"B5ZAD*,5Y5U9+F`U[M,W@WD\'$V M-RM1>25X%M,PSRW-8%UBW?#)>8'F"IIQZMKX(@-V*C(+%,I/5BT9F56`4/KE:<5Z MR\B-5$#"G7`026_"G/7I'1!>#TAV[N&]>D)OQJP.W&).%KJG&H!>N9C'#@4F84,:R:,BZ,[5P,!]5%`_JHZK(9!VI+%HV;DS' M^,2N(9UBZ@5Z$71X=3JQ/KKIJPD+PT>1HC@",#NU&=%@ACH0GF7@#/*Z_\(, MG;UB0AF>UH5Q_T*'GHS-Y'(L$F"9C6%L;5.'<9N+M\=[L7U&CGWBN)@-R6+6 M93A&#+_"+GFX7A=Q?^HZ+NT6%`T]&8IRY5FY/FR-0UN6=NUF-,J,UIII"YD4 M*W+D>5*+Y93%47MX"9QL\_C1C1VA:9)[!@@;2N%-YWYE17D0U)@QMI$-Z<0VO`.TR-,->-3[+Z[!\"3-Y! M[N":^%Z?#Q?F-4*>55@-0/:DK[:=G\T3Q93IG=8=7S28N,8>E2`(R=Q/(G*B^,C@L;N#IZ;WA;3?.U6)DFBP_&NTD(:T MG$/OU3*@KWEC6[<.+FJH)X-G#Z"*8HRI3+OT?$\R'H2!`,\VT0I()*!5``U% M!5*)H*[$F?QP$`C""(";@P`:+XYKNZMWPFX_JD1H7Z0.U%.=E#'N"W@NB%6DD\OH6.896GY6$KR['U85*(\3KG;C?%BT@J M:7%2*=NDW8CYO0`9&+ M=,]>7-M$7,.Y0H+]])S,Q<0@/5,7-@C)/7KE7$(>:2>2$D$H4C@MCC4TFROD MMA9R-_G/VN1.F:2+>2+6?,Q1M$OVJ[K7K# M=I>9AL+WFIW!]G``]"?G9-$&M$H^$\U1W]^NH2DQO'[ZI"#F1=4SSD'U^\,, MDH4R@"1HZ\AQY@P/TR\F3ECB#5S$N#];"L8",.:1*ND[P?P9A]OGRE\X?5`, M>Z+:V=`FR\.,CF(D0GC'L+HI85<05[';[=B0H\GY0,J!?M+X9B"?O3^W7T`H M$RKU6WJ=?J>=RX@F]='J6Q?.I3W-9LITD1PQ"3T(4`ZW8IXTJ::R-A:) M9\6P)%:`,2/$L"T?$B26(KS5J&50HN&P76?50DQ<-[#I.$16#BOVG-`80K"W M(1EE1!.D8JSMT%1HV41I4F-RE(WA*%^;?FXME-E#$UN4?/R5TD=\NX+"T0)% M([)#*#IJFO="LQ[E29J,^AEOVN[0RS2Q#("%A+OFZ'EH00PYSJ#PLN/D)C>R M_9QLEHMBP,;UA(_*"P"6HD>>,T2PX@%Z*[R&BJ]E\"WL0I]<6HZSWX=_5KC+ MIZ8PCLRJIR'CF6"9=NBB6D"R&C)=G:RH81<#G=TS80*#\2]/ZARU:=I4)%6/ M0WV2S$>X303=IS#`Y\H>/??5,J%Y^_[D0U-U[BU'=PS+68V,P'HMVKA000!' M6K-KQ7A'08]>Y(4DDY.3@,H&M^\`2R<9E*A\$%<@9MAV%@>0L1PQ?D.-?WX' M'[8^F3+_`2QWYNN%YO-B=75P)YEGH^E8G7X&H_%"_2)^'%H?_?5H+GS$FJ.J MZKQ"/SBBL&5HQ+EA)4H^!UCOY36VLCW-`W%A'[3/ZEQK5:G7Y3YHOG-,P/ZZ]&\ MJ8Y2X!X>F=HQ;@12^JP]+KCG($-;9Z/<\!A\QPGBFET\UP`9P;> MYCE-$%_#I"\XWW'^NT\\PY=U<<6,Y[DZ]/`T)E:4B0@7%]8$UK)`IA;89U.= M@?&U5">DGBH+,-'F0L\494)[CYY[%@IA8"+-4BK_4MY[R7V>)S/SE&`]=4F3 M\*>2@Z43APF"_0DL2^SW"9-C-B4_6"G64O0H]$2CJ%(V="PMUP3J5-L<(TFR M5$HA\4/`$QI+VD1M\;,R`]%-;Q^4KX_*=*[\(':,QXI*)G(=,8++255&ME0L MW&@R5[=W=S/FS;BPEN*=BJQ<)<8,4U);#E./A=MG`A?L9,97;YY]_B0K2)S> M3BFV'-J)ZQ M]>G<1/L'M?UV]GPCR[)^ZG'6],-=M?-HWE1[5&8CO/](Z("M`$G)IC//:ZT<:VD9NA-$ET$B M"Q^1/);$1-S5X$E;SK8Q[DV7NM$$;E(_D%*0[&Y,JHCS^&4V2HDKF9`K1[-&`/XK>$C5 MOLQ.=%B'LT\:2?:H(DN*).]DDX<4+<(VJVA21]?[ZX.`M@&R*%)O[LO:8 M:*";_>$BT+V]GZP6_Q']G(@5<+_F7XJFZ]5TOD4]>8G5BZ1Z58PWBM)EQYDZ M"J_2J9]MLO-3-0!XB*G3"38(DNEIKGZ7KK#GJ*A18A=@LMO-][@SECQ?2M&E MU1H-@;+[S@6%FH:BXCYM;W@[2M+1^#XTB),ZE.S%2EI"!#HPI7:A`7;`0&AC M?(J1[\[UMO3(WOZKX:>#<6O>*Z!@@R@5MP9Z8G8HK`NDD5,R$J2=:`UL'D;?TL+Q=MJ6^-;74B`BN\RAL6$?>^**X0>7;#%I_/"4UGD9C`M+H<`M+8QT.W:FV$& MX;U+`I$DEHF;?K1.9<<)947D.2M6$C^[*-@W5>#EFZ<5J&T\/M,^?6YLOG_C MF#S4Y/%-OT520@`F?-I6`7/^C6ZS`VF"PE`X$=+%%FXDORU`UF$`268P+_3% MV&G]R680+:2RT(US\.HOO@E_DG\RJ8B]T"I&\UPX%T^MX5#( M]()DX&*!O#&\M2<^C)B_\^BZ&^KM^*)"YQ.PPDVR"6H1,-E$=Q!<0HVD!GG, MF%R>L4Q*)D(T8;*)$(ZSX5J[XKVTXF)/Z`LY&D'<95042_ELBD6XE?!A%&WQ M)^\GUE]8?^D[YOQ":/!E6P+,"#\8=]7027DD%M@&T"HHJ08LV,,QAAKD`)22VAZ++U%2CY.8KB,F3 MPAV+H,I:!I\L,?$$O5OY)!I!HGIHS]SKJ*GY7;=T:!J4LMJHX?A;YVN'_=>- MET6_D=$7]B_GT[C?B.,Z-!B91,;G!%G$$+L<#PR(5]+O?B'\&I1X:$8/].V) M+2V#?U7F[,&!,.6Y>O!B2R/!=C0L,[R=YIB)HVSY26L@)9N%L:@YP"_)_?#H M6"`RNFW)-_Y3ARVOFNL&P&N-"O>2"@?WF7V)H=`XC#G=@F\!<(_-0`+"5>B)::CR#80-TR*P,^CD9F$Y)+"4C8&F MN.W>JO`*1=9[;+,.S*HJ6PA;?(!3C&X_#<\SG),?)5>(GC[P8U-M83'7D75$ MZFW9'B[#Q!#`L4Y3$)W,9&N`T<9OU2-?$LTXGTD[QL#*^BKHC#-FN4^V]2+. M8;80.Y6?%G-W9B9L\!)'P,7\M\39ZI)2D)`$-`UX!2`^>9+B,W4!0JX&FTN) M4`;6>BTAX['*=,&60\QPHZ>=PV4)-]=!##4?-M$[PZ8/QHGG;OYDJ]JI:]OT M(&_RBG,T)]@9L@H2D4@OV4S@R8[^;5]%/:^,A+6)C:"X/CY21S76=Q"MCC[@ M>C92C.0M/YY6G1E=5W&)E=O0;:R?2Y\&+R$!L5O(:1;P9FVGJ^\&&.[7.Q%> M%_7UF$!%.3=!FXZ&EW?J/(Z+[(;-[0^Y7S'_DWH'RP?-UL^*()&9;0?,#_N: M=7(@C43B\+FKH*`"-!J(X;`%NU1MX4SGA#JPE(9!(DG-]HKF#'GZ(LV2I&T' M=-[6CS>#M<,76:EC&#>"4AT:"I3N%O^>SX((,E_(:KY'1J?0ZS+HY!NBEKBQ M6WJPV?`MI^EBLCJCGO7!?OZ@B6S6>W=BFI:\0+TQ+'/A3(VC=3*4T3XKRVPZ MYFS5!H/\;8.FDAV=804GJ^0Z.S)2^&&+>%&+V'S]Y!(C-A<_$/&KY9"#K)N\'UW^ MB_]J\\`(X00$+9!N73U4%&:WEI>#,6\)(CEL##8J[-EK]65(BT1@OJ(0HF4D M-#BK*=$LX&>F[C#J1&3\$R&;)(4GXW'BQ]J\C@E$Y["=+R=[-@_:3+;[/\A^ M.UGM>.(TY#C`%SAS/BP,^Z'O(:BTY^^`_%$R"?K_(_$<.4OON=]'1,DHZ+XQ(W'9%NHW9)OXQ?X M=1K=@`.F$2JR"!)')\\Z\'A];`'./R.S__&=/[:XY[A/3E.V MHO^TG)>\&W%EI33+6IFF`>=.HT$T>(7B9;Y=<4:#_Y"H@DQX,EY9">95N^N9 MHIM3!H!?$MQ)2B!!#DG)P7+^R3L+_Q6V07Y^$3H<"G9IB(=^YDD#D MV`"%BC!7SM)RZ(+]J.O]%0\V2<-9[<##8+1 M_J!W-I,3Y;&1*:M$=@*G5Z)Q!E+NHO3V6%DN%W$@42+9@VU:"='`_VZ^D_OZ^7L_EV]PN9_^MQ ML?_C'^T")'\VE&N(=@"SO>XG9/U'9E.=M_)W7+]@RQ6 M=^OMPX0?#$>%M9PWIU`M8;U:+L\E*[QW7?.G92NO`RF?:_J2FZH1L(G5N'LS MD!?7PG+$D#F:3'T6U:_-7DZKJ-UY!Q$*0;@]5E&77NI-L>:]VR+AO;A/WIZ4 MMX4$11>VM/:X?+3UZ>'KB_OQ=Y-:W*S[^K\ M[PV,D6>5PL:"SG`89&@("A-9NEGOKM+X'JSQU_9:K5-P;U7K5\M0\X-:+Z\G M:DX^J&>\T-4[#W?_S?"MP\RRW]D?BG*/7"JEZ6&J?!.!EV4'_8X%7[=?/L)VT4V@<[\\OUC2&GUM\GV_F./.[F,S:#)M/UP^9Q MOUC=DV^3W6)*)JL9FW`O'_G]R]5\3]C$>T:<2CI!W9L3N:WQRU,+$"5R/C#X`A),YJU[BADF(0JAW=:M1_X<((9_:/'_ MNRWXT1^7#[>MT^-NJS4.P^E%I_/MV[=C[(X0;0>B]6,GF'1:[?;BR[]%,EZT M?CKNOCD^3_WF(9@1]Z+UYN2=@X?G;]OOSM^>MM\,SL_:[[IOANW!\-W@+3[! M;]^BDU2M*XHCX5R0^Z)U>M(];9_\V#XY?3H]N^B^O3CI_B==.IC.J3<:AZU_ M./^$PE`2:G0S>/S0ZA/GN-7S_=8#+\I:#X`!?<;N<=R2'^/0`M`)^W"44OUE M0/WC@(XZT/999U'PZ+N_M:+"%R_,RU3X=K8HWNW\\>GVT1GC"6I[A(6(.)F* MO+&\JMWS\_..^&U4FGD73+1R&S@"&@4!6](2_%_M1;$V_U$;$#[K'K\P]^AG M_L'W-/#Q`QZVA`P7X7R*/QPQ;S+U\5'\LS'%PP]'Y-D/.=RG)V=1_>\_!LYL M`L-K\2)\.`3H3T1RW>_I>'?D8-$CQC/V!B=(7Q8.WP@AVE-CN; M2OX`-;\^PKS`_!MWPQN/0']YR+\/F,<_<>4CQKRAA]VJ"BBVND\5[A'%E3NB M0M/A&(>>@_SM*P53.9C@GA]B2J#KG_$&6JRWM75QKQ`;W_C!-]8GKD>Q$VX@ M[GI;VQ'W*_[1(VYZ(TD-B*3R1X\Y MH-.,8BC]Z(T(#`\'D;#G.+`QA+"1W4-[C@??QB_AI1\X?U8%IT&2[[HK;I!' M?T/^#"?"[0*WXL_L6LE/F(Z`3O2<_\V\:%UAT`,@RC1>9MANM:_Y_5W#\AC" M5\:![X)LUR!:..=E$U%V@(3Z)W>M?/)-6`&#R103)F;N`_:AB'L5,)!V#)O. M):>P]V@N:NT`DDT%V350T6X&1'^G`Z/P*[M6\1I1`JLON\=4(+T#_>2?V+5R MMWB$_$\H#/D*1&`\B9T&#GV[V2'5/K=KI>/)`Z0QG#]1!%/*65EG=Z!ZE8_& M`$Q3G(&?FC-(0&%,7'XPB'[*/[_-PXT0`80`@3+?]?EY,*#9+H@_*PY]##O' MH^"YXV*OPX_%_"_B?-P^Z<9'ON_A1U][\&F7?_[&1Z-%C@,I[.5MJ7[(]X)''MRL2?D83Z=18+;9[Z02;C;[=>_'R%N#5$KN7 M":@E'\6/\\D@\',DROY^*4^::O9H5C9$G45#\-CTJ#5CH&4PY7(@/3BI[O<+6+*[68)*]Z!163EE)+"<'C0L$FJ6P'-F MX7?0\,AM M=`E"YP>-4.YI;@E.][`ILHK)(,'*/.*<:V):@+-VFC7Y8%6(1/&06L!R,Q8>X30-++I8#]DBY^L M&G?B'W^-_8'8/9KSL=LC+OR$S@!T#PT\7XSJ>)M<,?_4::&^P6H##5W7BSK_ M'GENGURAJ1>B56-666DMDC.&PU4[X,HO]2*R9)6"75&J0'I\#XM11)55/CS9LS!UAX`_N\?:,?.XK MT@NO$*5SX*/"+5*JD4I=+5H!P_9"X?:RZN4CTZ6@ABX-XC-"81>L%M,AZ\>8 M=3T`>E?PIQ>63H;"*GITH#"`N3N\,HTIK*)'!\XFIWP0`WT<8>#*F`*S91C@ M]AR/NW+/)C/A!O9Q1F&`K]:0:KIQPZ9<:M?OG5^#P/WF^3(:N?RU6=?&]?%* M32H)9.D2FB7D(1-KSN/E8N=7:Z(N)313N;IFW8I7](:LX^MBJ*/?!*:?$J>4 M".27;8S4ZL#GU-&B14!&3YA.A!]X;&"1"9]75(?,=^$8T^B@6CI>\LOJD/I^ M86PL)>EY)35)/$6>>_W"HWBXV2T%9O'"J%)3CT;!%--P?N_S0$7B\LU&D,[/ M6*Y*014=.CQ@6"X\AP=3;7`6K]J*#DV7-NVU^[$597(*:I4WQP9?LC$H5=6J M4YZ7MZ20'CD5V71#^'-EQJS"D?=X]59LJ>>W;R76Y^55W*E9GGOJP!1O1@D^ M9CGNJ>.3&$`2+,SRT%/'0D)Y$V#,\M&KNKJDD:CCCQ?PBY97@(3D>)\&1)$4 M)GB9Y:!7&:_*=#I!SBS'O5Z5!DM*2YUO/::NUXUV"5+SP"I M:BA/CYDBPZZI@4%;QBW/-&MJT-"6H=LT>*BYB]0V@"IT&3$UI&@;P!65-C7F M:,LS4W)[O%E,TJN:KBJ$JXK?L:GQ2O6@*W9N,C5RJ1Y696ZJIH8RU4.K<#S5 M"F!Z59IHAJKA#9`^(69<#TRV$^2X6!Q?E M7`Y'T40T-\A9W6-DY7)FW=LP67',/.56M^!E0Z82?,P\V5;#1QK6G-R`VIFV MG2BJ!-&B([#09[9T+8OP%&YB'0*[1,@3!Q@!::%Q\[0.NZS"N9N9NB'[8I#> M"%.0Y8X*L5VQ`9"X+JK4U!PS&^75ZNEN'B45&J*'H5+2$&%ILA?OI"4 MU;*Q+C;6I7*LB_6Q:X#)J-`RJ[H9F>Y95P>M]2W.=">Z^B@M-E!34V]OCE!^ M_E)#?>748%(Z79ON'E<9JJ)ER:R\W!M"M+XFF7H#4`L>R8)DZBV`O9>U][(& MWLMJ--Q'#_[V?)"7",=9'1;ZRQD#X!F#Y6W@$:'N(X:.!2G]^0-V@A'AFV3Z M,=?DCB_U9G?J96_^7G,WZJWJLTTR$=<1"R).`KA1K@JPEUA=I<1VR MK[XC?8F8YXC'Y/U9*!UQ9;5,N0O8('K3 M./X=>Z,Q\.?>,\R7$?X\FPPP%=PZ)M9E]^MU6]%IU2@[/:VD"BJ:O:;;5JM` M57H`,=W(6@6LG=MM3(]!K@+VNFG']/CCDB/T(9KXK0?-RAA1/N!D]\,U'FAZ M#&@MG#:Q!)D>)%H34!73DND)$VI!5W:2-CUM0BW0E/"JXY+3?/*@ZE`A(V#6 MF5)J<=O,@]*4H:,P(:TC98Z=?S.W25-&3^D%\F&[3-:VZQV,&Z7U[;*^726^ M73PA_(T??&-]F!P4PXZDX5:@Y_YWQJ)TLT\!MPD2Q_-Q9D]X"KBD]S1X]D#G MR_D7AMT^65*/G@.'RR@O4C MU=?3!ND%U,0+W%4;4"7U)$WH>3-Z$"8&JJN``*D(/=@T+C$1Z4Z0'_V0P9RY MP2B<2>.[:S6E1V?894`6U>%L";'Q7O"./,%_OAIF'O9:O>LF<+M4J:_'@FTP!YX6#.YP-1GQV M1H`#%X(Y2KP0^]XS=J]?''_&CPXEKY9OU&0SO#A5\HHK>W`J-=8,O1?I=NNH MF5>W&5H=FD_NJKB+JY1X`!;YY"I4;89.RW-(G+&NW&E/U^-5K0@O!13"`CC]W`C=B2YM9#F3T%L%ENUM)3H)J_7 M"&TR%C+N=%1B8:O00"/T>QP'-.3O/T7KN3VG"$T:+":EZQ%=V:\BN"3_PB MC!_X^*NSOH]%0!`<6?G,#]56C0U:;`("*Y>Z9 MPBI;L1\]8"=^?.G8[Y.3\`DW7A?=QTL*V[CT2AF_EQYQZIF^UZN8&5N_)3EG MTZDO9$#^`KD^&09T@E02K"O6WLHND?Z8Y/)?7DZGS^LN/2JS[T.I>`\M/8S/ MS/0PWA?:LMT@P;=.D+?%-QG-=?S_$O2+HL"$[J_S?;-]P5_QFC/!W1N."L*/#.=D*-3I#[MR6@FQFV M5]W7KQA)-4\ZM1C_5SR4MPVKFHMT`JL=K"JHYKGJFOZB][8QS'5B-_79;YOE M:C7Y2VW'N.R+5@57VZ:_C;Y]"&6WT6IOHA\ZDO*;&[4'TU\Q:]D=@-++O033 M(GO*P6.JX#J3(&FF363[0*[[!208&IJK;3L8*OBQ)D@:>L+;+I3*+K0)KD5' M/(MK56>V!%2S*J&-Z_OOM0%C%G5TM M2;YYRV=52*OXAYJ>"W]'HS0_*$$M=;X=H)NX54><,J1YDO$WM0A MC@9-T40&;X,PP%P7&'^-!><>"=?6^AL>\M M:,*E6MQCWIMP48I%XY^=J@[4EF+Z-WNUREQDZV3;-/YAJ_K3N2`C_&8O7QF- M6FXN3K4GL%ZQN;;NE,T/7=_?TU?[?M-(K#I/06QQ0/Z28[`[.D(DCD6'98H% MON>B.$[]/B7-W3"GK.FDS!*W M_]71^".V-5F]+I-5<^CT\O":3"SSN.\67GO+A2=_\RZN8QG\:V#PEE5:5FE9 M9<.V\T)66;)26PIH*:"E@+EK310@R5(!4@S.5C"-ID'\3Y.Y85-8U79X0,V^ MS.<+-1NS;-*R26,IH*:.EC+GK3C)? MA*OZ\HV<=#*WY!6=93J(S8ED_0US4Y'SM]%-6]T]B;64VE+J5TRI+>FTI+.! M$%4CG1OO/9:*6BIJJ6CN:A1E,'I"+P8;+.OOO87HY._$A54L0[0,T3)$RQ`M M0]PN0RQ>IRW]L_3/TK_8:4>*1$<_D)DY06FV,6L7M*S/LC[+ M^AJU/UG6MV765[!?6,IG*9^E?+GKC!@'-D550)``,A0:1/(4&D3W5X"P`!!"4.```$.0$``.U:;7/B.!+^ MOE7['W1\N=VJ,<9YF214,EL..!G7$>!L9W9VOTP)6Q#5&HF5Y+SKSW][G*?HG@A).;MH.>U."Q$6\X2RV47K-K3< ML.?[K=\^_/S3^3\L"WG]:S=`(Y921I!OW1`EZ"/Z').4"*P(BO`C9WS^A,+X MCLSQ.S3!DB2(,_3Y,AB@@[:#T)U2BZYM/SP\M$DRP\+B1ET[YG,;6=:JJT]+ MH[KH?=LY:I\56@*>L:2+CCJG,9F>G5BG9R<'UM'D[-`Z=8ZFUF1Z.CDA'7)R M@CL%5$\0K$`A2L#0+CKH.`=6Y]CJ'$0'AUWGI-MQ_BQ*\\63H+,[A7Z)?P5A MD`2$LQ&`=\AG<1NY:8H"+2I10"01]R1IYYJDB0*"&#-YT2HX_G#8YF)F@U[' M_GPS6$:K]?-/:"G;?9R(E&X@]),5YM"F3"K,8E*`@$5_52!TLR:CV,D+2&Z6 MQ#IU-E'I:$%D*,RWE.':?J@W3 M&+\G*9)I4UR2N#WC]W;>6!Z&A-!R%#24(RB[)U*5@Y9MVSB%Q8RH(9X3 MN<`QJ1=U>.'GA*DK+N9],L699NOO#*=T2DG20EC!P##)%-D0R-A:Y(/6/UDL*)OR_!8>Z#3L"IZ2"*A`^N(V\%\U4N4#D*T%[3Z/,VWFZA^S MQ&.*JB2B54ORV:B560F94D:-^4['019:P8N7H`HM=:&"LG-[ M6\.V\@Q&SA'[8*YCG,99:H`#N,_!N405<"%@2&)J!^3:LM=Q^=,5.]^&M!"L M-F82V-*+\52YCFF:0L`\*4FH)J]0Z#L61%<]T;#<#3P^V[D M]=&E.W"'/0^%'STO"O?4O8VZ,18@CW/6&O$C;DBLB(/P]^SZ&5 M(S'#C/['.-/C3/*4)N;&9*(77<]:X6;H1K>!IY/O\C;TAUX8OD.C MX-H=^G^:H0.YPSZZ'OG#:YVX/2\8[E.S>6I>82H^X30CZ]@WS*-J#=6DGVZ3 M?N7Z`?KD#FZ]/9G-R;PAL!<4THW_SNARX27A]80`+_)UF-R9Y1U55]-_MDV_ MV_OWK1_Z^O7>\]^<_U!!S.]XF@!3'A"EGK3L.L+-**^OK9)EI[/-O_Z M.!KTO2#\)_*`\NB//=W-Z5X'%=9^?+X@3!K'`@*A(4F/2R#Q#O9'E_HS[A@_ M&52S)'AK']6IX92FAG7IAK`"[8UNQMXP=/>CP6[IL=R_1?AQUP&@4D$UL0?; MQ/I#H--#D?O9VV\A=B#3PX+!JEJ.B3"O6S,F7T=7TWCX8E'N16@P"D,$&W@4 M?G2#_3IM!S('9(;3&ZR47E$Q&$3-CHFPYINX>IJJ23[:)AFV4Q%LJ[QAS]^_ MK+OPFT^.8RS44R0P3)GQUA*Y&`-S.>>L1M$?Z`H<&'"[?V_ M?)G3/_I4-2!39`Y,N_K`\*(EZ7R1DE;^#(M8XZN/6NV%X`LB%+QWZ\/:7,$+ M].;9KDFFK?CE5JTTW`DRO6CI4U5K=8[W!1#MQWFZ$E%4Z5YZ:SU(*Y+O$$[3 MEOW]>KY)8PW'`5#B>/]9S0_B=XHG)*WI,LB6N#S0&GX0;[=?\QI.`Z3$Z>*G MR3+?S^WB&33<;9Y1GX/K7"C$2@_,7RG30,M*D`&/C:(*B+ZS5CA+/[*<`^O0 M:3_*)#>QB07K2#>S8(5K:D%I)43=OE<`W>EQK>XJJTE>Z]9T65J^8I-4R6== MUEI7\^B_*!ZI%81ME([$F0Z_\_XM)A3J7AJ:P=EP-TNJRH/>0(Q^TI27KY7; M5)I3AEO=O,F0K0J>6D:L,/KB39V_K`2JU7\!EE^_8D5>'F3,J%=$9;&)\6/SJ-5L+X5SJHJ5$IF<=(P6S$>5)9'!))O)J M($93F"SU1+&4E1F`J^@/O,>XSL, M>ZLK+F";=:_G0NC'+-H+7N\"+OH.$**P>"KS?HI3^17WEVT3G&H;+EJQ(`E5 MWR0JK^].2KBO(_P=,1Z0."]0B?,CSSYT=6^*'@843VA*]<(GXFZ2F"4F3L>8 M)C[KX055JRH8X_G;5?WOLB$ADV^4#&&V6"P?X/2:\^0!5!:"4-[\0Z3Y[T37 M`I/$A7<4SPA,GQ,B+K&D<9^F&328[V=RE"F]QM.%U@6_=P%OO`:F><>8-'?^ MW%[.&G#Y7U!+`0(>`Q0````(`%6&I$"L;E4R358``*AB`@`1`!@```````$` M``"D@0````!N=FQT+3(P,3(P,S,Q+GAM;%54!0`#(4&D3W5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`%6&I$"2!RYCJ0L``)&/```5`!@```````$```"D M@9A6``!N=FQT+3(P,3(P,S,Q7V-A;"YX;6Q55`4``R%!I$]U>`L``00E#@`` M!#D!``!02P$"'@,4````"`!5AJ1`_CCAJ7P2``!:-@$`%0`8```````!```` MI(&08@``;G9L="TR,#$R,#,S,5]D968N>&UL550%``,A0:1/=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`58:D0-1"L;(;)0``.K8!`!4`&````````0`` M`*2!6W4``&YV;'0M,C`Q,C`S,S%?;&%B+GAM;%54!0`#(4&D3W5X"P`!!"4. M```$.0$``%!+`0(>`Q0````(`%6&I$!W'Y)B)A,``*AO`0`5`!@```````$` M``"D@<6:``!N=FQT+3(P,3(P,S,Q7W!R92YX;6Q55`4``R%!I$]U>`L``00E M#@``!#D!``!02P$"'@,4````"`!5AJ1`?#[;:W$'``!*+@``$0`8```````! M````I($ZK@``;G9L="TR,#$R,#,S,2YX`L``00E#@`` ;!#D!``!02P4&``````8`!@`:`@``]K4````` ` end XML 16 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS (USD $)

Mar. 31, 2012

Dec. 31, 2011

CURRENT ASSETS:

Cash and cash equivalents $ 3,787,576 $ 5,505,960

Restricted cash 55,000 55,000

Prepaid expenses and other current assets 183,300 254,967

Total current assets 4,025,876 5,815,927

FIXED ASSETS, NET 2,919,943 3,044,565

GOODWILL 1,675,462 1,675,462

OTHER ASSETS 27,222 27,222

TOTAL ASSETS 8,648,503 10,563,176

CURRENT LIABILITIES:

Accounts payable and accrued liabilities 471,629 478,041

Derivative liability 32,397 23,305

Capital lease obligations, current portion 2,275 2,235

Total current liabilities 506,301 503,581

LONG-TERM LIABILITIES:

Notes payable, net of current portion 450,000 450,000

Deferred rent 127,368 124,381

Capital lease obligations, net of current portion 3,507 4,091

Total long-term liabilities 580,875 578,472

TOTAL LIABILITIES 1,087,176 1,082,053

COMMITMENTS AND CONTINGENCIES (Note 8)

STOCKHOLDERS' EQUITY:

Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of March 31, 2012 and December 31, 2011

Common stock, $0.00001 par value; 150,000,000 shares authorized; 36,962,264 and 36,907,824 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively 369 369

Additional paid-in capital 41,398,287 40,961,180

Deficit accumulated during the development stage (33,837,329) (31,480,426)

Total stockholders' equity 7,561,327 9,481,123

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 8,648,503 $ 10,563,176

X

- Definition

Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Topic 210

-SubTopic 10

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

-Section S99

-Name Accounting Standards Codification

-Publisher FASB

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid within one year (or one operating cycle, if longer) of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 7, 10, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CapitalLeaseObligationsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6455314&loc=d3e45023-112735

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 7, 10, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 30

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6455398&loc=d3e45280-112737

+ Details

Name: us-gaap_CapitalLeaseObligationsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 19

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.26(c))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Technical Bulletin (FTB)

-Number 85-3

-Paragraph 2

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 13

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 840

-SubTopic 20

-Section 25

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6453417&loc=d3e39927-112707

+ Details

Name: us-gaap_DeferredRentCreditNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FIN39-1

-Paragraph 10A, 10B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 4, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 3

-Section A

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6905597&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22, 23, 24, 25, 26, 27

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 17

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Section 45

-SubTopic 10

-Topic 210

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

-Publisher FASB

-Name Accounting Standards Codification

-Paragraph 1

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 8

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. For a classified balance sheet represents the current portion only (the noncurrent portion has a separate concept); there is a separate and distinct element for unclassified presentations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Audit and Accounting Guide (AAG)

-Number AAG-BRD

-Chapter 4

-Paragraph 80

-Subparagraph Exhibit 4-8, 3

-IssueDate 2006-05-01

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN
3 Months Ended

Mar. 31, 2012

NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

1. NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN

Novelos Therapeutics, Inc. (“Novelos” or the “Company”) is a pharmaceutical company developing compounds for the treatment and diagnosis of cancer. On April 8, 2011, Novelos completed a business combination with Cellectar, Inc. (“Cellectar”), a privately held Wisconsin corporation that designed and developed products to detect, treat and monitor a wide variety of human cancers, and Cell Acquisition Corp. (the “Merger Subsidiary”), a Wisconsin corporation and a wholly owned subsidiary of Novelos. Pursuant to the transaction Cellectar was merged into the Merger Subsidiary (the “Acquisition”, see Note 3). References in these financial statements and notes to “Cellectar” relate to the activities and financial information of Cellectar prior to the Acquisition, references to “Novelos” relate to the activities and financial information of Novelos prior to the Acquisition and references to “the Company” or “we” or “us” or “our” relate to the activities and obligations of the combined Company following the Acquisition.

Immediately prior to the Acquisition, Novelos completed a 1-for-153 reverse split of its common stock. Novelos then issued to the shareholders of Cellectar at that date 17,001,596 shares of its common stock as consideration for the Acquisition, representing a ratio of 0.8435 shares of Novelos common stock in exchange for one share of Cellectar common stock (the “Exchange Ratio”) as set forth in the Agreement and Plan of Merger (the “Merger Agreement”) dated April 8, 2011. The shares issued to Cellectar shareholders in the Acquisition constituted approximately 85% of Novelos’ outstanding common stock after giving effect to the Acquisition.

Accounting principles generally accepted in the United States require that a company whose security holders retain the majority voting interest in the combined business be treated as the acquirer for financial reporting purposes. Accordingly, the Acquisition was accounted for as a reverse acquisition whereby Cellectar, Inc. was treated as the acquirer for accounting and financial reporting purposes. The financial statements presented herein as of and for the three months ended March 31, 2011 represent the historical financial information of Cellectar, except for the capital structure which represents the historical amounts of Cellectar, retroactively adjusted to reflect the legal capital structure of Novelos by applying the Exchange Ratio. On April, 8, 2011, Cellectar was merged into the Merger Subsidiary a wholly owned subsidiary of Novelos; as such, the financial statements presented herein as of and for the three months ended March 31, 2012 include the consolidated results of the combined company from January 1, 2012 through March 31, 2012. All per-share amounts and outstanding shares, including all common stock equivalents, and stock options, have been retroactively restated in these financial statements and notes for all periods presented to reflect the capital structure of Novelos by applying the Exchange Ratio. The number of authorized shares of common stock disclosed on the balance sheet (150,000,000) represents the number of authorized shares of Novelos common stock following the Acquisition.

As a result of the Acquisition, the Company has implemented a revised business plan focused on the development of the Cellectar compounds. Development of Novelos’ other compounds (NOV-002 and NOV-205) has been suspended. The Company conducts its operations from its headquarters in Madison, Wisconsin and the Company’s executive offices are in Newton, Massachusetts.

The Company is subject to a number of risks similar to those of other small pharmaceutical companies. Principal among these risks are dependence on key individuals, competition from substitute products and larger companies, the successful development and marketing of its products in a highly regulated environment and the need to obtain additional financing necessary to fund future operations.



The accompanying financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has incurred losses since inception in devoting substantially all of its efforts toward research and development and has an accumulated deficit of $33,837,329 at March 31, 2012. During the three months ended March 31, 2012, the Company generated a net loss of $2,356,903 and the Company expects that it will continue to generate operating losses for the foreseeable future. The Company believes that its cash on hand is adequate to fund operations into the middle of the third quarter of 2012. The Company’s ability to execute its operating plan beyond that time depends on its ability to obtain additional funding via the sale of equity and/or debt securities, a strategic transaction or otherwise. The Company plans to continue to actively pursue financing alternatives, but there can be no assurance that it will obtain the necessary funding. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.



The accompanying balance sheet as of December 31, 2011 has been derived from audited financial statements. The accompanying unaudited consolidated balance sheet as of March 31, 2012, the consolidated statements of operations for the three months ended March 31, 2012 and 2011 and the cumulative period November 7, 2002 (date of inception) through March 31, 2012, and the consolidated statements of cash flows for the three months ended March 31, 2012 and 2011 and the cumulative period November 7, 2002 (date of inception) through March 31, 2012 and the related interim information contained within the notes to the consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and the notes required by U.S. generally accepted accounting principles for complete financial statements. In the opinion of management, the unaudited interim consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company’s consolidated financial position at March 31, 2012 and consolidated results of its operations and its cash flows for the three months ended March 31, 2012 and 2011 and the period from November 7, 2002 (inception) to March 31, 2012. The results for the three months ended March 31, 2012 are not necessarily indicative of future results.

These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and related notes thereto included in the Company’s Form 10-K, which was filed with the SEC on March 9, 2012.

Goodwill — Intangible assets at March 31, 2012 consist of goodwill recorded in connection with the Acquisition. Goodwill is not amortized, but is required to be evaluated for impairment annually or whenever events or changes in circumstances suggest that the carrying value of an asset may not be recoverable. The Company evaluates goodwill for impairment annually in the fourth fiscal quarter and additionally on an interim basis if an event occurs or there is a change in circumstances, such as a decline in the Company’s stock price or a material adverse change in the business climate, which would more likely than not reduce the fair value of the reporting unit below its carrying amount.

Stock-Based Compensation — The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for awards that are not performance-based is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Non-employee stock-based compensation is accounted for in accordance with the guidance of Topic 505, Equity of the Financial Accounting Standards Board Accounting Standards Codification (“FASB ASC”). As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.



Fair Value of Financial Instruments — The guidance under FASB ASC Topic 825, Financial Instruments, requires disclosure of the fair value of certain financial instruments. Financial instruments in the accompanying financial statements consist of cash equivalents, accounts payable and long-term obligations. The carrying amount of cash equivalents and accounts payable approximate their fair value due to their short-term nature. The carrying value of long-term obligations, including the current portion, approximates fair value because the fixed interest rate approximates current market interest rates available on similar instruments.

Derivative Instruments – The Company generally does not use derivative instruments to hedge exposures to cash flow or market risks. However, certain warrants to purchase common stock that do not meet the requirements for classification as equity, in accordance with the Derivatives and Hedging Topic of the FASB ASC, are classified as liabilities. In such instances, net-cash settlement is assumed for financial reporting purposes, even when the terms of the underlying contracts do not provide for a net-cash settlement. These warrants are considered derivative instruments because the agreements contain “down-round” provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants are subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. The number of shares issuable under such warrants was 50,419 at March 31, 2012. The primary underlying risk exposure pertaining to the warrants is the change in fair value of the underlying common stock. Such financial instruments are initially recorded at fair value with subsequent changes in fair value recorded as a component of gain or loss on derivatives on the consolidated statements of operations in each reporting period. If these instruments subsequently meet the requirements for equity classification, the Company reclassifies the fair value to equity. At March 31, 2012 and December 31, 2011, these warrants represented the only outstanding derivative instruments issued or held by the Company.

New Accounting Pronouncements — In May 2011, the FASB issued ASU No. 2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. Generally Accepted Accounting Principles (“GAAP”) and International Financial Reporting Standards (“IFRSs”). This standard updates accounting guidance to clarify the measurement of fair value to align the guidance and improve the comparability surrounding fair value measurement within GAAP and IFRSs. The standard also updates requirements for measuring fair value and expands the required disclosures. The standard does not require additional fair value measurements and was not intended to establish valuation standards or affect valuation practices outside of financial reporting. The adoption of this standard on January 1, 2012 did not have a material impact on the Company’s financial statements or required disclosures.

In September 2011, the FASB issued ASU No. 2011-08, Intangibles – Goodwill and Other (Topic 350): Testing Goodwill for Impairment. This standard simplifies how an entity tests goodwill for impairment and allows an entity to first assess qualitative factors in determining whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. This standard is effective for entities as of the beginning of a fiscal year that begins after December 15, 2011, interim and annual periods thereafter. Early adoption is permitted. The Company adopted the provisions of this standard on January 1, 2012. The adoption of this standard did not have a material impact on the Company’s financial statements or required disclosures.

X

- Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Name FASB Interpretation (FIN)

-Publisher FASB

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 19 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

FAIR VALUE
3 Months Ended

Mar. 31, 2012

FAIR VALUE

2. FAIR VALUE

In accordance with Fair Value Measurements and Disclosures Topic of the FASB ASC 820, the Company groups its financial assets and financial liabilities generally measured at fair value in three levels, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value.

· Level 1: Input prices quoted in an active market for identical financial assets or liabilities.

· Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data.

· Level 3: Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable or supported by an active market.

Assets and liabilities measured at fair value on a recurring basis are summarized below:

March 31, 2012

Level 1 Level 2 Level 3 Fair Value

Liabilities:

Warrants $ - $ 32,397 $ - $ 32,397

December 31, 2011

Level 1 Level 2 Level 3 Fair Value

Liabilities:

Warrants $ - $ 23,305 $ - $ 23,305

The Company uses the Black-Scholes option pricing model and assumptions that consider, among other variables, the fair value of the underlying stock, risk-free interest rate, volatility, expected life and dividend rates in estimating fair value for the warrants considered to be derivative instruments. Assumptions used are generally consistent with those disclosed for stock-based compensation (see Note 5).

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Mar. 31, 2012

Dec. 31, 2011

Preferred stock, par value $ 0.00001 $ 0.00001

Preferred stock, shares authorized 7,000 7,000

Preferred stock, issued

Preferred stock, outstanding

Common stock, par value $ 0.00001 $ 0.00001

Common stock, shares authorized 150,000,000 150,000,000

Common stock, shares issued 36,962,264 36,907,824

Common stock, shares outstanding 36,962,264 36,907,824

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 21 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information
3 Months Ended

Mar. 31, 2012

May 01, 2012

Document Information [Line Items]

Document Type 10-Q

Amendment Flag false

Document Period End Date Mar. 31, 2012

Document Fiscal Year Focus 2012

Document Fiscal Period Focus Q1

Trading Symbol NVLT

Entity Registrant Name NOVELOS THERAPEUTICS, INC.

Entity Central Index Key 0001279704

Current Fiscal Year End Date --12-31

Entity Filer Category Smaller Reporting Company

Entity Common Stock, Shares Outstanding 37,570,245

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Details

Name: dei_DocumentInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 22 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
3 Months Ended 113 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2012

COSTS AND EXPENSES:

Research and development $ 1,328,314 $ 471,404 $ 22,133,353

General and administrative 997,671 131,726 10,660,282

Merger costs 250,434 799,133

Total costs and expenses 2,325,985 853,564 33,592,768

LOSS FROM OPERATIONS (2,325,985) (853,564) (33,592,768)

OTHER INCOME (EXPENSE):

Grant income 44,479 244,479

Loss on derivative warrants (28,846) (41,004)

Interest expense, net (2,072) (156,167) (449,197)

Other income 1,161

Total other expense, net (30,918) (111,688) (244,561)

NET LOSS $ (2,356,903) $ (965,252) $ (33,837,329)

BASIC AND DILUTED NET LOSS PER COMMON SHARE $ (0.06) $ (0.08) $ (2.87)

SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE 36,910,217 12,820,102 11,775,244

X

- Definition

Weighted Average Number of Shares Outstanding where Basic and Diluted are the same and reported as a single line

+ References

No definition available.

+ Details

Name: nvlt_WeightedAverageNumberBasicDilutedSharesOutstanding

Namespace Prefix: nvlt_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 57

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph n

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 805

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6909870&loc=d3e1392-128463

+ Details

Name: us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs of sales and operating expenses for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 18

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 20

-Section 35

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6439004&loc=d3e65527-113976

+ Details

Name: us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of nonoperating interest income (expense).

+ References

No definition available.

+ Details

Name: us-gaap_InterestIncomeExpenseNonoperatingNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 23 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

NET LOSS PER SHARE
3 Months Ended

Mar. 31, 2012

NET LOSS PER SHARE

7. NET LOSS PER SHARE

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss, as adjusted, by the sum of the weighted average number of shares of common stock and the dilutive potential common stock equivalents then outstanding. Potential common stock equivalents consist of stock options and convertible debt. Since there is a net loss attributable to common stockholders for the three months ended March 31, 2012 and 2011, the inclusion of common stock equivalents in the computation for those periods would be antidilutive. Accordingly, basic and diluted net loss per share is the same for all periods presented.

The following potentially dilutive securities have been excluded from the computation of diluted net loss per share since their inclusion would be antidilutive:

Three Months Ended
March 31, Cumulative
Development-
Stage Period
from November
7, 2002
(inception)
through
March 31,

2012 2011 2012

Convertible debt — 3,822,062 —

Warrants 17,176,679 — 17,176,679

Stock options 4,827,638 — 4,827,638

X

- Definition

The entire disclosure for earnings per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1278-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 24 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

INCOME TAXES
3 Months Ended

Mar. 31, 2012

INCOME TAXES

6. INCOME TAXES

The Company accounts for income taxes in accordance with the liability method of accounting. Under this guidance, deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax basis of assets and liabilities, and net operating loss carryforwards, using the enacted tax rates. Deferred income tax expense or benefit is based on changes in the asset or liability from period to period. The Company did not record a provision or benefit for federal, state or foreign income taxes for the three months ended March 31, 2012 or 2011 because the Company has experienced losses on a tax basis since inception. Because of the limited operating history, continuing losses and uncertainty associated with the utilization of the NOLs in the future, management has provided a full allowance against the value of its gross deferred tax asset.

The Company also accounts for the uncertainty in income taxes related to the recognition and measurement of a tax position taken or expected to be taken in an income tax return. The Company follows the applicable accounting guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition related to the uncertainty in income tax positions.

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONTINGENCIES
3 Months Ended

Mar. 31, 2012

CONTINGENCIES

8. CONTINGENCIES

Litigation

Following the Acquisition, the Company is party to certain legal matters that existed with Novelos prior to the Acquisition. The following summarizes the status of those matters.



Class Action

A putative federal securities class action complaint was filed on March 5, 2010 in the United States District Court for the District of Massachusetts by an alleged shareholder of Novelos, on behalf of himself and all others who purchased or otherwise acquired Novelos common stock in the period between December 14, 2009 and February 24, 2010, against Novelos and its President and Chief Executive Officer, Harry S. Palmin. On October 1, 2010, the court appointed lead plaintiffs (Boris Urman and Ramona McDonald) and appointed lead plaintiffs’ counsel. On October 22, 2010, an amended complaint was filed. The amended complaint claims, among other things, that Novelos violated Section 10(b) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder in connection with alleged misleading disclosures related to the progress of the Phase 3 clinical trial of NOV-002 for non-small cell lung cancer. On December 6, 2010, the defendants filed a motion to dismiss the complaint with prejudice. On January 20, 2011, the plaintiffs filed their opposition to our motion and on March 3, 2011, the defendants filed their response to the opposition. On June 23, 2011, the motion to dismiss was granted and the case was dismissed without prejudice. Because the dismissal was without prejudice, the plaintiffs could reinstitute the proceeding by filing an amended complaint. On August 5, 2011, the plaintiffs filed a second amended complaint realleging that the defendants violated Section 10(b) of the Exchange Act and Rule 10b-5 in connection with alleged misleading disclosures related to the Phase 3 clinical trial for NOV-002 in non-small cell lung cancer. On September 9, 2011, the defendants filed a motion to dismiss the second amended complaint. The plaintiffs’ opposition to the motion was filed on October 14, 2011 and the defendants filed a reply brief on November 4, 2011. The Company and Mr. Palmin believe the allegations are without merit and intend to continue to vigorously defend against them.

BAM Dispute

On June 28, 2010, Novelos received a letter from counsel to ZAO BAM and ZAO BAM Research Laboratories (Russian companies, collectively referred to as “BAM”) alleging that it modified the chemical composition of NOV-002 without prior notice to or approval from BAM, constituting a material breach of a technology and assignment agreement Novelos had entered into with BAM on June 20, 2000 (the “June 2000 Agreement”). The letter references the amendment, submitted to the FDA on August 30, 2005, to Novelos’ investigational new drug application dated August 1999 as the basis for BAM’s claims and demands the transfer of all intellectual property rights concerning NOV-002 to BAM. Mark Balazovsky, a director of Novelos from June 1996 until November 2006 and a shareholder of Novelos through at least June 25, 2010, is, to our knowledge, still the general director and principal shareholder of ZAO BAM. On September 24, 2010, Novelos filed a complaint in Suffolk Superior Court seeking a declaratory judgment by the court that the June 2000 Agreement has been replaced by a subsequent agreement between the parties dated April 1, 2005 (the “April 2005 Agreement”), that Novelos’ obligations to BAM are governed solely by the April 2005 Agreement and that the obligations of the June 2000 agreement have been performed and fully satisfied. On November 29, 2010, BAM answered the complaint, denying the material allegations, and stating its affirmative defenses and certain counterclaims. On January 14, 2011, Novelos responded to the counterclaims, denying BAM’s material allegations and stating its affirmative defenses. On June 9, 2011, BAM filed an amended counterclaim alleging additional claims related to Novelos’ acquisition of Cellectar. In that amended counterclaim, BAM alleges that the acquisition evidences Novelos’ abandonment of the technology assigned to it by BAM constituting a breach of the June 2000 Agreement or, if that agreement is determined to no longer be in effect, a breach of the April 2005 Agreement and/or a breach of the implied duty of good faith and fair dealing with respect to the April 2005 Agreement. On June 15, 2011 the Company filed its response to their amended counterclaim. On August 5, 2011, the Company filed a motion for judgment on the pleadings as to its declaratory judgment count and all counts of BAM’s amended counterclaim. The motion was opposed by BAM and a hearing on the motion was held on September 27, 2011. On October 17, 2011, the court ruled on the Company’s behalf for each of its declaratory judgment claims and dismissed all counts of BAM’s counterclaim. Judgment in favor of the Company was entered on October 20, 2011. On November 14, 2011, BAM filed a notice of appeal.

We do not anticipate that these litigation contingencies will have a material impact on the Company’s future financial position, results of operations or cash flows.

X

- Definition

The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.

+ References

No definition available.

+ Details

Name: us-gaap_LegalMattersAndContingenciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

RELATED PARTY TRANSACTIONS
3 Months Ended

Mar. 31, 2012

RELATED PARTY TRANSACTIONS

9. RELATED PARTY TRANSACTIONS

Jamey Weichert, the Company’s Chief Scientific Officer and principal founder of Cellectar, and a director and shareholder of the Company, is a faculty member at the University of Wisconsin-Madison (“UW”).



During the three months ended March 31, 2012, the Company made contributions to UW totaling $81,500 for use towards unrestricted research activities and paid UW $92,754 for costs associated with clinical trial agreements. No payments were made during the three months ended March 31, 2011.

X

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
3 Months Ended 113 Months Ended

Mar. 31, 2012

Mar. 31, 2011

Mar. 31, 2012

Net loss $ (2,356,903) $ (965,252) $ (33,837,329)

Adjustments to reconcile net loss to cash used in operating activities:

Depreciation and amortization 139,771 144,174 2,555,809

Stock-based compensation 417,353 58,462 3,272,226

Intrinsic value of beneficial conversion feature associated with convertible debt 471,765

Issuance of stock for technology and services 89,520

Impairment of intangible assets 19,671

Loss on disposal of fixed assets 36,477

Loss on derivative warrants 28,846 41,004

Changes in:

Prepaid expenses and other current assets 71,667 (5,458) (167,130)

Accounts payable and accrued liabilities (6,412) 293,383 91,500

Accrued interest 145,802 463,722

Deferred rent 2,987 4,323 127,368

Cash used in operating activities (1,702,691) (324,566) (26,835,397)

CASH FLOWS FROM INVESTING ACTIVITIES:

Cash acquired in a business combination 905,649

Purchases of fixed assets (15,149) (5,501,741)

Proceeds from sale of fixed assets 7,000

Purchases of short-term certificates of deposit (5,500,730)

Proceeds from short-term certificates of deposit 5,500,730

Change in restricted cash (55,000)

Payment for intangible assets (19,671)

Cash used in investing activities (15,149) (4,663,763)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from issuance of convertible notes 2,720,985

Proceeds from long-term obligations 1,677,945

Payments on long-term obligations (49,998) (1,227,944)

Payments on capital lease obligations (544) (508) (5,192)

Proceeds from issuance of common stock and warrants, net of issuance costs 31,874,254

Proceeds from exercise of warrant 250,000

Repurchase of common stock (31,667)

Cash in lieu of fractional shares in a business combination (145)

Change in deferred issuance costs 28,500

Cash provided by (used in) financing activities (544) (50,506) 35,286,736

INCREASE (DECREASE) IN CASH AND EQUIVALENTS (1,718,384) (375,072) 3,787,576

CASH AND EQUIVALENTS AT BEGINNING OF PERIOD 5,505,960 673,739

CASH AND EQUIVALENTS AT END OF PERIOD 3,787,576 298,667 3,787,576

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION

Interest paid 11,563 208,689

Fair value of derivative warrants reclassified to additional paid-in capital upon cashless exercise 19,754 68,093

Issuance of common stock in connection with the conversion of notes payable and accrued interest 3,184,707

Fair value of assets acquired in exchange for securities in a business combination 78,407

Fair value of liabilities assumed in exchange for securities in a business combination (439,615)

Goodwill resulting from a business combination $ 1,675,462

X

- Definition

Issuance of common stock in exchange for convertible notes

+ References

No definition available.

+ Details

Name: nvlt_IssuanceOfCommonStockInExchangeForConvertibleNotes

Namespace Prefix: nvlt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Reclassification Of Derivative Liabilities To Additional Paid In Capital

+ References

No definition available.

+ Details

Name: nvlt_ReclassificationOfDerivativeLiabilitiesToAdditionalPaidInCapital

Namespace Prefix: nvlt_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Goodwill acquired in a business combination.

+ References

No definition available.

+ Details

Name: nvlt_SupplementalGoodwill

Namespace Prefix: nvlt_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_CashAcquiredFromAcquisition

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Beneficial Conversion Feature

-URI http://asc.fasb.org/extlink&oid=6505963

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 98-5

-Paragraph 7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 00-27

-Paragraph 56

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The fair value of assets acquired in noncash investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_FairValueOfAssetsAcquired

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The difference between the sale price or salvage price and the book value of a property, plant, and equipment asset that was sold or retired during the reporting period. This element refers to the gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an indefinite-lived intangible asset, other than goodwill, to fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 46

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6905858&loc=d3e16373-109275

+ Details

Name: us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the period, which was recognized in earnings, in the unrealized gains or losses on derivative instruments that are not or are no longer designated as hedging instruments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 18

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 20

-Section 35

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6439004&loc=d3e65527-113976

+ Details

Name: us-gaap_IncreaseDecreaseInFairValueOfUnhedgedDerivativeInstruments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInterestPayableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets,or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The fair value of restricted stock or stock options granted to nonemployees as payment for services rendered or acknowledged claims.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The fair value of liabilities assumed in noncash investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_LiabilitiesAssumed1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to reacquire common stock during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for financing costs associated with business combinations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Section Appendix C

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireShortTermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net cash inflow or outflow from other financing activities. This element is used when there is not a more specific and appropriate element in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3095-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18, 19, 20

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3098-108585

+ Details

Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Section Appendix C

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 16

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26, 31

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfLongTermCapitalLeaseObligations

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 20

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_RepaymentsOfLongTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

STOCK-BASED COMPENSATION
3 Months Ended

Mar. 31, 2012

STOCK-BASED COMPENSATION

5. STOCK-BASED COMPENSATION

Accounting for Stock-Based Compensation

The Company uses the Black-Scholes option-pricing model to calculate the grant-date fair value of stock option awards. The resulting compensation expense, net of expected forfeitures, for non-performance based awards is recognized on a straight-line basis over the service period of the award, which is generally three years for stock options. For stock options with performance-based vesting provisions, recognition of compensation expense, net of expected forfeitures, commences if and when the achievement of the performance criteria is deemed probable. The compensation expense, net of expected forfeitures, for performance-based stock options is recognized over the relevant performance period. Evaluation of the probability of meeting performance targets is evaluated at the end of each reporting period. Non-employee stock-based compensation is accounted for in accordance with the guidance of FASB ASC Topic 505, Equity. As such, the Company recognizes expense based on the estimated fair value of options granted to non-employees over their vesting period, which is generally the period during which services are rendered and deemed completed by such non-employees.

The following table summarizes amounts charged to expense for stock-based compensation related to employee and director stock option grants and stock-based compensation recorded in connection with stock options granted to non-employee consultants:

Three Months Ended
March 31, Cumulative
Development-
Stage Period
from
November 7,
2002 through
March 31,

2012 2011 2012

Employee and director stock option grants:

Research and development $ 78,044 $ 23,526 $ 566,602

General and administrative 248,968 34,936 2,397,155

327,012 58,462 2,963,757

Non-employee consultant stock option grants:

Research and development 47,014 — 83,171

General and administrative 43,327 — 225,298

90,341 — 308,469

Total stock-based compensation $ 417,353 $ 58,462 $ 3,272,226

During 2011, the Company granted options to purchase 670,200 shares of common stock that vest based upon the achievement of performance-based milestones. As of March 31, 2012, 335,100 of these performance-based awards remain outstanding. No compensation expense has been recognized related to the performance-based awards as the Company does not believe that it is probable that the performance targets will be met.



Stock Option Activity

A summary of stock option activity under stock option plans is as follows:

Number of
Shares
Issuable Upon
Exercise of
Outstanding
Options Weighted
Average
Exercise Price Weighted
Average
Remaining
Contracted
Term in
Years Aggregate
Intrinsic
Value

Outstanding at December 31, 2011 4,827,638 $ 1.82

Granted —

Canceled —

Outstanding at March 31, 2012 4,827,638 $ 1.82

Vested, March 31, 2012 1,096,038 $ 4.27 9.09 $ 56,121

Unvested, March 31, 2012 3,731,600 $ 1.10 9.34 $ 527,919

Exercisable at March 31, 2012 1,096,038 $ 4.27 9.09 $ 56,121

No stock option awards were granted in the three months ended March 31, 2012 or 2011.

The aggregate intrinsic value of options outstanding is calculated based on the positive difference between the estimated per-share fair value of common stock at the end of the respective period and the exercise price of the underlying options. There have been no option exercises to date. Shares of common stock issued upon the exercise of options are from authorized but unissued shares.

As of March 31, 2012, there was $1,935,626 of total unrecognized compensation cost related to unvested stock-based compensation arrangements. Of this total amount, the Company expects to recognize $748,791, $728,122, $352,444 and $106,269 during 2012, 2013, 2014 and 2015, respectively. The Company expects 3,396,500 in unvested options, excluding performance-based awards, to vest in the future. The weighted-average grant-date fair value of vested and unvested options outstanding at March 31, 2012 was $1.15 and $0.89, respectively. There were no Cellectar options outstanding as of March 31, 2011.

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 8 101 1 false 0 0 false 3 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.novelos.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassified CONSOLIDATED BALANCE SHEETS false false R3.htm 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.novelos.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://www.novelos.com/taxonomy/role/StatementOfIncomeAlternative CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.novelos.com/taxonomy/role/StatementOfCashFlowsIndirect CONSOLIDATED STATEMENTS OF CASH FLOWS false false R6.htm 107 - Disclosure - NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock NATURE OF BUSINESS, ORGANIZATION AND GOING CONCERN false false R7.htm 108 - Disclosure - FAIR VALUE Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock FAIR VALUE false false R8.htm 109 - Disclosure - ACQUISITION Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsMergersAcquisitionsAndDispositionsDisclosuresTextBlock ACQUISITION false false R9.htm 110 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock STOCKHOLDERS' EQUITY false false R10.htm 111 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock STOCK-BASED COMPENSATION false false R11.htm 112 - Disclosure - INCOME TAXES Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock INCOME TAXES false false R12.htm 113 - Disclosure - NET LOSS PER SHARE Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock NET LOSS PER SHARE false false R13.htm 114 - Disclosure - CONTINGENCIES Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsLegalMattersAndContingenciesTextBlock CONTINGENCIES false false R14.htm 115 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.novelos.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock RELATED PARTY TRANSACTIONS false false All Reports Book All Reports Process Flow-Through: 103 - Statement - CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 104 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 105 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 106 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS nvlt-20120331.xml nvlt-20120331.xsd nvlt-20120331_cal.xml nvlt-20120331_def.xml nvlt-20120331_lab.xml nvlt-20120331_pre.xml true true

CONSOLIDATED BALANCE SHEETS (USD $)	Mar. 31, 2012	Dec. 31, 2011
CURRENT ASSETS:
Cash and cash equivalents	$ 3,787,576	$ 5,505,960
Restricted cash	55,000	55,000
Prepaid expenses and other current assets	183,300	254,967
Total current assets	4,025,876	5,815,927
FIXED ASSETS, NET	2,919,943	3,044,565
GOODWILL	1,675,462	1,675,462
OTHER ASSETS	27,222	27,222
TOTAL ASSETS	8,648,503	10,563,176
CURRENT LIABILITIES:
Accounts payable and accrued liabilities	471,629	478,041
Derivative liability	32,397	23,305
Capital lease obligations, current portion	2,275	2,235
Total current liabilities	506,301	503,581
LONG-TERM LIABILITIES:
Notes payable, net of current portion	450,000	450,000
Deferred rent	127,368	124,381
Capital lease obligations, net of current portion	3,507	4,091
Total long-term liabilities	580,875	578,472
TOTAL LIABILITIES	1,087,176	1,082,053
COMMITMENTS AND CONTINGENCIES (Note 8)
STOCKHOLDERS' EQUITY:
Preferred stock, $0.00001 par value; 7,000 shares authorized; none issued and outstanding as of March 31, 2012 and December 31, 2011
Common stock, $0.00001 par value; 150,000,000 shares authorized; 36,962,264 and 36,907,824 shares issued and outstanding at March 31, 2012 and December 31, 2011, respectively	369	369
Additional paid-in capital	41,398,287	40,961,180
Deficit accumulated during the development stage	(33,837,329)	(31,480,426)
Total stockholders' equity	7,561,327	9,481,123
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 8,648,503	$ 10,563,176

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Mar. 31, 2012	Dec. 31, 2011
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	7,000	7,000
Preferred stock, issued
Preferred stock, outstanding
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	36,962,264	36,907,824
Common stock, shares outstanding	36,962,264	36,907,824

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2012	May 01, 2012
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q1
Trading Symbol	NVLT
Entity Registrant Name	NOVELOS THERAPEUTICS, INC.
Entity Central Index Key	0001279704
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		37,570,245

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		113 Months Ended
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012
COSTS AND EXPENSES:
Research and development	$ 1,328,314	$ 471,404	$ 22,133,353
General and administrative	997,671	131,726	10,660,282
Merger costs		250,434	799,133
Total costs and expenses	2,325,985	853,564	33,592,768
LOSS FROM OPERATIONS	(2,325,985)	(853,564)	(33,592,768)
OTHER INCOME (EXPENSE):
Grant income		44,479	244,479
Loss on derivative warrants	(28,846)		(41,004)
Interest expense, net	(2,072)	(156,167)	(449,197)
Other income			1,161
Total other expense, net	(30,918)	(111,688)	(244,561)
NET LOSS	$ (2,356,903)	$ (965,252)	$ (33,837,329)
BASIC AND DILUTED NET LOSS PER COMMON SHARE	$ (0.06)	$ (0.08)	$ (2.87)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE	36,910,217	12,820,102	11,775,244